NCT number: [STUDY_ID_REMOVED]
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: 1 
Property of the [COMPANY_011] Group - Page 2 NAMES AND ADDRESSES OF
COORDINATING 
INVESTIGATOR[CONTACT_5627]:
Address:
Tel:
Fax:
E-mail:
MONITORING TEAM‚ÄôS 
REPRESENTATIVEName:
[CONTACT_2761]:
Tel:
Fax:
E-mail:
SPONSOR Company:
Address:
OTHER EMERGENCY 
TELEPHONE NUMBERS
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: 1 
Property of the [COMPANY_011] Group - Page 3 CLINICAL TRIAL SUMMARY
COMPOUND: Dupi[INVESTIGATOR_328634]: EFC13579
TITLE A randomized, double blind, placebo-controlled, parallel group study to 
evaluate the efficacy and safety of dupi[INVESTIGATOR_328635]/TRIAL LOCATION Worldwide
PHASE OF DEVELOPMENT 3 
STUDY OBJECTIVE(S) Primary Objective
x To evaluate the efficacy of dupi[INVESTIGATOR_328636](s)
x To evaluate the safety and tolerability of dupi[INVESTIGATOR_12458]
x To evaluate the effect of dupi[INVESTIGATOR_328637] (PROs) including health related quality of life (HRQoL)
x To evaluate dupi[INVESTIGATOR_328638]-
drug antibodies (ADA)
Exploratory Objective(s)
x To explore the association of biomarkers with treatment response
x To explore the association of genetic profiles with treatment 
response
x To explore the association of vaccine response with treatment
STUDY DESIGN General design
Multinational, multicenter, randomized, double blind, placebo-controlled, 
parallel group study assessing the effect of dupi[INVESTIGATOR_181149] (SC) for 52 weeks in patients with persistent asthma. 
Periods
The clinical trial consists of 3 periods:
x Screening Period (4¬±1 weeks): to determine a patient‚Äôs eligibility 
status and establish level of asthma control before randomization
x Treatment Period (52 weeks): treat with dupi[INVESTIGATOR_328639]     
x Post-treatment Period (12 weeks): to monitor a patient‚Äôs status 
when off study drug treatment for patients not participating in the 
long term extension study
Screening Period
Prior to screening, patients must be on a stable background therapy of a 
medium to high dose of inhaled corticos teroid (ICS) in combination with a 
second controller medication (eg, long-acting beta agonist [LABA], leukotriene 
receptor antagonist [LTRA], methylxanthine s, etc) for at least 3 months with a 
stable dose ¬ïPRQWKSULRUWR9LVLW3DWLHQWVUHTXLULQJDWKLUGFRQWUROOH UDUH
allowed to participate in this study. T he third controller should also be used for 
at least 3 months with a stable dose ¬ïPRQWKSULRUWR9LVLW (patients 
requiring systemic steroids as controller medication or biologics are 
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: 1 
Property of the [COMPANY_011] Group - Page 4 excluded).
The Screening Period will be 4¬±1 w eeks (21-35 days) in duration.
Randomized Treatment Period
Patients will be randomized to either dupi[INVESTIGATOR_328640] a treatment duration of 52 weeks.
During the Randomized Treatment Period, patients will continue the stable 
dose(s) of controller medication used during the Screening Period. 
Patients who permanently discontinue the study medication will be asked and 
encouraged to return to the site for study visits and participate in assessments 
according to the visit schedule until the end of the study with a +/-5 day window (See study flowchart for patients after permanent treatment
discontinuation in Section 1.3). At the time of permanent treatment 
discontinuation, patients will perform early treatment discontinuation visit 
(ETD) with all the assessments defined fo r Visit 18 (EOT). Under exceptional 
circumstances when a patient cannot come to the site for the scheduled visit, 
a phone contact [CONTACT_328722]. During the 
phone contact, at least information about AEs, concomitant medication and asthma exacerbation events should be collected. In addition, patients who 
discontinue early from treatment or pati ents who choose not to participate in 
the open label extension (OLE) study may be asked to return to the clinic to 
have additional ADA samples collected for analysis based on the overall 
assessment of antibody titers and/or clinical presentation at the time of
discontinuation or at the time of last study visit.
Post-treatment Period
After completing the treatment period, patients will be evaluated for [ADDRESS_405862]-
treatment period of this trial.
STUDY POPULATION 
Main selection criteriaInclusion criteria:
Adults and adolesc HQWSDWLHQWVZLWKDSK\VLFLDQGLDJQRVLVRIDVWKPDIRU¬ï
months, based on the Global Initiative for Asthma (GINA) 2014 Guidelines 
and the following criteria:
A) Existing treatment with medium to KLJKGRVH,&6¬ïPFJRI
fluticasone propi[INVESTIGATOR_328641] 
a maximum of 2000 mcg/day of fluticasone propi[INVESTIGATOR_308178]) in combination with a second controller (eg, LABA, LTRA) for at least 3 PRQWKVZLWKDVWDEOHGRVH¬ïPRQWKSULRUWR
Visit 1.
- Note for Japan: for subjects aged [ADDRESS_405863] be on ¬ïPFJRIIOXWLFDVRQHSURSLRQDWHWZLFHGDLO\RU
equivalent; for subjects aged [ADDRESS_405864] be 
¬ï mcg of fluticasone propi[INVESTIGATOR_328642].
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: [ADDRESS_405865] 3 months with a stable dose ¬ïPRQWKSULRUWR9LVLW   
B) Pre-bronchodilator forced expi[INVESTIGATOR_12194] (FEV 1) ¬î80% of 
predicted normal for adults and ¬î90% of predicted normal for 
adolescents at Visits 1 and 2, prior to randomization.
C) Asthma Control Questionnaire 5-question version (ACQ-5) score 
¬ïDW9LVLWVDQGSULRUWRUDQGRPL]DWLRQ . 
D) Reversibility of at least 12% and 200 mL in FEV 1after the 
administration of 200 to 400 mcg albuterol/salbutamol or levalbuterol/levosalbutamol (2 to 4 inhalations of albuterol/salbutamol or levalbuterol/levosalbutamol, or of a nebulized solution of albuterol/salbutamol or 
levalbuterol/levosalbutamol, if considered as a standard office 
practice) before randomization.
E) Must have experienced, within 1 year prior to Visit 1, any of the 
following events:
- Treatment with a systemic steroid (oral or parenteral) for 
worsening asthma at least once.
- Hospi[INVESTIGATOR_328643].
Exclusion Criteria:
x Patients <12 years of age or the minimum legal age for adolescents 
in the country of the investigat ive site, whichever is higher (For 
those countries where local regulat ions permit enrollment of adults 
only, subject recruitment will be restricted to those who are 
¬ïyears of age). 
x Weight is less than 30 kilograms.
x Chronic obstructive pulmonary di sease (COPD) or other lung 
diseases (eg, idiopathic pulmona ry fibrosis, Churg-Strauss 
Syndrome, etc) which may impair lung function.
x A subject who experiences a severe asthma exacerbation (defined 
as a deterioration of asthma that results in emergency treatment, 
hospi[INVESTIGATOR_96648], or treatment with systemic steroids at
any time from 1 month prior to the Screening Visit up to and including the Baseline Visit).
x Evidence of lung disease(s) other than asthma, either clinical 
evidence or imaging [eg, Chest X-ray, computed tomography (CT), 
Magnetic resonance imaging(MRI)] within [ADDRESS_405866] of care.  
x Note for Japan: According to the request from the health authority, 
chest X-ray should be performed at screening visit if there is no 
chest imaging (Chest X-ray, CT, MRI) available within 3 months 
prior to screening to exclude patient s with suspected active or 
untreated latent tuberculosis.
x Current smoker or cessation of smoking within 6 months prior to 
Visit 1.
x Previous smoker with a smoking history >10 pack-years.
x Comorbid disease that mi
ght interfere with the evaluation of IMP.
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: [ADDRESS_405867] 690 patients with a baseline blood eosinophil count ƒ±FHOOV/
(0.3 giga/L) and with approximately [ADDRESS_405868] 50% patients are on high dose of ICS. 
In addition, in order to have additional patients treated with drug 
manufactured using the intended commercial process, approximately 220 
patients will be randomized in addition to the originally planned sample size 
(1638).
STUDY TREATMENT(s)
Investigational medicinal 
product(s) 
Formulation Dupi[INVESTIGATOR_12458] (SAR231893/REGN668) or matching placebo
Dupi[INVESTIGATOR_12458]: 150 mg/mL in a prefilled syringe to deliver 300 mg in 2 mL;
175 mg/mL in pre-filled syringe to deliver 200 mg in 1.14 mL 
Placebo: Prefilled syringe to deliver 2 mL and 1.14 mL respectively.
Route(s) of administration Subcutaneous
Dose regimen Randomized 2:2:1:1 to the following regimens:
x dupi[INVESTIGATOR_12458] [ADDRESS_405869](s) (if applicable)
Formulation Inhaled corticosteroid in combination with other controllers
Screening Period
Prior to and during the Screening Period, patients must be on a stable dose of 
medium to high dose ICS in combination with a second controller medication 
(eg, LABA, LTRA, methylxanthines, etc). Patients needing a third controller 
are elligible for this study.
Randomized Treatment Period
During this period, patients will continue taking their controller medication(s)
at stable dose used during screening period.
Post-treatment Period
Upon completing the Randomized Treatment Period, patients not continuing 
with the OLE study, will continue treatment with the controller medication 
regimen and dose used during the randomized period, which could be adjusted based on the medical judgement of the Investigator of the patients‚Äò asthma control status.
Reliever Medication
Patients may administer albuterol/salbut amol or levalbuterol/levosalbutamol 
metered dose inhaler (MDI) as reliever medication as needed during the study. Nebulizer solutions may be used as an alternative delivery method.
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: 1 
Property of the [COMPANY_011] Group - Page 7 Route(s) of administration Oral inhalation, nebulizer: ICS, ICS combination, albuterol/salbutamol or 
levalbuterol/levosalbutamol; for other  background controllers: according to 
label
Dose regimen ICS: medium to high dose
Albuterol/salbutamol or levalbuterol/levosalbutamol: as needed
Other background controllers: referring to label
ENDPOINT(S) Primary Endpoints: 
x Annualized rate of severe exacerbation events during the 52-week 
placebo-controlled treatment period
x Absolute change from baseline in pre-bronchodilator FEV 1at 
Week 12
Key Secondary Endpoint:
x Percent change from baseline in pre-bronchodilator FEV 1at week 
12
Secondary Endpoint(s):
Efficacy
x Annualized rate of severe exacerbations events during the 52-week
placebo-controlled treatment period for patients with a baseline 
blood eosinophil count ¬ïJLJD/
x Absolute change from baseline in pre-bronchodilator FEV 1at 
Week 12 in patients with a baseline blood eosinophil count 
¬ï0.3 giga/L
x Percent change from baseline in pre-bronchodilator FEV 1at 
Week 12 in patients with a baseline blood eosinophil count 
¬ï0.3 giga/L
x Annualized rate of severe exacerbations events during the 52-week 
placebo-controlled treatment period for patients on high dose of ICS
x Absolute change from baseline in pre-bronchodilator FEV 1at 
Week 12 in patients on high dose of ICS
x Percent change from baseline in pre-bronchodilator FEV 1at 
Week 12 in patients on high dose of ICS
x Annualized rate of severe exacerbations events during the 52-week 
placebo-controlled treatment period for patients with a baseline EORRGHRVLQRSKLOFRXQW¬ïJ iga/L 
x Absolute change from baseline in pre-bronchodilator FEV
1at 
Week 12 in patients with a baseline blood eosinophil count 
¬ï giga/L
x Percent change from baseline in pre-bronchodilator FEV 1at 
Week 12 in patients with a baseline blood eosinophil count
¬ï0.15 giga/L
x Absolute change from baseline in pre-bronchodilator FEV 1at 
Weeks 2, 4, 8, 24, 36, and 52
x Percent change from baseline in pre-bronchodilator FEV 1at Weeks 
2, 4, 8, 24, 36, and 52
x Change from baseline in other lung function measurements (% 
predicted FEV 1, morning [AM]/evening [PM] peak expi[INVESTIGATOR_10229] 
[PEF], forced vital capacity [FVC], forced expi[INVESTIGATOR_10229] [FEF] 25-
75%, post-bronchodilator FEV1 at Weeks 2, 4, 8, 12, 24, 36, and 52
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: 1 
Property of the [COMPANY_011] Group - Page 8 x Annualized rate of loss of asthma control (LOAC) event during the 
52-week placebo-controlled treatment period
x Annualized rate of severe exacerbation events resulting in 
hospi[INVESTIGATOR_328644] 52-week placebo-controlled treatment period
x Time to first severe exacerbation event 
x Time to first loss of as thma control event (LOAC) 
x Change from baseline in Asthma Control Questionnaire (ACQ)-5 
score and ACQ-7 score at Weeks 2, 4, 8, 12, 24, 36, and 52
x Change from baseline at Weeks 2, 4, 8 12, 24, 36, and 52 in:
- Morning/evening asthma symptom score and nocturnal 
awakenings (e-diary)
- Use of daily puffs of rescue medication
x Change from baseline in Health care resource utilization at Weeks 
12, 24, 36, and 52
x Change from baseline in PROs at Week 12, 24, 36, and 52:
- Asthma Quality Of Life Questionnaire with Standardized 
Activities (AQLQ (S)) Self-Administered ¬ï\HDUV
- European Quality of Life Working Group Health Status 
Measure 5 Dimensions, 5 Levels (EQ-5D-5L) 
- Hospi[INVESTIGATOR_5620] (HADS)
- 22-item Sino Nasal Outcome Test (SNOT-22) in those patients 
with comorbid bilateral nasal polyposis and/or chronic rhinosinusitis
- Standardized Rhinoconjunctivitis Quality Of Life Questionnaire, 
ages 12+ (RQLQ(S)+12) in those patients with comorbid 
allergic rhinitis
Safety and tolerability
x Adverse events (AEs) 
x Vital signs
x Physical examination
x Electrocardiogram (ECG)
x Clinical laboratory tests
Systemic drug concentration and Anti-drug antibodies
x Serum functional dupi[INVESTIGATOR_181151]
x ADA
Biomarkers and others
x Fractional exhaled nitric oxide (FENO) levels
x Blood eosinophils
x Total and antigen-specific IgE
x Thymus and activation-regulated chemokine (TARC)
x Periostin
x Eosinophil cationic protein (ECP)
x Eotaxin-3 
x (Optional). Blood samples for ex ploratory genetic analysis of DNA 
and RNA to assess the relationship of DNA variants and/or RNA expression with asthma and response to dupi[INVESTIGATOR_24736].
x (Optional). Blood samples for ex ploratory analysis of vaccine IgG 
response durin
g treatment.
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: 1 
Property of the [COMPANY_011] Group - Page 9 Criteria for asthma exacerbations during the study
Two types of asthma exacerbation events are defined:
x A severe exacerbation event during the study is defined as a 
deterioration of asthma requiring:
-8VHRIV\VWHPLFFRUWLFRVWHURLGVIRU¬ïGD\VRU
- Hospi[INVESTIGATOR_328645], 
requiring systemic corticosteroids
x A LOAC event during the study is defined as any of the following:
-¬ïDGGLWLRQDOUHOLHYHUSXIIVRIVDOEXWDPRODOEXWHURORU
levosalbutamol/levalbuterol in a 24-hour period (compared with 
baseline) on 2 consecutive days; 
-¬ïGHFUHDVHLQSUH -bronchodilator FEV1 compared with 
baseline;
-,QFUHDVHLQ,&6GRVH¬ïWLPHVWKDQWKHGRVHDW9LVLW
- A decrease in AM or PM PEF of 30% or more on 
[ADDRESS_405870] 7 days prior to Day 1(randomization).
- Severe exacerbation event
Two events will be considered as different if the interval between their start
dates is equal or greater than 28 days.
ASSESSMENT SCHEDULE x Screening Period (4¬±1 weeks, 21-35 days) 
x Randomized Treatment Period (52 weeks)
x Post-treatment Period (12 weeks )
STATISTICAL CONSIDERATIONS Sample size determination:   
The sample size calculation of this study was based on a comparison 
between dupi[INVESTIGATOR_12458] [ADDRESS_405871] to the 2 primary 
endpoints: annualized rate of severe exacerbations during the 52-week 
treatment period and absolute change from baseline in FEV 1at Week 12. 
Assuming the number of severe exacerbations follows a negative binomial 
distribution with a dispersion parameter of 2, a placebo annualized rate of exacerbations being 0.6, a randomization ratio of 2:2:1:1, with 1638 randomized patients (546 for each dupi[INVESTIGATOR_328646] 273 for each 
matching placebo group), the study will have 99% power to detect a 55% 
relative risk reduction (ie, annualized rate of 0.27 for the dupi[INVESTIGATOR_24769]) in 
the annualized rate of severe exacerbations at the 2-tailed significance level RIƒÆ $VVXPLQJSDWLHQWVZLWKDEDVHOLQHHRVLQRSKLOFRX QW¬ï
cells/ŒºL (0.3 giga/L), approximately 690 patients (230 for dupi[INVESTIGATOR_12458] 300mg 
q2w and 115 for the matching placebo) will provide 91% power to detect a 55% relative risk reduction for the subgroup. Assuming a common standard 
deviation of 0.5 L, 1638 patients will prov ide 98% power to detect a treatment 
difference of 0.15 L in the change of FEV1 from baseline at Week 12 for the 
overall population, and 690 patients will provide 88% power to detect a treatment difference of 0.18 L for patients with a baseline eosinophil count ¬ïFHOOV  ≈ç(0.3 giga/L). The overall study re cruitment will continue until at 
least 1638 patients in total and 690 patient VZLWKHRVLQRSKLOV¬ïFHOOV ŒºL
(0.3 giga/L) are randomized. The recrui tment for patients on treatment of 
medium dose of ICS will stop when approximately [ADDRESS_405872] been randomized into the stud y. In addition, approximatel y 84 
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: 1 
Property of the [COMPANY_011] Group - Page 10adolescent patients will be randomized.
Patients will be randomized using a 2:2:1:1 randomization ratio for dupi[INVESTIGATOR_12458] 
300 mg q2w, dupi[INVESTIGATOR_12458] 200 mg q2w, placebo q2w in 2 mL and placebo q2w 
in 1.14 mL. 
Randomization will be stratified by [CONTACT_654] (<18 years, ¬ï\HDUV at screening, 
central eosinophil count (<300 cells/ ŒºL,¬ïFHOOV ŒºL) at screening, ICS 
dose level (medium, high) and country.
In addition, in order to have additional patients treated with drug 
manufactured using the intended comme rcial process, approximately 220 
patients will be randomized in addition to the originally planned sample size (1638).
Analysis populations:
The primary analysis population for the efficacy endpoints will be intent-to-
treat (ITT) population defined as a ll randomized patients. The efficacy 
analyses will be conducted according to the treatment to which they are 
randomized.
The secondary analysis population for the efficacy endpoints will be HEos
(High Eosinophils) ITT defined as all randomized patients with baseline 
eosiQRSKLOFRXQW¬ï cells/PL 
The analysis population for the safety endpoints will be the safety population, 
defined as all patients exposed to study medication, regardless of the amount 
of treatment administered. The safety analyses will be conducted according to 
the treatment that patients actually received.
Analysis of the primary endpoints: 
The annualized rate of severe exacerbation events will be analyzed using a 
negative binomial regression model. The model will include the total number 
of events occurring during the 52 weeks as the response variable, with the treatment group, age, region (pooled country), baseline eosinophil strata, 
baseline ICS dose level and number of severe exacerbation events within [ADDRESS_405873] model with 
repeated measures (MMRM) approach.  The model will include change from 
baseline FEV 1values up to Week 12 as response variables, and factors for 
treatment, age, sex, height, region (pooled country), baseline eosinophil
strata, baseline ICS dose level, visit, treatment by-visit interaction, baseline FEV
1value, and baseline-by-visit interaction as covariates. An unstructured 
correlation matrix will be used to model t he within-patient errors. Parameters 
will be estimated using restricted maximum likelihood method using the 
Newton-Raphson algorithm. Statistical in ferences on treatment comparisons 
for the change from baseline in FEV 1at Week [ADDRESS_405874] model. For patients discontinuin g the treatment before Week 12, 
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: 1 
Property of the [COMPANY_011] Group - Page 11off study-treatment FEV 1values measured up to Week 12 will be included in 
the primary analysis. 
Subgroup analyses will be performed for t he two primary endpoints using the 
same methods by [CONTACT_328723]OHYHOV¬ïFHOOV»ù L YVFHOOV»ù L 
DQG¬ï 15FHOOV»ù L vs. <15FHOOV»ù L). 
Multiplicity considerations 
To strongly control the type-I error rate for the primary family (2 primary 
endpoints and 2 doses), a hierarchical testing procedure will be applied at a 
2-sided 5% significant level, ie, each hypothesis will be formally tested only if 
the preceding one is significant at the 5% level. The hierarchy of the tests will 
be: 1) annualized severe exacerbation rate  for 300mg q2w versus placebo, 2) 
absolute change from baseline in FEV 1at Week 12 for 300mg q2w versus 
placebo, 3) annualized severe exacerbation rate for 200mg q2w versus placebo and 4) absolute change from baseline in FEV
1at Week 12 for 200mg 
q2w versus placebo.
If both doses are significant for both primary endpoints, a selective set of 
secondary endpoints will be tested following a hierarchical testing procedure 
at a 2-sided 5% significant level. The first four tests will be 1) % change from 
baseline in FEV 1at Week 12 for 300 mg q2w versus placebo 2) absolute 
change from baseline in AQLQ global score at Week 12 for 300 mg q2w versus placebo 3) % change from baseline in FEV
1at Week 12 for 200 mg 
q2w versus placebo, 4) absolute change from baseline in AQLQ global score 
at Week [ADDRESS_405875] of secondary 
endpoints to be tested in the hierarchical  order will be spec ified in SAP. The 
overall familywise error rate will be strongly controlled at a 2-sided 5% level for all tested endpoints across dose groups.
Handling of missing data
Sensitivity analyses excluding the additi onal off-treatment measurements will 
be performed to corroborate the primar y analyses. The reason and pattern of 
missing data will be carefully examined and tippi[INVESTIGATOR_328647].
Analysis of other secondary endpoints 
The annualized rate of exacerbation events, including severe exacerbation 
events resulting in hospi[INVESTIGATOR_328648], will be analyzed using the same way as for severe exacerbation events.
Time to severe exacerbation will be analyzed using a Cox regression model
with time to event as the dependent variable, and treatment, age, region 
(pooled country), baseline eosinophil strata, baseline ICS dose level and
number of asthma events prior to the study as covariates. The Kaplan-Meier 
method will be used to derive the proportion of patients with an asthma exacerbation event at Weeks 12, 24, 36, and 52, specific to each treatment 
group.
The change from baseline for continuous endpoints will be analyzed using a 
MMRM in the same fashion as for the endpoint of FEV
1. Sex and height will 
be included as covariates only in the models for spi[INVESTIGATOR_328649]. .
The safety variables, including AEs, l aboratory parameters, vital signs, ECG, 
and physical examinations will be summarized using descriptive statistics.
Interim Analysis
There is no interim analysis planned for this study. 
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: 1 
Property of the [COMPANY_011] Group - Page 12Planned database lock date : 
The database lock is planned based on the time when approximately 1638 
patients (originally planned sample size) complete week 52 visit or discontinue from the study before week 52. Analyses will be based on all data collected up to this database lock and will be considered as the final analyses 
in the CSR (Clinical Study Report). Additional data between database lock 
and last patient completing last visit will be summarized in a CSR addendum.
DURATION OF STUDY PERIOD (per 
patient) The total duration of the study (per pat ient) is expected to be up to 69 weeks:
x 4¬±[ADDRESS_405876]-treatment follow-up
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: 1 
Property of the [COMPANY_011] Group - Page 17Note for Japan: According to the request from the health authority, chest X-ray should be performed at screening visit if there  is no chest imaging (Chest X-ray, CT, MRI) available within [ADDRESS_405877] be on a stable background therapy of a medium to high dose of inhaled corticosteroid (ICS) in combination with a second controller medication (eg, long-acting beta agonist 
[LABA], leukotriene receptor antagonist [LTRA], methylxanthine  , etc) for at least 3 months with a stable GRVH¬ïPRQWKSULRUWR9LVLW3DWLHQWVUHTXLULQJDWKLUGFRQW UROOHUDUHDOORZHGWRSDUWLFLSDWHLQWKLVVWXG\
The tKLUGFRQWUROOHUVKRXOGDOVREHXVHGIRUDWOHDVWPRQWKVZLWK DVWDEOHGRVH¬ïPRQWKSULRUWR9LVLW  (patients requiring systemic steroids as controller medication or biologics are excluded ). 
iEvery 2 week (q2w) investigational product administrations must be separated by [CONTACT_2669] 11 days. The randomized Treatment Peri od visits occur every 2 weeks up to Week 12 and then every 4 weeks, alternating 
with q2w home administration of IMP (patient, caregiver, or health care professional) without study visit up to the end of treat ment period at Week 52. After Week 12, if the patient or Investigator decides not to 
administer IMP at home, the IMP injections can be performed at th e site by [CONTACT_181252]. Patients will be monitore d at the study site for a minimum of [ADDRESS_405878] 12 weeks. 
jElectronic diary/PEF meter is used for daily recording of salbutamol/albuterol or levosalbutamol/levalbuterol use, asthma contr oller drug use, oral steroid requirements, nocturnal awakenings due to asthma 
symptoms, morning and evening asthma symptom NRS scores and AM and PM PEF. This device is dispensed at Visit 1 and information is downloaded from this device on the other indicated days.
kACQ-7 is completed in the patient‚Äôs electronic diary during clinic visits. ACQ-7 (Asthma Control Questionnaire 7-question version ) score will be used to follow up evaluations in all patients.  ACQ-5 (the first 5 items 
of the ACQ-7) score is used for eligibility evaluation at visit [ADDRESS_405879] of ¬ï1 hour.
mVital signs, including blood pressure (mmHg), heart rate (beats per  minute), respi[INVESTIGATOR_697] (breaths per minute), body temper ature (degrees Celsius) and body weight (kg) will be measured at the screening and 
randomization visits (Visits 1 and 2) and every subsequent visi t. Height (cm) will be measured only at screening (Visit 1) for a dults, and be measured at the screening and randomization visits (Visits 1 and 2) and 
every subsequent visit for adolescents. Vital signs will be measured in the sitting position using the same arm at each visit, a nd will be measured prior to receiving inve stigational product at the clinic visits.
nSerum pregnancy test at Visit [ADDRESS_405880] be obtained at Visit s 1 and 2 prior to randomization.
oHematology: hemoglobin, hematocrit, platelet count, total white blood cell (WBC) count with five-part differential count, diffe rential count, and total red blood cell count. Serum chemistry: creatinine, blood urea 
nitrogen, glucose, uric acid, total cholesterol, total protein, albumin, total bilirubin (in case of values above the normal ra nge, differentiation in conjugated and non-conjugated bilirubin), alanine aminotransferase, 
aspartate aminotransferase, alkaline phosphatase, lactate dehydrogenase, electrolytes (sodium, potassium, chloride), bicarbonat e, and creatine phosphokinase. Clinical laboratory testing at Visit 1 and Visit 17 
(only applicable for patients who plan to participate in the OLE study) include hepatitis screen covering hepatitis B surface anti gen (HBs Ag), hepatitis B surface antibody (HBs Ab), hepatitis B core antibody (HBc
Ab) including HBcAb IgM and total, hepatitis C virus antibodies (HCV Ab), Human Immunodeficiency Virus (HIV) screen (Anti-HIV-1 and HIV-2 antibodies) and anti-nuclear antibody (ANA). In case of results 
showing HBs Ag (negative), and HBc Ab total (positive), a hepa titis B virus DNA (HBV DNA) testing must be performed prior to ran domization to determine eligibility. In case of results showing HCV Ab (positive), a 
HCV virus RNA (HCV RNA) testing must be performed prior to randomization to determine eligibility. Note: Anti- GV'1$DQWLERG\ZLOOEHWHVWHGLI$ 1$LVSRVLWLYH¬ïWLWHU The blood sample for serum 
chemistry must be taken with the patient in fasting state which means no intake of any food or drink except for water for at le ast 8 hours (if the visit can only be done at a different time of the day and the patient is 
not fasting, then he/she should be advised to eat light food and the site should document that serum chemistry was not obtained un der fasting conditions).
pThis is only applicable for patients in Japan or other countries/regions if there is local regulatory requirement who are HBs Ag  negative and HBs Ab positive at the screening visit.
qUrine dipstick analysis including specific gravity, pH, glucose,  ketones, blood protein, nitrite, leukocyte esterase, urobilinog en and bilirubin. If any assessment on the dipstick is abnormal, a urine sample should be 
sent to the central laboratory for testing.  If positive for proteins, microscopic analysis will be performed by [CONTACT_328724].
rSystemic drug concentration and ADA samples ar e to be collected prior to dosing. In t he event of any SAE or any AESI of anaphyl actic reactions or systemic allergic reactions that are related to IMP and require 
treatment, or severe injection site reaction lasting longer than 24 hours, samples will be collected near the onset and resolut ion of the event for any additional analysis if required or for archival purposes.. See 
Section 9.3.1 for more details. 
sBiomarker set includes Eotaxin-3, eosinophil cationic protein (ECP), total IgE, Thymus and Activation-Regulated Chemokine (TARC). Bl ood eosinophil count will be measured as part of hematology test. Exhaled 
nitric oxide assessment is described separately in the flowchart.
tArchival serum in case needed for retrospective safety follow-up or additional biomarker analysis, and this is optional and a s eparate written consent form must be signed.
uThis is optional and a separate written consent form must be signed before sampling. For those who consented, the sample should b e drawn at Week 0, before IMP administration. 
vHADS includes Hospi[INVESTIGATOR_5620]- Anxiety s ubscale (HADS-A) and Hospi[INVESTIGATOR_5620]- Depre ssion subscale. 
wFor those patients with bilateral nasal polyposis and/or chronic rhinosinusitis. 
xFor those patients with como rbid allergic rhinitis. 
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: 1 
Property of the [COMPANY_011] Group - Page 20iUrine dipstick analysis including specific gravity, pH, glucose, ketones, blood protein, nitrite, leukocyte esterase, urobilino gen and bilirubin. If any assessment on the dipstick is abnormal, a urine sample should be 
sent to the central laboratory for testing.  If positive for proteins, microscopic analysis will be performed by [CONTACT_328724].
jIn the event of any SAE, or any AESI of ana phylactic reactions or  systemic allergic reac tions that are relate d to IMP and requir e treatment, or severe injection site reaction lasting longer than 24 hours, samples will 
be collected near the onset and resolution of the event for any additional analysis if required or for archival purposes. See Se ction 9.3.1 for more details. 
kBiomarker set includes Eotaxin-3, eosinophil cationic protein (ECP), total IgE, Thymus and Activation-Regulated Chemokine (TARC). B lood eosinophil count will be measured as part of hematology test. Exhaled 
nitric oxide assessment is described separately in the flowchart.
lArchival serum in case needed for retrospective safety follow-up or additional biomarker analysis, and this is optional and a s eparate written consent form must be signed.
mHADS includes Hospi[INVESTIGATOR_5620]- Anxiety s ubscale (HADS-A) and Hospi[INVESTIGATOR_5620]- Depre ssion subscale. 
nFor those patients with bilateral nasal polyposis and/or chronic rhinosinusitis. 
oFor those patients with como rbid allergic rhinitis.
pIt indicates the sampling of post vaccination and if it is within 6 weeks after vaccination as applicable.
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: [ADDRESS_405881] OF ABBREVIATIONS ......................................................................................................... .28 
4 INTRODUCTION AND RATIONALE.............................................................................................32  
4.1 INTRODUCTION................................................................................................................... .........32  
4.2 RATIONALE...................................................................................................................... .............32  
4.2.1  Population rationale ........................................................................................................... ............33  
4.2.2  Design rationale ............................................................................................................... ..............33  
4.2.3  Endpoint rationale ............................................................................................................. .............33  
4.2.4  Rationale for dose and regi men selection .....................................................................................34  
5 STUDY OBJECTIVES ............................................................................................................... ....36  
5.1 PRIMARY........................................................................................................................ ...............36  
5.2 SECONDARY ...................................................................................................................... ..........36  
5.3 EXPLORATORY .................................................................................................................... ........36  
6 STUDY DESIGN ................................................................................................................... .........37  
6.1 DESCRIPTION OF THE PROTOCOL...........................................................................................37  
6.2 DURATION OF STUDY PARTICIPATION ....................................................................................37  
6.2.1  Duration of study participati on for each patient .............................................................................37  
6.2.2  Determination of end of clinic al trial (all patients) .......................................................................... 37 
6.3 INTERIM ANALYSIS............................................................................................................... .......37  
6.4 STUDY COMMITTEES............................................................................................................... ...37  
6.4.1  Data monitoring committee ...................................................................................................... ......37  
6.4.2  Executive advisory committee ................................................................................................... ....38  
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: 1 
Property of the [COMPANY_011] Group - Page 227 SELECTION OF PATIENTS ......................................................................................................... .39 
7.1 INCLUSION CRITERIA............................................................................................................. .....39  
7.2 EXCLUSION CRITERIA ............................................................................................................. ...39  
7.2.1  Exclusion criteria related to study methodology ............................................................................40  
7.2.2  Exclusion criteria related to the active com parator and/or mandator y background therapi[INVESTIGATOR_014].......[ADDRESS_405882](S) ..........................................................................[ADDRESS_405883](S) ..................................................................45  
8.2.1  Inhaled corticosteroid in combination wi th one or two other controllers ........................................45  
[IP_ADDRESS]  Screening period............................................................................................................... .............45  
[IP_ADDRESS]  Randomized treatment period.................................................................................................... ....46  
[IP_ADDRESS]  Post-treatment period .......................................................................................................... ..........46  
8.2.2  Reliever medication............................................................................................................ ............46  
8.3 BLINDING PROCEDURES............................................................................................................ 48 
8.3.1  Methods of blinding............................................................................................................ ............48  
8.3.2  Randomization code breaki ng during the study.............................................................................48  
8.4 METHOD OF ASSIGNING PATIENT S TO TREATMENT GROUP ..............................................49  
8.5 PACKAGING AND LABELING ......................................................................................................49  
8.6 STORAGE CONDITIONS AND SHELF LIFE................................................................................50  
8.7 RESPONSIBILITIES ............................................................................................................... .......50  
8.7.1  Treatment accountability  and compliance .....................................................................................50  
8.7.2  Return and/or destructi on of treatments ........................................................................................ [ADDRESS_405884] ..............................................53  
9.1 PRIMARY ENDPOINT ............................................................................................................... ....53  
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: 1 
Property of the [COMPANY_011] Group - Page 239.1.1  Primary endpoints .............................................................................................................. ............53  
[IP_ADDRESS]  Asthma exacerbation events..................................................................................................... .....53  
9.2 SECONDARY ENDPOINT(S)........................................................................................................53  
9.2.1  Efficacy endpoints............................................................................................................. .............54  
[IP_ADDRESS]  Disease-specific efficacy measures............................................................................................. ..55 
[IP_ADDRESS]  Disease-specific, daily efficacy assessments ................................................................................57  
[IP_ADDRESS]  Health care resource  utilization............................................................................................... .......59  
[IP_ADDRESS]  Patient-reported outcomes...................................................................................................... .......59  
9.2.2  Safety and tolerabi lity endpoints............................................................................................... .....61  
[IP_ADDRESS]  Adverse events ................................................................................................................. .............61  
[IP_ADDRESS]  Vital signs.................................................................................................................... ...................61  
[IP_ADDRESS]  Physical examination ........................................................................................................... ..........62  
[IP_ADDRESS]  ECG ............................................................................................................................ ...................62  
[IP_ADDRESS]  Clinical laborato ry tests...................................................................................................... ............62  
[IP_ADDRESS]  Hepatitis B vira l load ......................................................................................................... .............63  
[IP_ADDRESS]  Pregnancy test ................................................................................................................. ..............63  
9.3 OTHER ENDPOINTS................................................................................................................ .....63  
9.3.1  Systemic drug concentration and anti-drug antibodies..................................................................63  
[IP_ADDRESS]  Sampling time .................................................................................................................. ..............63  
[IP_ADDRESS]  Handling procedures............................................................................................................ ..........64  
[IP_ADDRESS]  Bioanalytic method............................................................................................................. ............65  
9.3.2  Pharmacodynamics............................................................................................................... .........65  
[IP_ADDRESS]  Whole blood biomarkers .......................................................................................................... ......66  
[IP_ADDRESS]  Plasma biomarkers .............................................................................................................. ..........66  
[IP_ADDRESS]  Serum biomarkers............................................................................................................... ...........66  
[IP_ADDRESS]  Exhaled nitric oxide........................................................................................................... .............66  
9.3.3  Pharmacogenetics ............................................................................................................... ..........66  
[IP_ADDRESS]  Optional stored DNA and RNA samples........................................................................................66  
9.3.4  Vaccine response............................................................................................................... ............67  
9.4 FUTURE USE OF SAMPLES ........................................................................................................6 7 
9.5 APPROPRIATENESS OF MEASUREMENTS ..............................................................................68  
10 STUDY PROCEDURES ............................................................................................................... .69 
10.1  VISIT SCHEDULE................................................................................................................. .........69  
10.1.1  Visit 1 (Week -4 ¬± 1, -35 days to -21 days) ................................................................................... .70 
10.1.2  Visit 2 (Week 0, Day1) ........................................................................................................ ...........73  
10.1.3  Visit 3 (Week 2)............................................................................................................... ...............75  
10.1.4  Visit 4 (Week 4)............................................................................................................... ...............76  
10.1.5  Visit 5 (Week 6)............................................................................................................... ...............77  
10.1.6  Visit 6 (Week 8)............................................................................................................... ...............78  
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: 1 
Property of the [COMPANY_011] Group - Page 2410.1.7  Visit 7 (Week 10).............................................................................................................. ..............79  
10.1.8  Visit 8 (Week 12).............................................................................................................. ..............81  
10.1.9  Visit 9 (Week 16).............................................................................................................. ..............83  
10.1.10  Visit 10, 12, 13, 15, 16, 17 (Week  20, 28, 32, 40, 44, 48) .............................................................84  
10.1.11  Visit 11, 14, 18 (Week 24, 36, 52 / End-of-Treatment Visit) ..........................................................86  
10.1.12  Visit 19 and Visit 20 (Wee k [ADDRESS_405885]-Treatment  Period).........................................88  
10.1.13  Visit 21 (Week 64, End-of-Study Visit)........................................................................................... [ADDRESS_405886](s) ...........................[ADDRESS_405887](s) ...........................[ADDRESS_405888] of criteria for permanent treatment discontinuation................................................................. 91  
10.3.4  Handling of patients after permanent  treatment disc ontinuation ...................................................92  
10.3.5  Procedure and consequence for pati ent withdrawal from study....................................................92  
10.4  OBLIGATION OF THE INVESTIGATOR REGARDING SAFETY REPORTING ..........................93  
10.4.1  Definitions of adverse events.................................................................................................. .......93  
[IP_ADDRESS]  Adverse event .................................................................................................................. ..............93  
[IP_ADDRESS]  Serious adverse event .......................................................................................................... .........93  
[IP_ADDRESS]  Adverse event of special interest.............................................................................................. .....94  
10.4.2  Serious adverse events waived from expedi ted regulatory reporting to regulatory 
authorities.................................................................................................................... ...................95  
10.4.3  General guidelines for report ing adverse events ...........................................................................95  
10.4.4  Instructions for reporting se rious adverse events ..........................................................................97  
10.4.5  Guidelines for management of specif ic laboratory abno rmalities ..................................................97  
10.5  OBLIGATIONS OF THE SPONSOR .............................................................................................98  
10.6  SAFETY INSTRUCTIONS ............................................................................................................ .98 
10.6.1  Hypersensitivity............................................................................................................... ...............98  
10.6.2  Severe injection site reactions ................................................................................................ .......99  
10.6.3  Infections..................................................................................................................... ...................99  
10.6.4  Elevated liver function tests .................................................................................................. .......100  
10.7  ADVERSE EVENTS MONITORING............................................................................................101  
11 STATISTICAL CONSIDERATIONS............................................................................................102  
11.1  DETERMINATION OF SAMPLE SIZE.........................................................................................102  
11.2  DISPOSITION OF PATIENTS .....................................................................................................10 2 
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: 1 
Property of the [COMPANY_011] Group - Page 2511.3  ANALYSIS POPULATIONS.........................................................................................................10 3 
11.3.1  Efficacy populations ........................................................................................................... ..........103  
11.3.2  Safety population .............................................................................................................. ...........103  
11.3.3  Systemic drug concentrat ion population......................................................................................103  
11.3.4  Anti-drug antibody population .................................................................................................. ....103  
11.4  STATISTICAL METHODS ...........................................................................................................1 04 
11.4.1  Extent of study treatment ex posure and compliance...................................................................104  
[IP_ADDRESS]  Extent of investigational medi cinal product exposure..................................................................104  
[IP_ADDRESS]  Compliance ..................................................................................................................... .............104  
11.4.2  Analyses of efficacy endpoints .....................................................................................................104  
[IP_ADDRESS]  Analysis of primary efficacy endpoints......................................................................................... 104 
[IP_ADDRESS]  Multiplicity considerations .................................................................................................... ........105  
[IP_ADDRESS]  Handling of missing data .................................................................................................................106  
[IP_ADDRESS]  Loading dose evaluation ........................................................................................................ ......106  
11.4.3  Analyses of safety data........................................................................................................ ........106  
[IP_ADDRESS]  Adverse events ................................................................................................................. ...........107  
[IP_ADDRESS]  Vaccine response............................................................................................................... ..........108  
11.4.4  Analyses of systemic drug concentration, anti-drug antibodies and pharmacodynamic 
variables...................................................................................................................... .................108  
[IP_ADDRESS]  Drug concentration analysis.................................................................................................... .....108  
[IP_ADDRESS]  Anti-drug antibodies analysis .................................................................................................. .....108  
[IP_ADDRESS]  Pharmacodynamics............................................................................................................... .......109  
11.4.5  Analyses of Patient Reported Outcomes (Health -related Quality of Life/health  economics 
variables...................................................................................................................... .................[ADDRESS_405889]/INDEPENDENT  ETHICS COMMITTEE (IRB/IEC) ............112  
13 STUDY MONITORING............................................................................................................... ..114  
13.1  RESPONSIBILITIES OF THE IN VESTIGATOR(S).....................................................................114  
13.2  RESPONSIBILITIES OF THE SPONSOR...................................................................................114  
13.3  SOURCE DOCUMENT REQUIREMENTS..................................................................................114  
13.4  USE AND COMPLETION OF CASE REPO RT FORMS (CRFS) AND ADDITIONAL
REQUEST........................................................................................................................ ............115  
13.5  USE OF COMPUTERIZED SYSTEMS........................................................................................115  
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: [ADDRESS_405890] OF PROHIBITED LIVE A TTENUATED VACCINES.................................................125  
APPENDIX B  LOW, MEDIUM AND HIGH DOSE INHALED CORTICOSTEROIDS  ADULTS AND
$'2/(6&(176¬ï YEARS)....................................................................................................126  
APPENDIX C  EXAMPLES OF CYP SUBSTRATES WITH NARROW THERAPEUTIC RANGE ...........128  
APPENDIX D  ASTHMA CONTROL QUESTIONNAIRE (ACQ)...............................................................129  
APPENDIX E  ASTHMA SYMPTOM SCORE NUMERICAL  RATING SCALE (NRS)..............................[ADDRESS_405891] (SNOT-22) ......................................................139  
APPENDIX H  HOSPI[INVESTIGATOR_328650] ..........................................................141  
APPENDIX I  EUROQUAL QUESTIONNAIRE  (EQ-5D-5L) .....................................................................143  
APPENDIX J  STANDARDIZED RHINOCON JUNCTIVITIS QUALITY OF LIFE QUESTIONNAIRE  
RQLQ(S)+12 ..................................................................................................................... ...........146  
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: [ADDRESS_405892] OF OPPORTUNISTIC INFECTIONS .......................................................................159  
APPENDIX O  EXAMPLES OF COMMONLY USED ASTHMA CONTROLLER THERAPI[INVESTIGATOR_5165] ................160  
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: [ADDRESS_405893] ALT Alanine Aminotransferase
ANA Anti-nuclear Antibodies
ATS American Thoracic SocietyAQLQ(S) Asthma Quality Of Life Questionnaire with Standardized Activities (AQLQ 
(S)) Self- $GPLQLVWHUHG¬ï\HDUV
BCG Bacillus Calmette-Gu√©rin
CDMS Clinical Data Management System 
CI Confidence IntervalCOPD Chronic Obstructive Pulmonary DiseaseCRFsCPKCase Report Forms 
Creatine phosphokinase
CSR Clinical Study Report
CV Curriculum VitaeCV% Coefficient of VariationCYP Cytochrome P450CT Computed Tomography
DMC Data Monitoring Committee 
DNA Deoxyribonucleic acidDRF Discrepancy Resolution FormECG Electrocardiography ECP Eosinophil Cationic Protein 
e-CRF Electronic Case Report Form
ERS European Respi[INVESTIGATOR_328651]-5D-5L EuroQoL Working Group Health Status Measure 5 Dimensions, 5 Levels
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: 1 
Property of the [COMPANY_011] Group - Page 29EOS End-of-Study
EOT End-of-Treatment
ETD Early Treatment DiscontinuationFEF Forced expi[INVESTIGATOR_328652]
1 Forced Expi[INVESTIGATOR_328653]-A Hospi[INVESTIGATOR_70506]- Anxiety subscale
HADS-D Hospi[INVESTIGATOR_80776]- Depression subscale
HBc Ab Hepatitis B Core AntibodyHBs Ab Hepatitis B Surface AntibodyHBs Ag Hepatitis B Surface Antigen
HBV Hepatitis B Virus
HCV Hepatitis C VirusHCV Ab Hepatitis C Virus AntibodyHEos High EosinophilsHLGT High-Level Group Term 
HLT High Level Term
HIV Human Immunodeficiency Virus HRQoL Health related quality of life ICH International Conference on HarmonizationICS Inhaled Corticosteroid ID De-identification Code
IgE Immunoglobulin E
IgG Immunoglobulin GIL-4 Interleukin 4IL-5ƒÆ Interleukin 4 Receptor Alpha Subunit
IL-13 Interleukin 13
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: [ADDRESS_405894]
IRB/IEC Institutional Review Board / Institutional Ethics Committee 
IVRS/IWRS Interactive Voice Response Syst em/Interactive Web Response System 
IUD Intrauterine DeviceIUS Intrauterine System ITT Intent-To-Treat
K-M Kaplan-Meier
LABA Long-Acting Beta AgonistLAMA Long-Acting Muscarinic AntagonistLFT Liver Function TestLOAC Loss Of Asthma Control
LTRA
Leukotriene receptor antagonist
MCID Minimal Clinically Important Difference
MDI Metered Dose Inhaler
MID Minimal Important Difference
MMR Measles, Mumps, Rubella
MMRM Mixed-effect Model with  Repeated Measures 
MMRV Measles, Mumps, Rubella, Varicella
MRI Magnetic Resonance Imaging
NIMP Noninvestigational Medicinal Product
NRS                       Numerical Rating Scale
OLE Open label extension
PCSA Potentially Clinically Significant Abnormalities  
PD Pharmacodynamics
PEF Peak Expi[INVESTIGATOR_328654]-Reported Outcomes 
PT Preferred Term
RNA Ribonucleic Acid
RQLQ(S)+12 Standardized Rhinoconjunctivitis Quality Of Life Questionnaire , ages 12+
SAP Statistical Analysis Plan
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: [ADDRESS_405895] Upper Limit of Normal 
VAS Visual Analogue Scale 
WBC White Blood Cell 
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: [ADDRESS_405896] asthma patients, a regimen of controller th erapy and reliever therapy provides adequate long-
term control. However, it is estimated that 5%  to 10% of asthma patients have symptomatic 
disease despi[INVESTIGATOR_181165] w ith combinations of anti-inflammatory and 
bronchodilator drugs. These patients account for up to 50% of the total health cost through 
hospi[INVESTIGATOR_614], use of emergency servi ces, and unscheduled physician visits (1). 
The long term adverse effects of systemic a nd inhaled corticosteroids on bone metabolism, 
adrenal function, and growth in ch ildren lead to attempts to mini mize the amount of corticosteroid 
usage. Additionally, the consequences of unresponsiv eness to therapy or la ck of compliance with 
therapy is loss of asthma control and ultimatel y, asthma exacerbation. The poor response of some 
patients with asthma may reflect the number of cellular and molecular mechanisms operative in 
asthma. There is increasing interest in distinct phenotypes because targeted  therapy is more likely 
to be successful in patients with similar underly ing pathobiologic features (2). Recent therapeutic 
approaches in asthma have been focused on tryi ng to control the type 2 T-helper cell (Th2) 
response. Up-regulation of interleukin-4 (IL-4)  and interleukin-13 (IL-1 3) activity has been 
implicated as an important inflammatory compon ent of asthma disease progression. Dupi[INVESTIGATOR_328655] a potential novel treatme nt for asthma. Dupi[INVESTIGATOR_12458], a fully human 
monoclonal antibody, is directed agains t the IL-4 receptor alpha subunit (IL- 5ƒÆZKLFKLVD
component of IL-4 receptors Type I and Type II , as well as the IL-13 receptor. The binding of 
dupi[INVESTIGATOR_209320]- 5ƒÆUHVXOWVLQEORFNDGHRIGRZQV WUHDPVLJQDOLQJLQLWLDWHGE\ER WK,/ -4 and 
IL-13. For complete information regarding the prec linical and clinical ev aluation of dupi[INVESTIGATOR_328656], see the Investigator‚Äôs Brochure. 
4.[ADDRESS_405897] assessm ent of the efficacy and safety 
of dupi[INVESTIGATOR_12458]. 
The proposed study design provides the opportunity to confirm the efficacy of dupi[INVESTIGATOR_328657], prevention of severe exacerbations and 
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: [ADDRESS_405898] on lung function an d symptom control will be evaluated over short 
term and long terms.  
4.2.1 Population rationale 
In this study, dupi[INVESTIGATOR_328658]-on to an inha led corticosteroid in combination with one or 
two other controller medications in patients with persistent asthma.  The population is comprised 
of patients with a phys ician diagnosis of DVWKPDIRU¬ïP onths, based on the Global Initiative for 
Asthma (GINA) 2014 Guidelines (3) and entry cr iteria described in Section 7. As described 
above, in addition to suffering the symptoms associ ated with a lack of asthma control, such 
patients utilize a disproportionate level of health  care services, may suffe r the long term adverse 
effects of systemic and inhaled corticosteroids, and ultimately, are at increased risk of a severe asthma exacerbation.
4.2.2 Design rationale
This study is a randomized, double blind, placebo-contro lled, parallel group study. The clinical 
trial consists of three periods, using an add-on therapy approach to inhaled corticosteroid in 
combination with one or two other controller medicines: 
xScreening Period (4¬±1 weeks)
xRandomized Treatment Period (52 weeks)
xPost-treatment Period (12 weeks)
This study has two arms of placebo with different  volume, which is to match the different dose 
regimens of dupi[INVESTIGATOR_12458] 300 mg q2w and 200 mg  q2w respectively. Both the patient and 
investigator will be blinded to assigned active drug or placebo, but will not be blinded to the dose 
level of  dupi[INVESTIGATOR_12458] 300 mg/matching placebo or   dupi[INVESTIGATOR_12458] 200 mg/matching placebo due to 
different volume size (2 mL vs 1.14 mL).  
4.2.[ADDRESS_405899] of a drug on lung function. Safety endpoints are typi[INVESTIGATOR_328659].
Other endpoints including systemic drug concen tration/ADA and biomarkers of drug action have 
been used previously to evaluate the exposure/ effect relationship of dupi[INVESTIGATOR_328660].
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: 1 
Property of the [COMPANY_011] Group - Page 344.2.4 Rationale for dose and regimen selection 
The dose regimens of subcutaneous (SC) dupi[INVESTIGATOR_328661] 300 mg every 
2 weeks (q2w) or [ADDRESS_405900] 3%, partially controlled or 
uncontrolled by [INVESTIGATOR_49377]-to-high doses of IC S plus LABA (fluticasone/salmeterol, 
budesonide/formoterol, or mometasone/formote rol) were randomized to the study. The study 
showed significant efficacy in a population of mostly severe asth matics with poor asthma control 
and decreased lung function with mostly high do ses of ICS in combination with a LABA.  
In the dose ranging study (DRI12544 study), 776 patie nts with asthma uncontrolled by [INVESTIGATOR_49377]-
to-high dose ICS plus LABA were randomized in the study. Four dose regimens (300 mg q2w 
with 600mg loading dose, 200 mg q2w with 400mg loading dose, 300mg q4w with 600 mg 
loading dose and 200mg q4w with 400 mg loading dose) were tested in the study. The results 
showed that [ADDRESS_405901] proposed 
adult Phase 3 dose (300 mg q2w) is not expected  to exceed the observed adult exposure at the
dupi[INVESTIGATOR_328662] 300 mg once weekl y, which was observed to be generally well 
tolerated in adults. Therefore, adolescent dos ing at 300 mg q2w or 200 mg q2w regimen is 
expected to yield dupi[INVESTIGATOR_328663] a height ened safety risk in this age population. 
Dupi[INVESTIGATOR_328664]- tolerated in all clinical trials completed to date in healthy 
volunteers and patients with Atopic dermatitis (AD) or asthma who were dosed for up to [ADDRESS_405902]  been established during the dupi[INVESTIGATOR_328665]. A low discontinuation rate has been obser ved across the completed clinical trials in 
dupi[INVESTIGATOR_181175].  The reported rate of suspected unexpected serious adverse reaction
(S[LOCATION_003]R) has also been low. In addition, no im balance in the frequency of TEAEs between 
patients treated with dupi[INVESTIGATOR_328666], with the exception of injection 
site reactions, nasopharyngitis and headache. In summary, the safety data observed so far in 
completed and currently ongoing studies in AD and asthma patients (at the same or even higher 
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: 1 
Property of the [COMPANY_011] Group - Page 35doses than that proposed for this study) have demonstrated a positive be nefit-risk profile for 
dupi[INVESTIGATOR_328667]. 
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: [ADDRESS_405903] of dupi[INVESTIGATOR_125308] b on improving PROs including HRQoL 
To evaluate dupi[INVESTIGATOR_328638]-drug antibodies  
5.3 EXPLORATORY
To explore the association of bi omarkers with treatment response
To explore the association of gene tic profiles with treatment response
To explore the association of vaccine response with treatment
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: [ADDRESS_405904] of  dupi[INVESTIGATOR_181149] (SC) for 52 weeks in 
patients with persistent asthma with a medium to  high dose of ICS in combination with a second 
controller medication (a thir d controller is allowed).
6.2 DURATION OF STUDY PARTICIPATION
6.2.1 Duration of study participation for each patient
The clinical trial consists of three periods:
Screening Period  (4¬±1 weeks): to determine a patient‚Äôs elig ibility status and establish level of 
asthma control before randomization. 
Treatment Period (52 weeks): treat with dupi[INVESTIGATOR_328668].      
Post-treatment Period (12 weeks): to monitor a patient‚Äôs status when off study drug treatment 
for patients not partic ipating in the long term extension study.
6.2.2 Determination of end of clinical trial (all patients)
The last patient last visit will occur at last patient who has completed [ADDRESS_405905] not to enter extension study as well as for 
those who permanently discontinue medicati on and continue for all the remaining visits. 
6.3 INTERIM ANALYSIS
Not applicable. 
6.4 STUDY COMMITTEES
6.4.1 Data monitoring committee
A data monitoring committee (DMC) is independent from sponsor and is commissioned for the 
dupi[INVESTIGATOR_181182]. This committee is comprised of externally-based 
individuals with expertise in the diseases unde r study, biostatistics, or clinical research. The 
primary responsibilities of the DMC are to review and evaluate the safety data during the course 
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: [ADDRESS_405906] of the clinical trial to 
the Sponsor. 
The DMC procedures and safety data to be reviewed by [CONTACT_181246]. In the above capacities , the DMC is advisory to the S ponsor. The Sponsor is responsible 
for promptly reviewing and for taking into acco unt in a timely manner the recommendations of 
the DMC in terms of trial continuation with or wi thout alterations or of potential trial termination. 
6.4.2 Executive advisory committee
An executive advisory committee is commissioned for the dupi[INVESTIGATOR_328669]. The executive advisory committee is ma de up of 5-7 key academic clinicians, with 
selection criteria including a key opi[INVESTIGATOR_328670], US, 
Europe and Latin America. These clinicians ha ve been selected base d on their publications, 
experience in conducting clinical asthma/nasal pol yps studies, and their ab ility to both challenge 
and provide input during the protocol review pr ocess, speak to heath authority/ethics committee
for operational issues/challenges/une xpected safety issues.  Furthermore, they can speak with 
credibility to feasibility issues and impact th e recruitment. These clinicians will provide 
invaluable insight and direction to ensure a successful clinical program. 
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: 1 
Property of the [COMPANY_011] Group - Page 397 SELECTION OF PATIENTS 
7.1 INCLUSION CRITERIA
I 01. Ad XOWVDQGDGROHVFHQWSDWLHQWVZLW KDSK\VLFLDQGLDJQRVLVRIDVWK PDIRU¬ïPRQWKVEDVHG
on the Global Initiative for Asthma (GINA) 2014 Guidelines  and the following criteria:
A) Existing treatment with medium to KLJKGRVH,&6¬ïPFJRIIOXWLFDVRQHSURSLRQD te 
twice daily or equipotent ICS daily dosage to  a maximum of 2000 mcg/day of fluticasone 
propi[INVESTIGATOR_117476]) in combination w ith a second controller (eg, LABA, LTRA) for 
at least 3 PRQWKVZLWKDVWDEOHGRVH¬ïPRQWKSULRUWR9LVLW
- Note for Japan: IRUVXEMHFWVDJHG\HDUVDQGR OGHU,&6PXVWEHRQ¬ïPFJR I
fluticasone propi[INVESTIGATOR_328671]; for subjects aged 12 to 17 years, ICS 
PXVWEH¬ï  mcg of fluticasone propi[INVESTIGATOR_328672]. 
- Patients requiring a third controller for their asthma will be consider ed eligible for this 
VWXG\DQGLWVKRXOGDOVREHXVHGIRUDWOHDVWPRQWKVZLWKD VWDEOHGRVH¬ïPRQWK
prior to Visit 1. 
B) Pre-bronchodilator forced  expi[INVESTIGATOR_12194] (FEV 1¬îRISUHGLFWHGQRUPDOIRUDGXOWV
DQG¬î  90% of predicted normal for adolescents at Visits 1 and 2, pr ior to randomization.
C) Asthma Control Questionnaire 5-question version (ACQ-5 VFRUH¬ïDW9LVLWVDQG
prior to randomization. 
D) Reversibility of at leas t 12% and 200 mL in FEV 1after the administration of 200 to 400 
mcg albuterol/salbutamol or levalbuterol/le vosalbutamol (2 to  4 inhalations of 
albuterol/salbutamol or leva lbuterol/levosalbutamol, or of a nebulized solution of 
albuterol/salbutamol or levalbut erol/levosalbutamol, if consid ered as a standard office 
practice) before randomization.
E) Must have experienced, within 1 year prio r to Visit 1, any of the following events: 
- Treatment with a systemic steroid (oral or  parenteral) for worsening asthma at least 
once. 
- Hospi[INVESTIGATOR_328673].
I 02. Signed written informed consent. 
7.[ADDRESS_405907] met all the above inclusion criter ia listed in Section 7.1 w ill be screened for the 
following exclusion criteria whic h are sorted and numbered in the following 4 subsections:  
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: 1 
Property of the [COMPANY_011] Group - Page 407.2.1 Exclusion criteria related to study methodology
E 01. Patients <12 years of age or the minimum le gal age for adolescents in the country of the 
investigative site, whichever is higher (For those countries where local regulations permit 
HQUROOPHQWRIDGXOWVRQO\VXEMHFW UHFUXLWPHQWZLOOEHUHVWULFW HGWRWKRVHZKRDUH¬ï years 
of age). 
E 02. Weight is less than 30 kilograms. E 03. Chronic obstructive pulmonary disease (COP D) or other lung diseases (eg, idiopathic 
pulmonary fibrosis, Churg-Strauss Syndrom e, etc) which may impair lung function. 
E 04. A subject who experiences a severe asthma exacerbation (defined as a deterioration of 
asthma that results in emergency treatment, hospi[INVESTIGATOR_96648], or treatment with systemic steroids at any time from 1 month prior to the Screening Visit up to and 
including the Baseline Visit).
E 05. Evidence of lung disease(s) other than asthma , either clinical evidence or imaging (Chest
X-ray, CT, MRI) within [ADDRESS_405908] of care. 
Note for Japan: According to the request from  the health authority, chest X-ray should be 
performed at screening visit if there is no chest imaging (Chest X -ray, CT, MRI) available 
within [ADDRESS_405909] infection within the 
4 weeks prior to Visit 1 or dur ing the screening period.   
E 07. Current smoker or cessation of smoking within 6 months pr ior to Visit 1. 
E 08. Previous smoker with a smoking history >10 pack-years.
E 09. Comorbid disease that might in terfere with the evaluation of IMP.
E 10. Known or suspected al cohol and/or drug abuse. 
E 11. Inability to follow the procedures of the study (eg, due to language problems or 
psychological disorders). 
E 12. Patients requiring non-selective beta-1 adre nergic receptor blockers for any reason, or 
initiation or change in dose of a selective beta-1 adrenerg ic receptor blocker within 1 
month prior to Visit 1 or plan to  initiate or change in dose of a selective beta-1 adrenergic 
receptor blocker during the screening period or the randomized treatment period. 
E 13. Anti-immunoglobulin E (IgE) therapy (omalizumab) within 1 30 days prior to Visit 1 or 
any other biologic therapy/immunosuppressant  to treat inflammatory disease or 
autoimmune disease (eg, rheumatoid arthritis,  inflammatory bowel disease, primary biliary 
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: 1 
Property of the [COMPANY_011] Group - Page 41cirrhosis, systemic lupus erythematosus, multiple  sclerosis, etc.) as well as other diseases 
within 2 months or 5 half-lives pr ior to Visit 1, whichever is longer. 
E 14. Initiation of allergen immunotherapy within 3 months prior to Visit 1 or dose change from 
1 month prior to Visit 1 or a p lan to begin allergen immunothe rapy or to change its dose 
during the Screening Period or th e Randomized Treatment Period. 
E 15. Patients on or initiati on of Bronchial thermoplasty within 3 years prior to Visit 1 or plan to 
begin therapy during the Screening Peri od or the Randomized Treatment Period.
E 16. Exposure to another investiga tive antibody within a time period prior to Visit 1 that is less 
than 5 half-lives of the antibody. In case th e half-life is not kn own, then the minimum 
interval since exposure to the prior investigative anti body is 6 months. The minimum 
interval since exposure to any other (non-antibody) inve stigative study medication is 
30 days prior to Visit 1.
E 17. Patients receiving medications or therapy th at are prohibited as concomitant medications 
(See Section 8.8).
E 18. Patients who have previously been trea ted in any clinical trial of dupi[INVESTIGATOR_12458]. 
E 19. Patient is the Investigator or any Sub-Investigator, research  assistant, pharmacist, study 
coordinator, other staff or re lative thereof directly involve d in the conduct of the study. 
7.2.2 Exclusion criteria related to the active comparator and/or mandatory background 
therapi[INVESTIGATOR_014] 
E 20. Non-compliance with use of the ma ndatory background therapy, eg, ICS/LABA 
combination, during the screening period, as defined as: 
x<80% of total number of prescribed doses  of background medication taken during the 
screening period. Compliance is verified base d on background medica tion use recorded on 
the patient electronic diary during the screening period.
E 21. A subject with a history of clinically significant renal, he patic, cardiovascular, metabolic, 
neurologic, hematologic, ophthalmologic, respir atory, gastrointestinal , cerebrovascular or 
other significant medical illness or disorder which, in the judgment of the investigator, 
could interfere with the study or require tr eatment that might interfere with the study. 
Specific examples include but are not limite d to uncontrolled diabetes, uncontrolled 
hypertension, bronchiectasis. Active tuberc ulosis or non-tuberculous mycobacterial 
infection, latent untreated tuberculosis or a hi story of incompletely treated tuberculosis will 
be excluded from the study unless it is well doc umented by a specialist that the patient has 
been adequately treated and can  now start treatment with a bi ologic agent, in the medical 
judgment of the investigator and/or infectious disease sp ecialist. Tuberculosis testing 
would be performed on a country by [CONTACT_328725] s according to local gui delines if required 
by [CONTACT_181248]. Other conditions that are well controlled and stable will not prohibit participation if deemed  appropriate per the investigator‚Äôs judgment.
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: [ADDRESS_405910]-feeding women. 
E 23. Women of childbearing potential (pre-m enopausal female biologically capable of 
becoming pregnant) who: 
xDo not have a confirmed negative serum beta-hCG test at Visit 1.
xWho are not protected by [CONTACT_328726]: 
- Established use of oral, injected, implant ed or inserted hormonal contraceptive. 
- Intrauterine device (IUD) with copper or in trauterine system (IUS) with progestogen
- Barrier contraceptive (condom, diaphragm or cervical/vault caps) used with spermicide 
(foam, gel, film, cream or supposit ory), if allowed by [CONTACT_1295]
- Female sterilization (eg tubal occlusion, hysterectomy or bilateral salpi[INVESTIGATOR_1656]),
- Male sterilization with post-vasectomy docum entation of the absence of sperm in the 
ejaculate; for female patients the study, th e vasectomized male partner should be the 
sole partner for that patient
- True abstinence in keepi[INVESTIGATOR_328674]; periodic abstinence (eg calendar, ovul ation, symptothermal, post-
ovulation methods) is not an acc eptable method of contraception 
- Postmenopausal women (defined as at le ast 12 consecutive months without menses) 
are not required to use additional contraception  
E 24. Deleted. 
E 25. Diagnosed active parasitic infection (helmi nthes), suspected or high risk of parasitic 
infection, unless clinical and (if necessary) laboratory assess ments have ruled out active 
infection before randomization. 
E 26. History of HIV infection or positive HIV serology at Visit 1.
E 27. Known or suspected history of immunos uppression, including hi story of invasive 
opportunistic infections (e g, histoplasmosis, listeriosis, coccidioidomycosis, 
penumocystosis, aspergillosis), despi[INVESTIGATOR_328675]; or unusually frequent, 
recurrent or prolonged infections, per investigator‚Äôs judgment.  
E 28. Evidence of acute or chroni c infection requiring systemic treatment with antibacterials, 
antivirals, antifungals, antiparas itics, or antiproto zoals within [ADDRESS_405911]  received antiviral treatment (eg, influenza 
receiving only symptomatic treatment). 
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: 1 
Property of the [COMPANY_011] Group - Page 43E 29. Live attenuated vaccinations within 4 weeks prior to Visit 1 or planned live attenuated 
vaccinations during the study; see Appendix A for list of prohibited live attenuated 
vaccines. 
E 30. Patients with active autoimmune disease or  patients using immunos uppressive therapy for 
autoimmune disease (eg, rheumatoid arthritis,  inflammatory bowel disease, primary biliary 
cirrhosis, systemic lupus erythematosus, multiple  sclerosis, etc.) or patients with high titer 
autoantibodies at screening who are susp ected of having high risk for developi[INVESTIGATOR_328676]. 
E 31. History of malignancy within 5 years before  the screening visit, except completely treated 
in situ carcinoma of the cervix, completely tr eated and resolved nonmetastatic squamous or 
basal cell carcinoma of the skin. 
E 32. Patients with a history of a systemic hype rsensitivity reaction,  other than localized
injection site reaction, to any biologic drug. 
E 33. Patients with any of the following result at screening: 
xPositive (or indeterminate) HBs Ag or,  
xPositive IgM HBc Ab or 
xPositive total HBc Ab confirmed by [CONTACT_328727] 
E 34. Liver injury related criteria: 
xClinically significant/active  hepatobiliary disease or 
xAlanine Aminotransferase (ALT) >3 Upper Limit of Normal (ULN) 
E 35. Abnormal lab values at Screening: 
xCreatine phosphokinase (CPK) >[ADDRESS_405912] or 
xPlatelets <100,000 cells/mm3 or 
xEosinophils >1500 cells/mm3
7.2.4 Additional exclusion criteria during or at the end of screening
E 36. Patient who has withdrawn consen t before enrollment/randomization. 
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: [ADDRESS_405913](S)
8.1.1 Dupi[INVESTIGATOR_328677] 150 mg/mL in glass pre-filled 
syringe to deliver 300 mg in 2 mL and 175 mg/mL in  glass pre-filled syringe to deliver 200 mg in 
1.14 mL. 
8.1.2 Placebo
Sterile placebo for dupi[INVESTIGATOR_328678]-filled syringe to 
deliver 2 mL or 1.14 mL, which will match dup ilumab 300 mg (2 mL) and 200 mg (1.14 mL)
respectively. 
8.1.[ADDRESS_405914]
Dupi[INVESTIGATOR_208456]-filled syringes will be dispensed to the patients.
8.1.4 Dosing schedule
Two injections of IMP will be administered on Da y 1 at Visit 2 as a loading dose. Subsequently 
one injection of IMP will be given every 14 ¬± 3 da ys (q2w). The doses of investigational product 
PXVWEHVHSDUDWHGE\¬ïGD\VWRDYRLGDQRYHUGRVH
The Investigator or delegate will  train the patient (or caregiver(s )) how to prepare and inject IMP 
at Visit [ADDRESS_405915] of the 2 inje ctions. The patient (or car egiver(s)) will perform the 
second injection under the supervis ion of the Investigator or de legate. This training must be 
documented in the patient‚Äôs study file. At subsequent  study visits, patients ar e trained to self-inject 
IMP, and the patients are allowed to self-inject IM P at home after 6 injecti ons at investigational 
site, counting from Visit 3.
Patients should be instructed to avoid missi ng any doses of medicati on during the study. Any 
patient who misses one dose should be reminded to be  diligent, in order to avoid further missing 
doses thereafter. In case of missed dose(s) no load ing dose of [ADDRESS_405916] admini stration for any signs or symptoms of a 
hypersensitivity reaction.   
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: [ADDRESS_405917] information related to the 
injections. The diary will be kept as source data in the patient‚Äôs study file.  
If the patient (or caregiver) is un able or unwilling to administer IMP, arrangements must be made 
for qualified site personnel and/or health care professionals (eg, visiting nurse service) to 
administer IMP for the doses that are not sc heduled to be given at the study site.  
If the study visit is not performe d at the site as scheduled, the dose will be administered by [CONTACT_181250]/or their caregiver/h ealth care professional, or arra ngements must be made for an 
unscheduled visit at the site to administer the IMP. When IMP is administered at home, the 
patients must be advised by [CONTACT_181251] -monitor for potential signs and symptoms that 
may suggest a hypersensitivity reaction for at least 30 minutes after administration.
If the patient, or caregiver(s) do not develop the comfort to inject the investigational drug at home, 
or the Investigator determines that patient (or caregiver) injection at home is not appropriate, 
injections can be performed at the site by [CONTACT_181252]. 
Subcutaneous injection sites should be alte rnated among the 4 quadrants of the abdomen 
(avoiding navel and waist areas), th e upper thighs or the upper arms, s o that the same site is not 
injected twice consecutively. In jection in the upper arms could be done only by a trained person 
(Parent/ caregiver trained by [CONTACT_260123]) or heal th care professional but not the 
patient themselves. This instruction pertains to the day that the loading dose is injected as well as 
the administration of q2w injections. For each inj ection, the anatomic site of administration will 
be recorded in the electroni c case report form (e-CRF) and, as applicable, the home diary.  
Detailed instructions for transport, storage, prep aration, and administration of IMP are provided to 
the patient. Patients will complete a dosing diar y to document compliance with self-injection (or 
caregiver) injection of IMP.
8.[ADDRESS_405918](S)
8.2.[ADDRESS_405919] prior to screening. The controller drugs will 
not be dispensed or supplied by [CONTACT_456]. 
The recognized asthma controllers for the study w ill include the following 5 classes: ICS, LABA, 
LAMA, Anti-leukotrienes and methylxanthines.  Please refer to Appendix O for a list of 
commonly used asthma controller medication. 
[IP_ADDRESS] Screening period
Prior to screening, patients must be on a stab le background therapy of a medium to high dose of
ICS¬ïPFJRIIOXWLFDVRQHSURSLRQD WHWZLFHGDLO\RUHTXLSRWHQW, &6GDLO\GRVDJHWRD
maximum of 2000 mcg/day of fluticasone propi[INVESTIGATOR_328679]) [Note for Japan: subjects 
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: [ADDRESS_405920] be ¬ïPFJ of fluticasone propi[INVESTIGATOR_328680]; subjects aged [ADDRESS_405921] be ¬ï100 mcg of fluticasone  propi[INVESTIGATOR_328681]] in combination with a sec ond controller medication (Refer to Appendix O on 
the recognized controller medication class IRUDWOHDVWPRQWKVZLWKDVWDEOHGRVH¬ïPRQWKSULRU
to Visit 1. Patients requiring a th ird controller are allowed to pa rticipate in this study. The third 
controller should also be used for at least 3 months with a stable d RVH¬ïPRQWKSULRUWR9LVLW
1(patients requiring systemic ster oids as controller medication or  biologics are excluded). If 
patients take two different ICS, the total daily do se of ICS should be calculated to evaluate the 
eligibility criteria on daily dose of ICS which will  be still considered as one controller. Please 
refer to medium and high dose of ICS in Appe ndix B. The minimum daily dose of flucticasone 
SURSLRQDWHLVPFJ¬ïPFJRIIOXWLFDVRQHSURSLRQDW e twice daily), which is equal to the 
upper limit of medium daily dose for fluticasone pr opi[INVESTIGATOR_328682] B. For ICS 
other than fluticasone propi[INVESTIGATOR_16847] , please refer to the table in Appendix B which indicates the 
upper limit of the medium daily dose for each IC S which is equivalent to 500 mcg/day of 
fluticasone propi[INVESTIGATOR_16847].
If the Study Investigator based on his/her medical judgment, decides to optimize use of asthma 
medications prior to Visit [ADDRESS_405922] 1 
month prior to Visit 1.
[IP_ADDRESS] Randomized treatment period
During this period, patients will cont inue to take their controller  medication(s) used during the 
screening period. The dose and regimen should not be  changed. Only a transient increase in dose 
of ICS in addition to other rescue medication will  be allowed to treat acute symptoms of asthma 
as per investigator's guidance. This will be recorded in the eDiary.
[IP_ADDRESS] Post-treatment period
Upon completing the randomized treatment period , patients not continuing with the open label 
extension study will proceed to be  treated with the controller me dication regimen and dose used 
during the randomized treatment period, which coul d be adjusted based on the medical judgment 
of the investigator of the pa tients‚Äô asthma control status. 
8.2.2 Reliever medication
The reliever medication will not be dispensed or supplied by [CONTACT_456]. 
Patients may administer albuterol/salbutamol or levalbuterol/levosalbutamol MDI as reliever 
medication as needed during the study. Nebulizer so lutions may be used as an alternative delivery 
method.  
The description of the criterion for qualifying an asthma exacerbation event based on nebulizer 
using, will use the nebulizer-to-puff conversion fact or for application to loss of asthma control 
(LOAC) definition. 
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: 1 
Property of the [COMPANY_011] Group - Page 47Study personnel should convert salbutamol/albuter ol nebulizer and levosalbutamol/levalbuterol 
nebulizer use as shown on the following table:   
Salbutamol/Albuterol Nebulizer Solution -T otal Daily Dose (mg) Number of Puffs*
2.5 4
5.0 8
7.5 12
10 16
*Conversion factor:  salbutamol/a lbuterol nebulizer solution (2.5 mg) corresponds to 4 puffs
xExample of salbutamol/albuterol Nebuliz er-to-Puff Conversion: Patient received 3 
salbutamol/albuterol nebulizer treatments (2.5 mg/treatment) between 7 and 11 AM. Total 
daily = 7.5 mg ->12 puffs 
Levosalbutamol/Levalbuterol Nebulizer Solu tion  -Total Daily Dose (mg) Number of 
Puffs*
1.25 4
2.5 8
3.75 12
5 16
*Conversion factor:  levosalbutamol/le valbuterol nebulizer solution (1.25 mg) corresponds to 4 puffs
xExample of levosalbutamol/levalbuterol Nebuliz er-to-Puff Conversion: Patient received 3 
levosalbutamol/levalbuterol nebulizer treat ments (1.25 mg/treatment) between 7 and 11 
AM.  Total daily = 3.75 mg ->12 puffs.
Criterion used to specify an asthma exacerb ation event in eCRF based on nebulizer use:
After conversion of nebulizer-to- SXIILQHYHU\LQVWDQFHWKDWWKHQXPEHURISXIIVLV¬ïDGGLWLRQ DO
puffs of salbutamol/albuterol or levosalbutamo l/levalbuterol in a 24-hour period (compared to 
baseline) on 2 consecutive days, tick the ‚ÄúQua lifying criteria box‚Äù on the asthma exacerbation 
event .
All other reliever medications rather than albu terol/salbutamol or levalbuterol/levosalbutamol 
should be avoided. 
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: [ADDRESS_405923] the blind, each treatment kit of 2 mL (dupi[INVESTIGATOR_12458] / placebo) or 1.14 mL
(dupi[INVESTIGATOR_12458] / placebo) glass pre-filled syringes w ill be prepared such that the treatments 
(dupi[INVESTIGATOR_328683]) are identical and indistinguishable and 
will be labeled with a treatment kit number.  The randomized treatment kit number list will be 
generated by [CONTACT_13225].     
Both the patient and investigator will be blinde d to assigned active drug or placebo, but will not 
be blinded to the dose level of  dupi[INVESTIGATOR_71763] 300 mg/matching placebo or  dupi[INVESTIGATOR_12458] 
200 mg/matching placebo due to different  volume size (2 mL vs 1.14 mL).  
Study patients, Investigators, and study site pe rsonnel will not have access to the randomization 
(treatment codes) except under circum stances described in Section 8.3.2. 
8.3.2 Randomization code breaking during the study
In case of an adverse event (A E), the code should only be br oken in circumstances when 
knowledge of the IMP is require d for treating the patient.  
Code breaking can be performed at any time by [CONTACT_328728] (IVRS)/interact ive web response system (IWRS) and/or by [CONTACT_328729].   If the blind is broken, the Investigator 
should document the date, time of day and reason for code breaking.   
Subject withdrawal will only occur when the code break call is ma de at the site level, not the 
study level. This means that if the Emergenc y Unblinding transaction is performed by [CONTACT_1275] (ie, at the site level), then the subjec t will be withdrawn from treatment. However, if 
the Emergency Unblinding transaction is performed by [CONTACT_125460] (GSO) (ie, at the 
study level, as the GSO is not site based), then the subject will not be withdrawn from treatment.
At the facilities where the systemic drug con centration measurements, anti-drug antibodies and 
selected biomarkers are determined, the samples will be analyzed prior to data base lock leading to unblinding of responsible bioanalysts. Bioana lysts are excluded from the clinical trial team.
Patients, investigators and site personnel will not have access to assay results for 
immunoglobulins (IgG, IgG subclasses, IgA and Ig M) after the first administration of study 
medication because these values have the potential for unblinding.  Furthermore, neither patients, investigators nor site personnel will have access to eotaxin-3, antigen-specific IgE, total IgE, 
Eosinophil Cationic Protein (ECP),  TARC or periostin while the study is ongoing, as the related 
data are not essential for patient care and have the potential for unblinding. 
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: 1 
Property of the [COMPANY_011] Group - Page 49The Data Monitoring Committee will receive blinded by [CONTACT_181259] (if 
necessary) confidential reports fr om an independent st atistician for review, which have to be 
handled  None of these reports can be delivered to una uthorized persons. 
8.[ADDRESS_405924] (dupi[INVESTIGATOR_24885]) will be p ackaged in accordance with this list.
The [COMPANY_011] Clinical Supplies team will provide the randomized treatment kit number list and the 
Study Biostatistician will provid e the randomization scheme to  the centrali zed treatment 
allocation system. This centralized treatment allocation system will generate the patient randomization list according to which it will  allocate the treatments to the patients.
Patients who meet the entry crite ria will be randomized to rece ive either dupi[INVESTIGATOR_24885].  
Patients who meet exclusion criteria may be re-s creened once during the open screening period of 
the study; a different patient identification will be issued. Re-screening is not permitted if the 
patient fails to meet inclusion criteria. There is  no requirement for a waiting period between the 
screen-failure date and the re-screening date . The IVRS/IWRS report will flag re-screened 
patients. Patients that are re-screened must si gn a new consent form and all Visit [ADDRESS_405925] be repeated.  
The Investigator obtains treatmen t kit numbers at randomization a nd subsequent scheduled visits 
via an Interactive Voice Res ponse System/Interactive Web Response System (IVRS/IWRS) that 
will be available 24 hours a day.   
Patients will be randomized using a 2:2:1:1 randomization ratio for dupi[INVESTIGATOR_12458] 300 mg q2w, 
dupi[INVESTIGATOR_12458] 200 mg q2w, placebo q2w in 2 mL and placebo q2w in 1.14 mL. Randomization will 
EHVWUDWLILHGE\DJH \HDUV¬ï\HDUV at screening, central eosi nophil count (<300 cells/ ŒºL,
¬ï300 cells/ ŒºL) at screening, ICS dose level (medium, high) and country.  
A randomized patient is defined as  a patient who is registered a nd assigned with a treatment kit 
number from the centralized tr eatment allocation system, as documented from its log file. A 
patient cannot be randomized mo re than once in the study. 
8.5 PACKAGING AND LABELING
Dupi[INVESTIGATOR_328684]-filled syringe packed in a patient kit 
box.  Both glass pre-filled syringe and box will be labeled.  
Packaging is in accordance with the administratio n schedule. The content of the labeling is in 
accordance with the local regulatory  specifications and requirements. 
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: 1 
Property of the [COMPANY_011] Group - Page 508.6 STORAGE CONDITIONS AND SHELF LIFE
All investigational prod ucts should be stored at a temper ature between 2¬∞C and 8¬∞C in an 
appropriate, locked room under the responsibility of  the Investigator or other authorized persons 
(eg, pharmacists) in accordance with local  regulations, policie s and procedures.  
Control of investigational pr oduct storage conditions, especia lly control of temperature 
(eg, refrigerated storage) and information on in-u se stability and instru ctions for handling the 
[COMPANY_011] compound should be managed according to the rules provided by [CONTACT_1034]. 
8.[ADDRESS_405926], or other personnel allo wed to store and dispense the 
IMP will be responsible for ensuring that the IMP used  in the clinical trial is securely maintained 
as specified by [CONTACT_328730]. 
All IMPs will be dispensed in accordance with th e Investigator's prescription and it is the 
Investigator's responsibility to en sure that an accurate record of IMP issued and returned is 
maintained. 
Any quality issue noticed with the receipt or use of an IMP (deficiency in condition, appearance, 
pertaining documentation, labeling, expi[INVESTIGATOR_320], etc) should be promptly notified to the 
Sponsor. Some deficiencies may be r ecorded through a complaint procedure. 
A potential defect in the quality of IMP may be s ubject to initiation of a recall procedure by [CONTACT_429]. In this case, the Invest igator will be responsible for promptly addressing any request 
made by [CONTACT_1034], in order to reca ll IMP and eliminate potential hazards. 
Under no circumstances will the Investigator supply  IMP to a third party, to allow the IMP to be 
used other than as directed by [CONTACT_328731] l protocol, or dispose of IMP in any other manner. 
8.7.1 Treatment accountability and compliance
Measures taken to ensure and document treatme nt compliance and IMP accountability include: 
xProper recording of treatment kit number as  required on appropriate e-CRF page for 
accounting purposes; 
xAll medication treatment kits (whether empty or unused) are returned by [CONTACT_181261] a treatment dispensing is planned. 
- The completed patient injection diary (return ed to the site at each visit), returned 
treatment kit boxes and any unused pref illed syringes will be used for drug 
accountability purposes. 
xThe Investigator or designee tracks treatme nt accountability/complia nce, either by [CONTACT_155668], 
or by [CONTACT_328732].
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: 1 
Property of the [COMPANY_011] Group - Page 51The monitor in charge of the study then checks the data entered on the IMP administration page 
by [CONTACT_328733]. 
8.7.2 Return and/or destruction of treatments
All partially used or unused trea tment kits will be retrieved by [CONTACT_328734]. All used prefilled syringes should be kept in  a sharp container by [CONTACT_328735]. The Investigator will not destroy any unused IMP unless the Sponsor provides 
written authorization.  
A detailed treatment log of the destroyed IMP will  be established with the Investigator (or the
pharmacist) and countersigned by [CONTACT_737] a nd the monitoring team. The Investigator will 
not destroy the unused IMP unless the S ponsor provides writte n authorization. 
For non-investigational medicinal product not provided by [CONTACT_1034], tracking and 
reconciliation has to be achieved by [CONTACT_328736] (eg, medical notes). 
8.8 CONCOMITANT MEDICATION
A concomitant medication is any treatment received by [CONTACT_56449](s).
8.8.1 Prohibited Concomitant Medication
The following concomitant treatments are not permitted during the Screening Period or the Randomized Treatment Period:
xSystemic steroids (systemic steroids can only be used to treat an asthma exacerbation, and 
are not allowed to be used for other conditions from [ADDRESS_405927] eroids and are not allowed to 
be used in the above mentioned period.) 
xAnti-immunoglobulin E (IgE) ther apy (eg, omalizumab, is not allowed to be used from 
130 days prior to Visit 1, or during the sc reening period or the randomized treatment 
period) 
xBiologic therapy (Biologic therapy is not allowe d to be used from [ADDRESS_405928] 5 
half-lives prior to Visit 1, whichever is longer, or during the sc reening period or the 
randomized treatment period).
xSystemic immunosuppressant (immunosuppressant s are not allowed to be used from [ADDRESS_405929] 5 half-lives prior to Vis it 1, whichever is longer, or during the screening 
period or the randomized treatment period) 
xAllergen immunotherapy (except if initiated more than 3 months prior to Visit 1 and dose 
stabled 1 month prior to Visit 1) 
xBronchial thermoplasty
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: 1 
Property of the [COMPANY_011] Group - Page 52xIntravenous immunoglobu lin (IVIG) therapy 
xLive Attenuated Vaccines:  refer to Appendix A
xBeta-adrenergic receptor blockers (except fo r a selective beta-1 adrenergic receptor 
blocker used with dose stab led 1 month prior to Visit 1)
xAsthma relievers other than salbutamol/albuterol or levosalbutamol/levalbuterol: their use 
is not recommended during the study period. In  case of use in exceptional circumstances 
(eg, prescribed by a physician not participating in the study), their use will be documented 
in the patient's file and reported in the eCRF. 
xOther investigational drugs
8.8.2  Permitted concomitant medication
xAntihistamines are permitted as concomitant medication.
xTopi[INVESTIGATOR_2855], ocular or intranasal corticosteroids are permitted during the study.
CYP substrates :
The impact of dupi[INVESTIGATOR_181193] P450 (CYP ) enzyme activity has not been studied and 
the effect of dupi[INVESTIGATOR_181194]-4 and IL-13 has not been fully characterized. However, 
interleukin-4 (IL-4) was reported to upre gulate CYP2E1, 2B6, 3A4 mRNA expression or 
downregulate CYP1A2 mRNA (4), (5). Huma n peripheral blood mononu clear cells (PBMC) 
incubated with various Th2 cytokines showed that  IL-4 and IL-13 increased mRNA expression of 
CYP2B6 and CYP3A4 (6).  Since the clinical sign ificance of the limited in vitro findings for IL-[ADDRESS_405930] a narrow 
therapeutic index.  This means that close clin ical observation and/or laboratory monitoring as 
applicable are required in order to enable earl y detection of toxic manifestations or lack of 
activity/efficacy of these drugs, followed by [CONTACT_328737] (4), (5),
(6). Some examples of CYP450 substrates w ith narrow therapeutic index are provided in 
Appendix C.
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: [ADDRESS_405931]
9.1 PRIMARY ENDPOINT
9.1.1 Primary endpoints  
There are two primary endpoints for this study, the annualized rate of seve re exacerbation events 
during the 52-week placebo-controlled treatment period and the absolute change from baseline in
pre-bronchodilator FEV 1at week 12.
[IP_ADDRESS] Asthma exacerbation events
Two types of asthma exacerbation events are defined:
A severe exacerbation event during the study is defi ned as a deterioration of asthma requiring: 
x8VHRIV\VWHPLFFRUWLFRVWHURLGVIRU¬ïGD\V ; or 
xHospi[INVESTIGATOR_328645], requiring systemic 
corticosteroids 
A loss of asthma control (LOAC) event during th e study is defined as any of the following: 
x¬ïDGGLWLRQDOUHOLHYHU SXIIVRIVDOEXWDPRODOEXWHURORUOHYRVDO EXWamol/levalbuterol in a 
24 hour period (compared to baseline) on 2 consecutive days;  
x¬ï decrease in pre-bronchodilator FE V1 compared with baseline;  
x,QFUHDVHLQ,&6GRVH¬ïWLPHVWKDQWKHGRVHDW9LVLW ; 
xA decrease in AM or PM peak flow of 30% or more on [ADDRESS_405932] 7 days prior to randomization
(Day1);
xSevere exacerbation event 
Two events will be considered as different if th e interval between their start dates is equal or 
greater than 28 days. 
The reasons (ex, infections including viral and bacter ial, allergen exposure, exercise and others) of 
the exacerbation events will be collected in eCRF .
9.2 SECONDARY ENDPOINT(S) 
Key secondary Endpoints:
xPercent change from baselin e in pre-bronchodilator FEV 1at Week 12 
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: 1 
Property of the [COMPANY_011] Group - Page 549.2.1 Efficacy endpoints
xAnnualized rate of severe exacerbations ev ents during the 52-week placebo-controlled 
treatment period for patients with a baseline blood eosinophil count ¬ïJLJD/
xAbsolute change from baselin e in pre-bronchodilator FEV 1at Week 12 in patients with a 
baselineEORRGHRVLQRSKLOFRXQW¬ï 0.3 giga/L 
xPercent change from baselin e in pre-bronchodilator FEV 1at Week 12 in patients with a 
baseline blood eosinophil c RXQW¬ï 0.3 giga/L 
xAnnualized rate of severe exacerbations ev ents during the 52-week placebo-controlled 
treatment period for patients on high dose of ICS 
xAbsolute change from baselin e in pre-bronchodilator FEV 1at Week 12 in patients on high 
dose of ICS 
xPercent change from baselin e in pre-bronchodilator FEV 1at Week 12 in patients on high 
dose of ICS 
xAnnualized rate of severe exacerbations ev ents during the 52-week placebo-controlled 
WUHDWPHQWSHULRGIRUSDWLHQWVZLWKDEDVHOLQHEORRGHRVLQRSKLO FRXQW¬ïJ iga/L 
xAbsolute change from baselin e in pre-bronchodilator FEV 1at Week 12 in patients with a 
EDVHOLQHEORRGHRVL QRSKLOFRXQW¬ïJLJD/
xPercent change from baselin e in pre-bronchodilator FEV 1at Week 12 in patients with a 
baseline blood eosinophil count ¬ï0.15 giga/L 
xAbsolute change from baselin e in pre-bronchodilator FEV 1 at Weeks 2, 4, 8, 24, 36, and 
52
xPercent change from baselin e in pre-bronchodilator FEV 1 at Weeks 2, 4, 8, 24, 36, and 52 
xChange from baseline in other lung f unction measurements (% predicted FEV 1, morning 
[AM]/evening [PM] peak expi[INVESTIGATOR_328685] [PEF], forced v ital capacity [FVC], forced 
expi[INVESTIGATOR_10229] [FEF]25-75%, post-bronchodilator FEV 1 at Weeks 2, 4, 8, 12, 24, 36, and 
52
xAnnualized rate of loss of asthma contro l (LOAC) event during the 52-week placebo-
controlled treatment period 
xAnnualized rate of severe exacerbation events  resulting in hospi[INVESTIGATOR_328686] 52-week pl acebo-controlled treatment period
xTime to first severe exacerbation event 
xTime to first loss of asthma control event (LOAC) 
xChange from baseline in Asthma Control Questionnaire (ACQ)-5 score and ACQ-7 score 
at Weeks 2, 4, 8, 12, 24, 36, and 52 
xChange from baseline at Weeks 2, 4, 8 12, 24, 36, and 52 in: 
-Morning/evening asthma symptom score and nocturnal awakenings (e-diary) 
-Use of daily puffs of rescue medication
xChange from baseline in Health care re source utilization at  Weeks 12, 24, 36, and 52. 
xChange from baseline in PROs at Week 12, 24, 36, and 52: 
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: 1 
Property of the [COMPANY_011] Group - Page 55-Asthma Quality Of Life Questionnaire with  Standardized Activities (AQLQ (S)) Self-
Administered ¬ï\HDUV
-European Quality of Life Working Group Health Status Measure 5 Dimensions, 5 
Levels (EQ-5D-5L) 
-Hospi[INVESTIGATOR_5620] (HADS) 
-22-item Sino Nasal Outcome Test (SNOT-22) in those patients with comorbid bilateral 
nasal polyposis and/or ch ronic rhinosinusitis 
- Standardized Rhinoconjunctivitis Quality Of Life Questionnaire, ages 12+ 
(RQLQ(S)+12) in those patients with comorbid allergic rhinitis
[IP_ADDRESS] Disease-specific efficacy measures 
[IP_ADDRESS].1 Spi[INVESTIGATOR_038] 
A spi[INVESTIGATOR_181198] 2005 American T horacic Society (ATS) / European Respi[INVESTIGATOR_16362] (ERS) recommendations will be used. Spi[INVESTIGATOR_328687]/ ERS guidelines (7). For pre-br onchodilator measured pa rameters, including FEV 1,
PEF, FVC and FEF 25-75%, spi[INVESTIGATOR_208460] a wash out period of 
bronchodilators according to their action duration, for example, withholding the last dose of 
salbutamol/albuterol or levosalbut amol/levalbuterol for at least [ADDRESS_405933] 12 hours (ultra-long acti ng LABA like vilanterol should be withheld for 
at least 24 hours) and withholding the last dose of LAMA for at least [ADDRESS_405934] spi[INVESTIGATOR_328688], including calibration, wi ll be used to perform spi[INVESTIGATOR_328689], whenever 
possible, the same person should perform the measurements.  
Pulmonary function tests will be measured in th e sitting position; however, if necessary to 
undertake the testing with the subject standing or in another position, this should be noted on the 
spi[INVESTIGATOR_125377]. For any subject, the posit ion should be consistent throughout the study. 
Three measurements fulfilling the ATS acceptability and repeatability criter ia should be obtained 
at every visit, if possible. The acceptability cr iteria must be applied before the repeatability 
criteria. Unacceptable maneuvers must be discarded before applying the repeat ability criteria. If a 
subject fails to provide repeat able and/or acceptable maneuvers, an explanation should be 
recorded.  
The largest FEV [ADDRESS_405935] FVC should be recorded after the data are examined from all of the 
acceptable curves, even if they do not come from  the same curve. The FEF 25-75% should be 
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: [ADDRESS_405936] sum of 
FVC plus FEV 1(best test).
Automated best efforts, which combine FEV 1and FVC are not acceptable.
The spi[INVESTIGATOR_328690]/ERS guidelines every day
that a study subject is seen and sp irometry is carried out. The calibra tion records should be kept in 
a reviewable log. It is preferred th at the calibration equipment (ie, 3-liter syringe) that is used to 
calibrate the spi[INVESTIGATOR_125379] a vali dated calibration according to the manufacturer‚Äôs 
specifications.
Spi[INVESTIGATOR_328691]. Further details on spi[INVESTIGATOR_181203] a separate operational manual providedto the sites.
[IP_ADDRESS].2 Reversibility/Post-bronchodilator FEV [ADDRESS_405937] been withheld for the appropriate  intervals. Subjects will receive two to up to 
four puffs of albuterol/salbutamol or levalb uterol/levosalbutamol from a primed MDI. 
Alternatively and only if it is  consistent with usual offi ce practice (to be documented), 
reversibility may be performed using inhala tion of nebulized albuterol/salbutamol or 
levalbuterol/levosalbutamol. Spi[INVESTIGATOR_328692] 30 minutes after 
administration of bronchodilator. Re versibility, which is defined as an increase in absolute FEV 1
of 12% over the baseline value, with an abso lute increase of at least [ADDRESS_405938] does not meet the 
reversibility at Visit 1, up to 3 assessments can  be performed at any time during the screening 
period until the Baseline Visit (Visit 2).Whene ver the reversibility was repeated, the pre-
bronchodilator FEV 1 should again meet the inclusion criteria of ¬î of predicted normal for 
DGXOWVDQG¬î % of predicted normal for adolescents. 
For post-bronchodilator FEV 1, the measure should follow the step s as that at screening test for 
reversibility validation. If other attempt for reversibil ity test was performed at Baseline visit, then 
the post-bronchodilator FEV 1will come from the result of this reversibility test.
[IP_ADDRESS].3 ACQ (Asthma Control Questionnaire)
The ACQ was designed to measure both the adequ acy of asthma control and change in asthma
control which occurs either spontaneo usly or as a result of treatment. 
[IP_ADDRESS].3.1 ACQ-7 (Asthma Control Questionnaire, 7-question version)
The ACQ-[ADDRESS_405939] common asthma symptoms: 
1. frequency in past week awoken by [CONTACT_125470], 2. severity of asthma symptoms in 
the morning, 3. limitation of daily ac tivities due to asthma, 4. shortn ess of breath due to asthma 
and 5. wheeze, plus 6. short-acti ng bronchodilator use and 7. FEV 1(pre-bronchodilator use, % 
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: 1 
Property of the [COMPANY_011] Group - Page 57and % predicted use). Patients are asked to recall how their asthma has been during the previous 
week and to respond to the symptom questions  on a 7-point scale (0=no impairment, 6= 
maximum impairment) (see Appendix D).
Clinic staff scores the FEV 1% predicted on a 7-point scale. Th e questions are equally weighted 
and the ACQ score is the mean of the 7 questions and therefore between 0 (t otally controlled) and 
6 (severely uncontrolled).
A global score is calculated: the questions are eq ually weighted and the ACQ-7 score is the mean 
of the 7 questions and, therefore, between 0 (tot ally controlled) and 6 (severely uncontrolled). 
Higher score indicates lower asthma control. Pati ents with a score below 1.[ADDRESS_405940] change that 
can be considered clinically important, corr esponding to the Minimal Clinically Important 
Difference (MCID) defined by [CONTACT_125471].
Measurement properties such as reliability and abili ty to detect change have been documented in 
the literature (8). 
The ACQ-[ADDRESS_405941].
[IP_ADDRESS].3.2 ACQ-5 (Asthma Control Questionnaire, 5-question version)
The ACQ-[ADDRESS_405942] 5 questions and, 
therefore, between 0 (totally controlled) and 6 (severely uncontrolled).  Higher score indicates 
lower asthma control. Patients w ith a score below 1.[ADDRESS_405943] change that can be considered 
clinically important, corresponding to the Mini mal Clinically Important Difference (MCID) 
defined by [CONTACT_125471]. 
Measurement properties such as reliability and abili ty to detect change have been documented in 
the literature (9). 
[IP_ADDRESS] Disease-specific, daily efficacy assessments
[IP_ADDRESS].1 Electronic diary/ PEF meter  
On a daily basis throughout the study, the pati ent uses an electronic diary / PEF meter to:
xMeasure morning and evening PEF 
xRespond to the morning and evening asthma symptom scale questions 
xIndicate the number of inhalations /day of salbutamol/albuterol or 
levosalbutamol/levalbuterol for symptom relief
xRecord the number of inhalati ons/day of background product used 
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: [ADDRESS_405944] oral steroids use for exacerbation event 
At screening (Visit 1), patients will be issued an el ectronic diary/PEF. Patients will be instructed 
on the use of the device, and written instructions  on the use of the electronic PEF meter will be 
provided to the patients. In additi on, the investigator will instruct the patients on how to record the 
following variables in the electronic PEF meter: 
xAM PEF performed within 15 minut es after arising (between 5:30 AM and 12:00 PM) prior 
to taking any albuterol/salbutamol  or levalbuterol/levosalbutamol 
xPM PEF performed in the evening (between 5:30 PM and 12 A M) prior to taking any 
albuterol/salbutamol or leva lbuterol/levosalbutamol  
xPatients should try to withhold albuterol/salbut amol or levalbuterol/levosalbutamol for at 
least 6 hours prior to  measuring their PEF 
xThree PEF efforts will be performed by [CONTACT_42036]; all [ADDRESS_405945] 4 days‚Äô measurement for setting up the stab ility limit, and the first dosing visit should be 
rescheduled until data for 4 days are available. 
Information derived from the electronic PEF meter will be evaluated by [CONTACT_181268].   
[IP_ADDRESS].2 Asthma Symptom Score Numerical Rating Scale (NRS)
Patients will record overall symptom scores in an  electronic diary/PEF meter twice a day prior to 
measuring PEF. The patient‚Äôs overall asthma symptoms experienced during the waking hours will be recorded in the evening (PM symptom score) . Baseline symptom scores will be the mean AM 
and mean PM scores recorded for the 7 days  prior to randomization. The baseline AM/PM 
symptom score will be computed following the same algorithm used for baseline AM/PM PEF. 
Scores range between 0-[ADDRESS_405946] an AM score and a PM score. An MCID of 0.35 is being 
used (10) (see Appendix E). 
[IP_ADDRESS].3 Use of rescue medicine
The number of salbutamol/albuterol or levosalbu tamol/levalbuterol inhalations will be recorded 
daily by [CONTACT_328738]/PEF meter. Each pa tient should be reminded that 
salbutamol/albuterol or levosalbut amol/levalbuterol should be used only as needed for symptoms, 
not on a regular basis or prophylactically. The baseline number of salbutamol/albuterol or 
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: 1 
Property of the [COMPANY_011] Group - Page 59levosalbutamol/levalbuterol inhalations/day will be based on the mean of the 7 days prior to 
randomization.  
[IP_ADDRESS] Health care resource utilization
A questionnaire of health care resource utili zation (reliever medica tion, specialist visit, 
hospi[INVESTIGATOR_059], emergency or urgent medical care f acility visit, outcome, sick leaves, school days‚Äô 
loss, etc) will be administered at Visit 2 and every 4 weeks thereafter. 
[IP_ADDRESS] Patient-reported outcomes
Patients should complete the following PROs before spi[INVESTIGATOR_328693]. 
[IP_ADDRESS].1 Asthma Quality of Life Questionnaire (AQLQ (S)
The AQLQ (S) was designed as a self-administere d patient reported outcome to measure the 
functional impairments that are most troublesome to patients as a result of their asthma (seeAppendix F). The instrument is comprised of 32 ite ms, each rated on a 7-point Likert scales from 
1 to 7. The AQLQ(S) has 4 domains. The domains and the number of items in each domain are as 
follows: 
xSymptoms (12 items)
xActivity limitation (11 items)
xEmotional function (5 items) 
xEnvironmental Stimuli (4 items) 
A global score is calculated ranging from 1 to 7 and a score by [CONTACT_121982]. Higher scores indicate 
better quality of life.
The instrument has been used in many clinical tr ials, and it has been shown to be reliable, valid 
(patient interviews), and sensitive to change. The MCID for AQLQ(S) is 0.5 (11). 
[IP_ADDRESS].[ADDRESS_405947] in those patients comorbid with bilateral nasal 
polyposis and/or chronic rhinosinusitis
SNOT-[ADDRESS_405948] of chronic rhin osinusitis on health-
related quality of life (see Appendix G). The SN OT-22 has 22 items, 5 domains and a global 
score. The 5 domains include Nasa l (range 0-30) with MID of -2.5, Ear (range 0-15) with MID of 
-1.25, Sleep (0-20) with MID of  -1.67, General and Practical (0 -30) with MID of -2.50, and 
Emotional (0-15) with MID of -1.25. The range of the global score is 0-110 and an MID (the 
smallest difference between clinical trial arms mean change from baseline [point estimates] that 
will be interpreted as important) of 8.9 (12). Lo wer scores indicate less impact and the recall 
period is past 2 weeks. 
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: 1 
Property of the [COMPANY_011] Group - Page [IP_ADDRESS].[ADDRESS_405949] states of anxiety and depression alre ady used and validated 
in asthma, which includes HADS-A and HADS-D subscales (see Appendix H). The instrument is 
comprised of 14 items: 7 related to anxiety and 7 to depression. Each item on the questionnaire is 
scored from 0-3; one can score between 0 and 21 for either anxiety or depression. 
The HADS was found to perform well in assessi ng anxiety disorders a nd depression in both 
somatic and psychiatric cases and (not only in hosp ital practice for which it was first designed) in 
primary care patients and the general population (13). The MID for the HADS-A (anxiety) has 
been reported to be in the range of 0.41 (anxious  and depressed subjects in active treatment 
controlled studies) to 1.32 (COPD patients), in the range of 0.50 (anxious and depressed subjects 
in active treatment controlled studies) to 1.40 (COPD patients) for HADS-D (depression) and 
approximately 1.5 (COPD patients) for the HADS Total score (14, 15) 
Alternatively, a significant improvement in treatme nt versus placebo group was defined as the %
of subjects who moved from a defined category of moderate to severe d HSUHVVLRQRUDQ[LHW\¬ïWR
not having the disease (<8) (16). Using this me thodology Stelara (Ustekinumab) was able to make 
the claim in summary of product characteristics that ‚ÄúHADS was significantly improved in the 
treatment group compared with placebo‚Äù (17).
[IP_ADDRESS].4 EQ-5D-5L 
EQ-5D-5L is a standardized heal th-related quality of life ques tionnaire developed by [CONTACT_185250] a simple, generic measur e of health for clinical and economic appraisal 
(18). EQ-5D is designed for self-completion by [CONTACT_1962]. 
The EQ-5D essentially consists of 2 pages ‚Äì th e EQ-5D descriptive system and the EQ VAS (see
Appendix I). The EQ-5D descriptiv e system comprises 5 dimensions : mobility, self-care, usual 
activities, pain/discomfort and a nxiety/depression. Each dimension has 5 levels: no problems, 
slight problems, moderate probl ems, severe problems, and extreme problems. The EQ Visual 
Analogue Scale (VAS) records the respondent‚Äôs se lf-rated health on a vert ical visual analogue 
scale. The EQ VAS ‚Äòthermometer‚Äô has endpoints of 100 (Best imaginable health state) at the top 
and 0 (Worst imaginable health state) at the bo ttom. The MCID for the EQ-5D in asthma patients 
has been reported to be in the range of .001 to 0.074 (19, 20)  
[IP_ADDRESS].5 Standardized Rhinoconjunctivitis Quality Of Life Questionnaire (RQLQ(S))+12 in those 
patients with comorbid allergic rhinitis. 
RQLQ(S)+12 (see Appendix J) is a self-administe red questionnaire with standardized activities 
developed to measure health-related quality of life signs and symptoms that are most problematic 
in those 12 to 75 years of age, as a result of pere nnial or seasonal allergic rhinitis. There are 28 
items on the RQLQ(S) in 7 domains: 1. Activities (3 items), 2. Sleep (3 items), 3. Non-Hay Fever 
Symptoms (7 items), 4. Practical Problems (3 items), 5. Nasal Symptoms (4 items), 5. Eye 
Symptoms (4 items) and 7. Emotional (4 items) . The RQLQ(S)+12 responses are based on 7-point 
Likert scale with responses rangi ng from 0 (not troubled) to 6 (ext remely troubled). Higher scores 
indicated more health-related qua lity of life impairment (lower scores better). The instrument 
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: 1 
Property of the [COMPANY_011] Group - Page 61takes approximately 7 minutes to complete. An MI D of 0.5 has been established as the minimal 
important difference indicative of a c linically meaningful change (21).
9.2.2 Safety and tolerability endpoints
The same safety assessments will be applied ac ross all arms.  Adverse events, including serious 
adverse events (SAEs) and adverse events of spec ial interest (AESI), will  be collected at every 
visit. The Investigator will ask the patient how he /she has felt since the last study visit. The study 
specific and general safety criter ia are detailed in Section 10.4.1. To assure the continuing safety 
of patients in this study, an independent DMC will be responsible for reviewing the safety data on 
a periodic basis throughout the course of the study as outlined in Section 6.4.
Safety observations 
xThe Investigator should take a ll appropriate measures to ensure  the safety of the patients. 
Notably, he/she should follow up the outcome of  SAEs /AESI until clin ical recovery is 
complete and laboratory results have returned to normal or until progression has been 
stabilized or death. In all cases, this may im ply that observations will continue beyond the 
last planned visit per protocol , and that additional investigat ions may be requested by [CONTACT_429]. 
xWhen treatment is prematurely discontinued, the patient‚Äôs observations will continue until 
the end of the study as defined by [CONTACT_56485]. 
xIn case of any SAE/AESI with immediate no tification brought to th e attention of the 
Investigator at any time after the end of the study for the patient and considered by [CONTACT_12552]/her 
to be caused by [CONTACT_7198] w ith a reasonable possibility, this should be 
reported to the Sponsor. 
[IP_ADDRESS] Adverse events
Adverse events for each patient will be monitore d and documented from the time the subject gives 
informed consent at Visit 1 until the End-of Study Visit or till the rollove r to the extension study,  
except for: 
xSAEs 
xAEs that are ongoing at database lock.
Adverse events, adverse events with special inte rest (AESI) and serious adverse events (SAEs) 
will be reported as described in Section 10.4.
[IP_ADDRESS] Vital signs
Vital signs, including blood pressu re (mmHg), heart rate (beats per minute), respi[INVESTIGATOR_697] 
(breaths per minute), body temperature (degrees Ce lsius), body weight (kg) and height (cm) will 
be measured. Vital signs will be measured in the sitting position using the same arm at each visit, 
and will be measured prior to rece iving investigational product at th e clinic visits if applicable.  
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: 1 
Property of the [COMPANY_011] Group - Page [IP_ADDRESS] Physical examination
Physical examinations will include an asse ssment of general appearance, skin, eyes, 
ear/nose/throat, heart, chest, abdomen, reflex es, lymph nodes, spi[INVESTIGATOR_050], and extremities. All 
deviations from normal will be recorded, including those attributable to the patient‚Äôs disease.  
[IP_ADDRESS] ECG
One recording of a standard 12-lead ECG will be  performed centrally. At the post-randomization 
visits, ECGs will be performed prior to investigational product administration if applicable.  A 
minimum of 3 complexes in an appropriate lead (lead II) will be averaged to determine the PR-
interval, QT/QTc-interval, QRS-complex and heart rate will be measured for each ECG. All ECG 
recordings will be centrally read by [CONTACT_208548]. Refer to central ECG reading manual for 
more details.
[IP_ADDRESS] Clinical laboratory tests
The clinical laboratory tests will  be conducted by [CONTACT_181271] (College of American Pathologists 
or equivalent) central laboratory  with national and re gional clinical licens es as required for 
diagnostic testing and must provide evidence of  participation in proficiency testing, as 
appropriate. After reviewing the laboratory report and evaluating any results that are outside the 
normal range, the Investigator must sign and da te the laboratory report. Abnormal laboratory 
values that are considered to be clinically si gnificant by [CONTACT_328739] e laboratory report to rule ou t laboratory error. Persistent 
abnormal laboratory values should be repeated until they return to normal or until an etiology of 
the persistent abnormality is determined.
The clinical laboratory parameters that will be measured are:
xHematology: To include hemoglobin, hematocr it, platelet count, total white blood cell 
count with five-part differential count, diffe rential count, and total red blood cell count. 
xSerum chemistry: To include: creatinine, bl ood urea nitrogen, glucose,  uric acid, total 
cholesterol, total protein, albumin, total bi lirubin (in case of values above the normal 
range, differentiation in conjugated a nd non-conjugated bilirubin), alanine 
aminotransferase, aspartate aminotransfera se, alkaline phosphatase, lactate dehydrogenase,
electrolytes (sodium, potassium, chloride), bicarbonate, and crea tine phosphokinase. The 
blood sample must be taken with the patient in  fasting state which means no intake of any 
food or drink except for water for at least 8 hours (If the visit can only be done at a 
different time of the day and the patient is not  fasting, then he/she should be advised to eat 
light food and the site shoul d document that serum chemistry was not obtained under 
fasting conditions). 
xUrine dipstick analysis including specific gr avity, pH, glucose, ketones, blood, protein, 
nitrite, leukocyte estera se, urobilinogen and bilirubin (by [CONTACT_328740]).  If any assessment on 
the dipstick is abnormal, a urine sample should be  sent to the central laboratory for testing. 
If positive for proteins, microscopic analysis  is performed by [CONTACT_12115].  
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: 1 
Property of the [COMPANY_011] Group - Page 63xSerum immunoglobulins: quantitative immunoassa ys for total IgG, IgG subclasses 1-4, 
IgM, and IgA.  
xHepatitis screening: HBs Ag, HBs Ab, HBc Ab including HBcAb IgM and total, HCV Ab. 
In case of results showing HBs Ag (negative) and HBc Ab total (positive), a HBV DNA testing must be performed prior to randomizatio n to determine eligibility. In case of results 
showing HCV Ab (positive), a HCV RNA testing must be performed prior to 
randomization to determine eligibility.
xHIV screening (Anti-HIV-1 and HIV-2 antibodies)  
xAnti-nuclear antibody (ANA). Note: Anti-ds  DNA antibody will be tested if ANA is 
SRVLWLYH¬ïWLWHU
Decision trees for the management of certain laboratory abnormalities by [CONTACT_326926] K.
[IP_ADDRESS] Hepatitis B viral load
Hepatitis B viral load (HBV DNA) must be tested  at Visit 1 and Visit 17  (only applicable for 
patients who plan to participate in the OLE study)  in case of results showing HBs Ag (negative), 
HBs Ab (negative or positive) and HBc Ab total (positive), refer to Section [IP_ADDRESS] for details.  
In Japan or other countries/regions  if there is local regulatory requirement, hepatitis B viral load 
(HBV DNA) will be tested at Vi sit 2, then every 12 weeks until Visit 14 and at end of treatment 
visit for patients who are HBs Ag negativ e and HBs Ab positive at screening.   
[IP_ADDRESS] Pregnancy test
$VHUXPSUHJQDQF\WHVW»ï -human chorionic gonadotrophin) will be performed at screening 
(Visit 1) in women of childbear ing potential, and a urine dips tick pregnancy test will be 
performed at Visit [ADDRESS_405950] be obtained at 
Visit 1 and 2 prior to randomization.  
9.3 OTHER ENDPOINTS
9.3.1 Systemic drug concentration and anti-drug antibodies
[IP_ADDRESS] Sampling time
Serum samples for determination of functiona l dupi[INVESTIGATOR_181159]-dupi[INVESTIGATOR_328694] (also 
known as anti-drug antibodies (ADA)) will be collect ed as per study flow chart (see Section 1.2
and Section 1.3). The date of collection should be  recorded in the patien t e-CRF.  The date and 
time also will be collected on the central laborator y requisition form and entered into the database 
through data transfers from the cen tral laboratory. Patients who di scontinue early from treatment 
or patients who choose not to par ticipate in the long term extensio n study may be asked to return 
to the clinic to have additional ADA samples collected for analysis based on the overall
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: 1 
Property of the [COMPANY_011] Group - Page 64assessment of antibody titers and/or clinical presen tation at the time of di scontinuation or at the 
time of last study visit.  
In the event of any SAE or any AE SI of anaphylactic reactions or sy stemic allergic reactions that 
are related to IMP and require tr eatment, or severe injection site reaction lasting longer than [ADDRESS_405951] be completed as well.
Pre-existing anti-drug anti bodies are defined as:  
xAn ADA positive response in th e assay at baseline with a ll post treatment ADA results 
negative, OR 
xAn ADA positive response at baseline with all post treatment ADA responses less than 4-
fold over baseline titer levels.
Treatment-emergent anti-drug an tibodies are defined as:  
xAn ADA positive response in the assay post first dose, when baseline results are negative
or missing. 
Treatment-boosted anti-drug antibodies are defined as:  
xAn ADA positive response in the assay post firs t dose that is greater-than or equal to 4-
fold over baseline titer levels, wh en baseline results are positive.
Treatment-emergent (TE) ADA responses are furthe r classified as Transi ent, Persistent or 
Indeterminate
a) Persistent Response- define d as a treatment-emergent response with two or more 
consecutive ADA positive sampling time points, separated by [CONTACT_726] 12-week period 
(with no ADA negative samples in between).
b) Indeterminate Response- defined as a treatment-emergent response with only the last 
collected sample positive in the ADA assay 
c) Transient Response - defined as a treatment-emergent response that is not considered 
persistent OR indeterminate
Unused samples collected for drug concentration or ADA analyses may be used for research 
purpose. 
[IP_ADDRESS] Handling procedures
Special procedures for collection, storage, and shippi[INVESTIGATOR_181207].  An overview of  handling procedure of samples used in the determination of 
functional dupi[INVESTIGATOR_328695] 1. 
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: 1 
Property of the [COMPANY_011] Group - Page 65Table 1 - Summary of handling procedures for dupi[INVESTIGATOR_328696]-dupi[INVESTIGATOR_328697] 5 mL 5 mL
Anticoagulant None None
Blood handling procedures See Operati onal Manual See Operational Manual
Serum aliquot split 2 aliquots 2 aliquots
Storage conditions <6 months: below -20¬∞C
<24 months: below -80¬∞C (preferred)<6 months: below -20¬∞C
<24 months: below -80¬∞C (preferred)
Serum shipment condition In dry ice In dry ice
[IP_ADDRESS] Bioanalytic method
Serum PK and ADA samples will be assayed using validated methods as described in Table 2. 
Table 2 - Summary of bioanalytical methods for dupi[INVESTIGATOR_181159]-dupi[INVESTIGATOR_328698]-dupi[INVESTIGATOR_328699] 0.078 mg/L Not applicable
Site of bioanalysis Regeneron Regeneron
ELISA=enzyme-linked immunosorbent assay.
9.3.2 Pharmacodynamics
Several biomarkers related to asthmatic inflam mation and Th2 polarization will be assessed for 
their value in predicting therapeutic response an d/or in documenting the time course of drug 
response. In a prior asthma trial (ACT11457), tr eatment with dupi[INVESTIGATOR_328700] (CCL17; a ligand of CCR4 receptors that attracts Th2 cells), 
plasma eotaxin-3 (CCL26; a ligand of CCR3 recep tors that attracts eosinophils and lung mast 
cells), and serum total IgE (a product of immun oglobulin class switching driven by [CONTACT_8668]-4), as well 
as reduced the concentrations of fractional exhaled nitric oxide (a marker of airway 
inflammation).  Now added to these are the following serum biomarkers: eosinophil cationic 
protein (ECP; a stored protein released from activated eosinophils) and periostin, a protein 
reported to be elevated at baseline in patients re sponsive to treatment with anti-IL-13 antibodies. 
Assay methodologies are briefly summarized below.  More detailed inform ation on the collection, 
handling, transport and preservation of samp les (eg, minimum volumes required for blood 
collection and for aliquots for each biomarker assa y) will be provided in  a separate laboratory 
manual. 
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: 1 
Property of the [COMPANY_011] Group - Page 66Eotaxin-3, eosinophil cationic protein (ECP), to tal IgE and Thymus and Activation-Regulated 
Chemokine (TARC) will all be assayed at the same time points as a biomarker set and as 
indicated in the study flow chart. Periostin and antigen-specific IgE panels will be collected 
individually per the st udy flow chart.  
[IP_ADDRESS] Whole blood biomarkers
Blood eosinophil count will be measured as part of the standard 5-part WBC differential cell 
count on a hematology autoanalyzer. 
[IP_ADDRESS] Plasma biomarkers  
Eotaxin-3 will be measured in heparinized plasma  with a validated enzyme immunoassay (Human 
Eotaxin-3 Quantikine ELISA kit; R&D Systems).
[IP_ADDRESS] Serum biomarkers  
Concentrations of eosinophil cationic protein (ECP) will be measured using a quantitative 
ImmunoCAP assay (Phadia).  
Antigen-specific IgE will be detected using panels  of antigens appropriate to the location of the 
clinical site (ImmunoCAP test; Phadia).
Total IgE will be measured with a quantitativ e method (eg, ImmunoCAP) approved for diagnostic 
testing. 
TARC and periostin will be assa yed with validated immunoassays. 
[IP_ADDRESS] Exhaled nitric oxide
Exhaled nitric oxide will be performed centr ally and analyzed using a NIOX instrument 
(Aerocrine AB, Solna, Sweden), or  similar analyzer using a flow rate of 50 mL/s, and reported in 
parts per billion (ppb). This assessment should be  conducted prior to spi[INVESTIGATOR_125392] a 
fast of at least 1 hour. All exhaled nitric oxide recordings will be centra lly read by [CONTACT_328741]. Further details on the procedure for measuring exhaled nitric oxide with NIOX will be provided in a separate  instruction manual. 
9.3.3 Pharmacogenetics
[IP_ADDRESS] Optional stored DNA and RNA samples
Pharmacogenetic testing is optional and voluntar y. A separate written informed consent form 
must be signed before sampling.  
For those patients who signed the optional pha rmacogenetic informed consent form, blood 
samples for exploratory genetic analysis of DNA or RNA will be collected at the study visit as 
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: 1 
Property of the [COMPANY_011] Group - Page 67 specified in the study flow chart, and these samples will be stored for up to 15 years after 
completion of the final report of the main clinical trial or for a shorter time if there is local 
requirement. Specific procedures for collection, storage and shippi[INVESTIGATOR_328701] a lab manual.  
DNA or RNA samples may be used to determin e a possible relationship between genes and 
response to treatment with dupi[INVESTIGATOR_12458], possible adverse reactions to dupi[INVESTIGATOR_12458], and to study the 
genetics of asthma. The DNA may be subjecte d to a genome-wide association study by 
[CONTACT_328742]/or to whole exome sequ encing or whole genome analysis in order to 
thoroughly explore genetic associations with dise ase progression or treatment response. The RNA 
may be subjected to discrete panels of PCR an alyses, microarray analyses or RNA sequencing 
analyses.
The blood DNA sample, and the DNA or RNA that is extracted, will be assigned a second
number, a Genetic ID (de- identification code) that is different  from the Subject ID. This ‚Äúdouble 
coding‚Äù is performed to separate a su bject‚Äôs medical information and DNA data.
The clinical study data (coded by S ubject ID) will be stored in the clinical data management 
system (CDMS), which is a distinct database in a separate environment from the database 
containing the pharmacogenetic data (coded by [CONTACT_328743]). The key linking Subject ID and 
Genetic ID will be maintained by a third party, u nder appropriate access control.  The matching of 
clinical data and pharmacogenetic data, for the pu rpose of data analysis, will be possible only by 
[CONTACT_181278], which will be under strict access cont rol. All data will be reported only in coded 
form in order to maintain confidentiality.
9.3.4 Vaccine response
Patients will be encouraged to provide vaccinatio n plans for the following vaccines, tetanus (alone 
or combined), any injectable influenza, any pne umococcal and any meningococcal, which are in 
line with the patients age and local medical practi ce (live attenuated vaccin es are excluded) during 
the study. Subjects planning to receive any of th e above listed vaccines during the study may 
optionally sign a separate informed consent for co llection of 2 blood samples for assay of vaccine
IgG in serum for each vaccine: the first should be drawn within 6 weeks pr ior to vaccination and 
then the second should be drawn 3 to 4 weeks afte r vaccination (up to [ADDRESS_405952] allowed).
Vaccinations should preferably occur after comple tion of at least 12 weeks of treatment, while 
remaining in compliance with the patient‚Äôs r ecommended immunization schedule. Pre-vaccine 
blood sample collection will not ta ke place until patient is on treatment of IMP for at least 6 
weeks. Blood collections should be c onducted at regularly scheduled stud y visits but, if this is not 
feasible, could also be done at unscheduled vis its. The details on the date(s) of vaccination and the 
specific vaccines that are administered, such as brand and antigenic strain s, should be collected 
(see Appendix L).  
9.[ADDRESS_405953] consented to it, the samp les that are archived, unused or left 
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: 1 
Property of the [COMPANY_011] Group - Page 68over after planned testing may be  used for additional research purposes (any genetic analysis 
subject to additional consent per Section 9.3.3). For subjects who ha ve consented to it, archival 
blood samples will be collected at the visit specifi ed in the study flow chart, 15 mL each, will be 
collected into a dry, red topped tube (or into smal ler tubes of equivalent total volume) kept at 
room temperature for 30 minutes and then centr ifuged at approximately 1500 g for 10 minutes at 
room temperature.  The serum will then be transferred, in equal portions, into 3 storage tubes, 
which will be immediately capped and frozen in an upright position at -20¬∞C or colder. 
These archived serum samples, and any residual  or leftover serum, pl asma or blood remaining 
from planned laboratory work, may be used for research purposes  related to asthma 
(eg, exploratory biomarkers of disease or drug e ffect), additional drug safety assessments or 
development and validation of bioassay methods  beyond those defined in the present protocol. 
These samples will remain labelle d with the same identifiers as  the ones used during the study 
(ie, subject ID, sample ID). They will be transfer red to a [COMPANY_011] site (or a subcontractor site) 
which can be located outside of the country where the study is conducted. The Sponsor has 
included safeguards for protecting subject confid entiality and personal data (see Section 14.3 and 
Section 14.5).
9.[ADDRESS_405954] for the ev aluation of therapy in 
patients with asthma.
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: 1 
Property of the [COMPANY_011] Group - Page 6910 STUDY PROCEDURES
10.1 VISIT SCHEDULE
The clinical trial consists of three periods, using an add-on therapy approach to inhaled 
corticosteroid in combination with on e or two other controller medications:
xScreening Period (4¬±1 weeks; Visit 1) 
xRandomized Treatment Period ( 52 weeks; Visits 2-18) 
xPost-treatment Period (1 2 weeks; Visits 19-21) 
The study visits occur on the planned dates (relativ e to the first injection) , as scheduled. The visit 
schedule should be adhered to w ithin the ¬± [ADDRESS_405955] s. However, if the visit can only be done at a 
different time of the day and the patient is not fa sting, then he/she should be advised to have a 
light meal and the site should document that se rum chemistry was not obtained under fasting 
conditions. For spi[INVESTIGATOR_038], it should be performed at approximately the same time of the day at 
each visit throughout the study. 
Patients who permanently discontinue the study medication will be asked and encouraged to 
return to the clinic for study visits and particip ate in assessments according to the visit schedule 
until the end of the study with a +/-5 day window (See Section 1.3). Under exceptional 
circumstances when a patient cannot come to the site for the scheduled vi sit, a phone contact [CONTACT_328744]. Duri ng the phone contact, at least information about 
AEs, concomitant medication and asthma exacerbation events should be collected. 
Patients who discontinue early from treatment or  patients who choose not to participate in the 
OLE study may be asked to return to the clinic  to have additional ADA samples collected for 
analysis based on the overall assessment of anti body titers and/or clinical presentation at the time 
of discontinuation or at th e time of last study visit.
Reminder: sexually active female patients of re productive potential are re quired to practice an 
effective contraception throughout the participati on in the study including a 12-week period after
last IMP dose. Sites should c ounsel these patients, with spec ial attention towards adolescent 
patients regarding the importance of practicing responsible and effective contraception throughout 
the participation in the study including  a 12-week period af ter last IMP dose.
Prior to all screening assessments, after discus sion of participation in the study, the written 
consent form (including voluntar y participation in pharmacogenetic  testing/future use of blood 
samples/vaccination testing) must be signed and dated. 
Although the screening assessments for this stud y are grouped under the heading of a single visit 
in this protocol, it is possible for them to be pe rformed over more than 1 site visit if necessary, as
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: 1 
Property of the [COMPANY_011] Group - Page 70long as the screening visit window prior to randomization (Day 1) is respected. If certain dynamic 
laboratory tests do not meet the e ligibility criteria, these laborato ry assessments may be repeated, 
at the discretion of the investigator, if it is j udged to be likely to return to acceptable range for 
study inclusion within the screen ing visit window (35 days) prior to Day1. These patients do not 
need to sign a new ICF and be allocated a ne w patient number within this same screening 
window.  
Patients that fail the initial screening for exclus ion criteria, eg, concomitant medications, may be 
rescreened for study eligibility [ADDRESS_405956] sign a new 
consent form and will be allocated a new patient number; all of the Visit [ADDRESS_405957] be 
repeated (refer to Section 8.4 for further instru ctions related to rescreening) unless a prior 
assessment is performed within the ti me frame permitted prior to study entry. 
Patients that fail the Screening Visit (Visit 1) or Randomization Visit (Visit 2) because of eDiary 
/spi[INVESTIGATOR_181218], or patient-relate d / site personnel-relate d unintentional errors 
may be rescreened one time after approval is gran ted by [CONTACT_1034]‚Äôs clinical study director. In 
every case of rescreen allowance due to tech nical equipment malfunction and/or unintentional 
human error(s), the Study Investigator must document receipt of Sponsor approval and when 
applicable, document the site‚Äôs corrective ac tion plan to prevent future occurrences.  
When approaching the season appropriate for infl uenza vaccination, patients will be reminded to 
inform the clinic staff about vaccination plans. Similarly, when approaching the planned date of 
tetanus (alone or combined), any pneumococcal and any meningococcal vaccination, patients will be reminded about the related pre- and post-vacc ination blood sampling for vaccine IgG testing. 
Those who have not yet signed the separate cons ent for collection of blood pre-vaccination (eg, 
those who make mid-study decisions about vaccina tions) may do so just pr ior to blood collection.
It is recommended that assessments /procedures at a site visit are performed in the following order 
if applicable, and these assessments/procedures should be done prior to IMP administration: 
1. Patient-reported outcomes and other questionnaires 
2. Procedures: 
a) ECG
b) FENOc) Spi[INVESTIGATOR_328702]) Reversibility/Post-bronchodilator FEV
1
e) eDiary download 
3. Safety and laboratory assessments
4. IMP administration
10.1.1 Visit 1 (Week -4 ¬± 1, -35 days to -21 days) 
Following a discussion of participation in the clini cal trial, informed consent must be obtained and 
documented. These steps precede any study procedures.
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: 1 
Property of the [COMPANY_011] Group - Page 71The following procedures will then be performed: 
xCall IVRS/IWRS to assign patient numb er and register screening visit
xInterview to collect patient demographic in formation, asthma history (including smoking 
habits), other medical history and surgical history, and prior and concomitant medications 
xInterview to collect vaccination informati on and vaccination plan during the treatment 
period for patient who agree to particip ate to the vaccine response assessment. 
xReview entry criteria to assess eligibility, w ith special attention to verify the following:
- Prescribed treatment dosage meets the pre-prot ocol definition of  medium to high dose 
,&6¬ïPFJRIIOXWLFDVRQHSURS LRQDWHWZLFHGDLO\RUHTXLSRWH QW,&6GDLO\GRVDJH to 
a maximum of 2000 mcg/day of fluticasone prop ionate or equivalent) [Note for Japan: 
subjects aged [ADDRESS_405958] be ¬ïPFJ of fluticasone propi[INVESTIGATOR_328703] t; subjects aged [ADDRESS_405959] be ¬ï100 mcg of 
fluticasone propi[INVESTIGATOR_328704] e quivalent] in combination with a second 
controller (eg, /$%$/75$IRUDWOHDVWPRQWKV ZLWKDVWDEOHGRVH¬ïPRQWKS ULRU
to Visit 1. In addition, patie nts requiring a thir d controller for their asthma are 
considered eligible for this study. The third controller should al so be used for at least 3 
months with a stable dose ¬ïPRQWKSULRUWR9LVLWSDWLHQWVUHTXLULQJ systemic
steroids as controller medicati on or biologics are excluded). 
-3DWLHQWKDVH[SHULHQFH GZLWKLQ\HDUSULRUWR9LVLW7UH DWPHQWZLWK¬ïV\VWHPLF
(oral or parenteral) steroids bursts for wors ening asthma and/or 2) Hospi[INVESTIGATOR_328705]/urgent medical care visit for worsening asthma.
xMeasure vital signs [blood pressure, heart rate, respi[INVESTIGATOR_1487], body temperature, 
weight (kg), height (cm)] 
xPerform physical examination
xAdminister ACQ-7  
- Verify ACQ-5 VFRUHLV¬ï
xMeasure exhaled nitric oxide
- Exhaled nitric oxide assessment is conducted prior to spi[INVESTIGATOR_125392] a fast 
RI¬ïKRXU
xPerform spi[INVESTIGATOR_038]
- Entry criteria at Visit [ADDRESS_405960] dose of salbutamol/albuterol or 
levosalbutamol/levalbuterol for at least [ADDRESS_405961] 12 hours (ultra-long acting LABA like vilanterol should be withheld for at 
least 24 hours) and withholding the last dose of  LAMA for at least 24 hours. This will 
be verified before performing the measurements.
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: 1 
Property of the [COMPANY_011] Group - Page 72- Pre-bronchodilator Forced  expi[INVESTIGATOR_12194] (FEV 1) must be ¬î 80% of predicted 
normal for adults and ¬î 90% of predicted normal for adolescents.
xEstablish reversibility
- Reversibility must be at least 12% and 200 mL in FEV 1 after 200 mcg to 400 mcg 
albuterol/salbutamol or levalbuterol/le vosalbutamol (2 to 4 inhalations of 
albuterol/salbutamol or leva lbuterol/levosalbutamol, or of a nebulized solution of 
albuterol/salbutamol or levalbut erol/levosalbutamol, if consid ered as a standard office 
practice.
xPerform 12-lead electrocardiography (ECG)
xPerform chest X-ray or MRI (MRI is for Ge rmany only) if no chest imaging (X-ray, CT, 
MRI) available within th e previous [ADDRESS_405962] of care or if there is 
local requirement. 
xNote for Japan: According to the request from  the health authority, chest X-ray should be 
performed at screening visit if there is no chest imaging (Chest X -ray, CT, MRI) available 
within 3 months prior to screen ing to exclude patients with suspected active or untreated 
latent tuberculosis.
xObtain (fasting if morning visit) blood samples for screening clinical laboratory 
determinations:
- Hematology (see Section [IP_ADDRESS] for details)
- Serum chemistry (see Section [IP_ADDRESS] for details)
xObtain blood samples for hepatitis screen  (HBs Ag, HBs Ab, HBc Ab including HBcAb 
IgM and total, and HCV Ab). In case of resu lts showing HBs Ag (n egative) and HBc Ab 
total (positive), a HBV DNA testing must  be performed prior to randomization to
determine eligibility. In case of results s howing HCV Ab (positive), a HCV RNA testing 
must be performed prior to random ization to determine eligibility.  
xObtain blood sample for HIV screen  (Anti-HIV-1 and HIV-2 antibodies)  
xObtain blood sample for ANA test. Note: Anti-ds DNA antibody will be tested if ANA is 
SRVLWLYH¬ïWLWHU
xObtain blood sample for serum immunoglobulin s (total IgG, IgG subclasses1-4, IgM and 
IgA)
x2EWDLQVHUXP»ï -HCG pregnancy test if fema le of childbearing potential 
xObtain urine for urinalysis (dip stick) If any assessment on the dipstick is abnormal, a urine 
sample should be sent to the central laboratory for testing. 
xDispense electronic diary/PEF me ter, provide instructions for daily use, and remind patient 
to bring the device to the next visit. 
xRemind patients to use salbutamol/albuterol or levosalbutamol/levalbuterol as reliever 
medication throughout the study. Instruct patient to record usage in the electronic diary. 
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: [ADDRESS_405963] dose of salbutamol/albuterol or  levosalbutamol/levalbuterol for at least [ADDRESS_405964] 12 hours (ultra-long acting LABA like 
vilanterol should be withheld for at least 24 hours) and withhold the last dose of LAMA 
for at least 24 hours prior to next visit.
xSchedule a site visit within 21 to 35 days (Visit  2, Week 0) and request patient to come at 
approximately the same time of this visit (fasting if morning visit). 
10.1.2 Visit 2 (Week 0, Day1) 
xRecord all medication use with start date a nd dose in eCRF; inquire about AEs/SAEs and 
background asthma therapy tolerability. 
xReview entry criteria and reconfirm eligibil ity based on review of Inclusion/Exclusion 
Criteria. 
xAdminister ACQ-7 and all other scales (AQLQ(S), health care resource utilization 
questionnaire, EQ-5D-5L, SNOT-22 (only for thos e patients with bila teral nasal polyposis
and/or chronic rhinosinusitis), RQLQ(S) +12 in those patients with allergic rhinitis and 
HADS (HADS-A and HADS-D subscales)). Verify ACQ-5 score is ¬ï1.5. 
xCompliance with use of the mandatory bac kground therapy, ICS in combination with one 
or two other controller product as used ju st prior to screening, as defined as:
-¬ïRIWRWDOQXPEHURISUHVFULEHGGRVHVRIEDFNJURXQGPHGLFDWL RQWDNHQGXULQJWKH
screening period. Compliance is verified  based on background medication use 
recorded on the patient electronic diary during the sc reening period. 
xMeasure exhaled nitric oxide
- Exhaled nitric oxide assessment is conducted prior to spi[INVESTIGATOR_125392] a fast 
RI¬ïKRXU
xMeasure vital signs (blood pressure, heart rate , respi[INVESTIGATOR_1487], body temperature, weight 
for all patients and height for adolescents only) 
xPerform spi[INVESTIGATOR_328706] [ADDRESS_405965] dose of salbutamol/albut erol or levosalbutamol/levalbuterol for at 
least [ADDRESS_405966] 12 hours (ultra-long 
acting LABA like vilanterol should be withhe ld for at least 24 hours) and withholding 
the last dose of LAMA for at least [ADDRESS_405967]. This  will be verified before performing the measurements. 
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: 1 
Property of the [COMPANY_011] Group - Page 74- Pre-bronchodilator Forced  expi[INVESTIGATOR_12194] (FEV 1) mXVWEH¬î  80% of predicted 
normal for adults and ¬î 90% of predicted normal for adolescents.
- Post-bronchodilator FEV 1 should be determined 
- Treatment Period stability limits will be established for FEV 1and PEF (The Treatment 
Period stability limit for PEF is defined as the respective mean AM or PM PEF obtained over the last 7 days prior to Day 1).
If the patient meets all inclusion and does not meet any exclusion criteria:
xCall IVRS/IWRS to register visit, randomize the patient if entry criteria are met, and 
receive the first assignment for 2 treatment kit numbers.
- Note: Please screen-fail the patient  if entry criteria are not met.
xPerform urine dipstick pregnancy test (for women of childbearing potential) 
xPerform blood sampling (fasting if morning visit,  prior to administra tion of IMP) for the 
following tests:
- Clinical lab testing: hematology/bi ochemistry (refer to Section [IP_ADDRESS]) 
- Hepatitis B viral load for patients in Japan or other countries/regi ons if there is local 
regulatory requirement who are HBs Ag negative and HBs Ab positive at screening.  
- Systemic drug concentration and ADA (refer to Section 9.3.1) 
- Biomarker set, Periostin and Antigen -specific IgE (refer to Section 9.3.2) 
- Archival serum for those patients who have signed a specific Future Use of Specimens 
informed consent (refer Section 9.4).
- For those patients who have signed a specific pharmacogenetic informed consent form, 
collect blood samples for DNA and RNA sam pling (prior to administration of 
investigational product duri ng the Randomized Treatment Period), please refer to 
Section 9.3.3.
xDownload electronic diary/PEF meter and remind patient to bring the device to the next 
visit. 
xDispense and administer IMP
- For those patients willing to perform self-inj ection:  The Investigator or delegate will 
train the patient (or caregive r) regarding preparation and in jection of IMP at Visit [ADDRESS_405968] of the 2 injections. The patient (or caregiver) will perform the second injection under the superv ision of the Investigator or delegate. Document the 
training for IMP self-injection in the patient‚Äôs study file.
- Patients should be monitored for at least [ADDRESS_405969] admini stration for any signs or symptoms of a hypersensitivity 
reaction.   
xRemind patients to use salbutamol/albuterol or levosalbutamol/levalbuterol as reliever medication throughout the study. Instruct patient to record usage in the electronic diary.
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: [ADDRESS_405970] dose of salbutamol/albuterol or  levosalbutamol/levalbuterol for at least [ADDRESS_405971] 12 hours (ultra-long acting LABA like 
vilanterol should be withheld for at least 24 hours) and withhold the last dose of LAMA 
for at least 24 hours prior to next visit.
xSchedule a site visit 2 weeks la ter (Week 2 ¬± 3 days) at approximately the same time of 
this visit.  
10.1.3 Visit 3 (Week 2)
xRecord all concomitant medication use; i nquire about AEs/SAEs and background asthma 
therapy tolerability
xMeasure vital signs (blood pressure, heart rate , respi[INVESTIGATOR_1487], body temperature, weight 
for all patients and height for adolescents only) 
xAdminister ACQ-[ADDRESS_405972] 
RI¬ïKRXU
xPerform spi[INVESTIGATOR_038]
- Spi[INVESTIGATOR_328707] a wash 
out period of bronchodilators according to their action duration, for example, 
withholding the last dose of salbutamol/albut erol or levosalbutamol/levalbuterol for at 
least [ADDRESS_405973] 12 hours (ultra-long 
acting LABA like vilanterol should be withhe ld for at least 24 hours) and withholding 
the last dose of LAMA for at least [ADDRESS_405974]-bronchodilator FEV 1 should be determined 
xPerform 12-lead electrocardiography (ECG)
xPerform blood sampling (fasting if morning visi t, prior to administra tion of IMP) for the 
following test: 
- Systemic drug concentration. 
xDownload electronic diary/PEF meter and remi nd patient to bring the device to the next 
visit
xCall IVRS/IWRS to register visit and obtain next treatment kit number 
xDispense and administer IMP. 
- Patients will be monitored at the study site for a minimum of 30 minutes after the 
injection.
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: 1 
Property of the [COMPANY_011] Group - Page 76- For those patients willing a nd trained to perform self-i njection:  The patient (or 
caregiver) will perform the injection under th e supervision of the Investigator or 
delegate. 
xRemind patients to use salbutamol/albuterol or levosalbutamol/levalbuterol as reliever medication throughout the study. Instruct patient to record usage in the electronic diary. 
xRemind patient to continue thei r stable dose of ICS in combin ation with one or two other 
controllers as used during the screening period and instruct patient to  record daily usage in
the electronic diary. 
xRemind patient to withhold bronchodilators acco rding to their action duration, for example, 
withhold last dose of salbutamol/albuterol or  levosalbutamol/levalbuterol for at least [ADDRESS_405975] 12 hours (ultra-long acting LABA like 
vilanterol should be withheld for at least 24 hours) and withhold the last dose of LAMA 
for at least 24 hours prior to next visit.
xSchedule a site visit 2 weeks later (Week 4 ¬± 3 days) and as k patient to come in at 
approximately the same time of this visit (fasting if morning visit). 
10.1.4 Visit 4 (Week 4)
xRecord all concomitant medication use; i nquire about AEs/SAEs and background asthma 
therapy tolerability
xMeasure vital signs (blood pressure, heart rate , respi[INVESTIGATOR_1487], body temperature, weight 
for all patients and height for adolescents only) 
xAdminister ACQ-[ADDRESS_405976] 
RI¬ïKRXU
xPerform spi[INVESTIGATOR_038]
- Spi[INVESTIGATOR_328707] a wash 
out period of bronchodilators according to their action duration, for example, 
withholding the last dose of salbutamol/albut erol or levosalbutamol/levalbuterol for at 
least [ADDRESS_405977] 12 hours (ultra-long 
acting LABA like vilanterol should be withhe ld for at least 24 hours) and withholding 
the last dose of LAMA for at least [ADDRESS_405978]-bronchodilator FEV 1 should be determined 
xPerform 12-lead electrocardiography (ECG)
xAdminister health care res ource utilization questionnaire
xPerform urine dipstick pregnancy test (for women of childbearing potential) 
xPerform blood sampling (fasting if morning visi t, prior to administra tion of IMP) for the 
following tests: 
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: 1 
Property of the [COMPANY_011] Group - Page 77- Clinical laboratories, systemic drug concentration and Periostin (refer to Section
9.3.2). 
xDownload electronic diary/PEF meter and remind patient to bring the device to the next 
visit. 
xCall IVRS/IWRS to register visit and obtain treatment kit number
xDispense and administer IMP
- Patients will be monitored at the study site for a minimum of 30 minutes after the 
injection.
- For those patients willing a nd trained to perform self-i njection:  The patient (or 
caregiver) will perform the inje ction of IMP under the superv ision of the Investigator 
or delegate.  
xRemind patients to use salbutamol/albuterol or levosalbutamol/levalbuterol as reliever medication throughout the study. Instruct patient to record usage in the electronic diary. 
xRemind patient to continue thei r stable dose of ICS in combin ation with one or two other 
controllers as used during the screening period an d instruct patient to record daily usage in 
the electronic diary. 
xRemind patient to withhold bronchodilators acco rding to their action duration, for example, 
withhold last dose of salbutamol/albuterol or  levosalbutamol/levalbuterol for at least [ADDRESS_405979] 12 hours (ultra-long acting LABA like 
vilanterol should be withheld for at least 24 hours) and withhold the last dose of LAMA 
for at least 24 hours prior to next visit.
xSchedule a site visit two weeks later (Week 6 ¬± 3 days) at approximately the same time of 
this visit. 
10.1.5 Visit 5 (Week 6)
xRecord all concomitant medication use; i nquire about AEs/SAEs and background asthma 
therapy tolerability
xMeasure vital signs (blood pressure, heart rate , respi[INVESTIGATOR_1487], body temperature, weight 
for all patients and height for adolescents only) 
xAdminister ACQ-[ADDRESS_405980] dose of salbutamol/albut erol or levosalbutamol/levalbuterol for at 
least [ADDRESS_405981] 12 hours (ultra-long 
acting LABA like vilanterol should be withhe ld for at least 24 hours) and withholding 
the last dose of LAMA for at least [ADDRESS_405982]: 
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: [ADDRESS_405983] signed a specific informed 
consent for vaccine assessment and who plan  to receive a vaccine in the coming 6 
weeks (refer to Section 9.3.4) 
xDownload electronic diary/PEF meter and remind patient to bring the device to the next 
visit
xCall IVRS/IWRS to register visit and obtain treatment kit number
xDispense and administer IMP
- Patients will be monitored at the study site for a minimum of 30 minutes after the 
injection.
- For those patients willing a nd trained to perform self-i njection:  The patient (or 
caregiver) will perform the inje ction of IMP under the superv ision of the Investigator 
or delegate.  
xRemind patients to use salbutamol/albuterol or levosalbutamol/levalbuterol as reliever 
medication throughout the study. Instruct patient to record usage in the electronic diary. 
xRemind patient to continue thei r stable dose of ICS in combin ation with one or two other 
controllers as used during the screening period an d instruct patient to record daily usage in 
the electronic diary. 
xRemind patient to withhold bronchodilators acco rding to their action duration, for example, 
withhold last dose of salbutamol/albuterol or  levosalbutamol/levalbuterol for at least [ADDRESS_405984] 12 hours (ultra-long acting LABA like
vilanterol should be withheld for at least 24 hours) and withhold the last dose of LAMA 
for at least 24 hours prior to next visit.
xSchedule a site visit 2 weeks later (Week 8 ¬± 3 days) and as k patient to come in at 
approximately the same time of this visit (fasting if morning visit). 
10.1.6 Visit 6 (Week 8)
xRecord all concomitant medication use; i nquire about AEs/SAEs and background asthma 
therapy tolerability
xMeasure vital signs (blood pressure, heart rate , respi[INVESTIGATOR_1487], body temperature, weight 
for all patients and height for adolescents only) 
xAdminister ACQ-[ADDRESS_405985] dose of salbutamol/albut erol or levosalbutamol/levalbuterol for at 
least [ADDRESS_405986] 12 hours (ultra-long 
acting LABA like vilanterol should be withhe ld for at least 24 hours) and withholding 
the last dose of LAMA for at least [ADDRESS_405987]. This  will be verified before performing the measurements. 
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: [ADDRESS_405988] (for women of childbearing potential) 
xPerform blood sampling (fasting if morning visi t, prior to administra tion of IMP) for the 
following tests:
- Clinical laboratories and systemic drug concentration  
- Blood sample for pre-vaccine IgG for patie nts who have signed a specific informed 
consent for vaccine assessment and who plan  to receive a vaccine in the coming 6 
weeks (refer to Section 9.3.4) 
- Blood sample for post-vaccine IgG for patients who have signed a specific informed 
consent for vaccine assessment and who have  received a vaccine in the past 3 to 4 
weeks (preferred but up to 6 weeks allowed) (refer to Section 9.3.4) 
xDownload electronic diary/PEF meter and remind patient to bring the device to the next 
visit
xCall IVRS/IWRS to register visit and obtain treatment kit number
xDispense and administer IMP
- Patients will be monitored at the study site for a minimum of 30 minutes after the 
injection.
- For those patients willing a nd trained to perform self-i njection:  The patient (or 
caregiver) will perform the inje ction of IMP under the superv ision of the Investigator 
or delegate. 
xRemind patients to use salbutamol/albuterol or levosalbutamol/levalbuterol as reliever medication throughout the study. Instruct patient to record usage in the electronic diary. 
xRemind patient to continue thei r stable dose of ICS in combin ation with one or two other 
controllers as used during the screening period an d instruct patient to record daily usage in 
the electronic diary
xRemind patient to withhold bronchodilators acco rding to their action duration, for example, 
withhold last dose of salbutamol/albuterol or  levosalbutamol/levalbuterol for at least [ADDRESS_405989] 12 hours (ultra-long acting LABA like 
vilanterol should be withheld for at least 24 hours) and withhold the last dose of LAMA 
for at least 24 hours prior to next visit.
xSchedule a site visit 2 weeks later (Week 10 ¬± 3 days) at ap proximately the same time of 
this visit. 
10.1.7 Visit 7 (Week 10)
xRecord all concomitant medication use; i nquire about AEs/SAEs and background asthma 
therapy tolerability
xMeasure vital signs (blood pressure, heart rate , respi[INVESTIGATOR_1487], body temperature, weight 
for all patients and height for adolescents only) 
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: [ADDRESS_405990] dose of salbutamol/albut erol or levosalbutamol/levalbuterol for at 
least [ADDRESS_405991] 12 hours (ultra-long 
acting LABA like vilanterol should be withhe ld for at least 24 hours) and withholding 
the last dose of LAMA for at least [ADDRESS_405992]. This  will be verified before performing the measurements. 
xPerform blood sampling for the following tests:
- Blood sample for pre-vaccine IgG for patie nts who have signed a specific informed 
consent for vaccine assessment and who plan  to receive a vaccine in the coming 6 
weeks (refer to Section 9.3.4) 
- Blood sample for post-vaccine IgG for patients who have signed a specific informed 
consent for vaccine assessment and who have  received a vaccine in the past 3 to 4 
weeks (preferred but up to 6 weeks allowed) (refer to Section 9.3.4) 
xDownload electronic diary/PEF meter and remind patient to bring the device to the next 
visit
xCall IVRS/IWRS to register visit and obtain treatment kit number 
xDispense and administer IMP
- Patients will be monitored at the study site for a minimum of 30 minutes after the 
injection.
- For those patients willing a nd trained to perform self-i njection:  The patient (or 
caregiver) will perform the inje ction of IMP under the superv ision of the Investigator 
or delegate.  
xRemind patients to use salbutamol/albuterol or levosalbutamol/levalbuterol as reliever medication throughout the study. Instruct patient to record usage in the electronic diary. 
xRemind patient to continue thei r stable dose of ICS in combin ation with one or two other 
controllers as used during the screening period an d instruct patient to record daily usage in 
the electronic diary
xRemind patient to withhold bronchodilators acco rding to their action duration, for example, 
withhold last dose of salbutamol/albuterol or  levosalbutamol/levalbuterol for at least [ADDRESS_405993] 12 hours (ultra-long acting LABA like 
vilanterol should be withheld for at least 24 hours) and withhold the last dose of LAMA 
for at least 24 hours prior to next visit.
xSchedule a site visit 2 weeks later (Week 12 ¬± 3 days) and ask patient to come in at 
approximately the same time of this visit (fasting if morning visit). 
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: 1 
Property of the [COMPANY_011] Group - Page 8110.1.8 Visit 8 (Week 12)
xRecord all concomitant medication use; i nquire about AEs/SAEs and background asthma 
therapy tolerability
xMeasure vital signs (blood pressure, heart rate , respi[INVESTIGATOR_1487], body temperature, weight 
for all patients and height for adolescents only) 
xAdminister ACQ-[ADDRESS_405994] 
RI¬ïKRXU
xPerform spi[INVESTIGATOR_038]
- Spi[INVESTIGATOR_328707] a wash 
out period of bronchodilators according to their action duration, for example, 
withholding the last dose of salbutamol/albut erol or levosalbutamol/levalbuterol for at 
least [ADDRESS_405995] 12 hours (ultra-long 
acting LABA like vilanterol should be withhe ld for at least 24 hours) and withholding 
the last dose of LAMA for at least [ADDRESS_405996]-bronchodilator FEV 1 should be determined.
xAdminister AQLQ(S), h ealth care resource utilizati on questionnaire, EQ-5D-5L, SNOT-
22 (only for those patients with bilateral na sal polyposis and/or chronic rhinosinusitis), 
RQLQ(S) +12 in those patients with alle rgic rhinitis and HADS (HADS-A and HADS-D
subscales).
xPerform 12-lead electrocardiography (ECG)
xObtain urine for urinalysis (dipstick) If any a ssessment on the dipstick is abnormal, a urine 
sample should be sent to the central laboratory for testing. 
xPerform urine dipstick pregnancy test (for women of childbearing potential) 
xPerform blood sampling (fasting if morning visit, prior to ad ministration of IMP) for the 
following tests:
- Clinical laboratories,   - Serum immunoglobulins (total IgG, IgG subclasses1-4, IgM and IgA), 
- Systemic drug concentration,  - Anti-drug antibodies,
- Biomarker set, Periostin and Antigen -specific IgE (refer to Section 9.3.2) 
- Archival serum for those patients who have signed a specific Future Use of Specimens 
informed consent (refer to Section 9.4).
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: [ADDRESS_405997] an to receive a vaccine in the coming 6 
weeks (refer to Section 9.3.4) 
- Blood sample for post-vaccine IgG for patients who have signed a specific informed 
consent for vaccine assessment and who have  received a vaccine in the past 3 to 4 
weeks (preferred but up to 6 weeks allowed) (refer to Section 9.3.4) 
- Hepatitis B viral load for patients in Japan or other countries/regi ons if there is local 
regulatory requirement who were HBs Ag negative and HBs Ab positive at screening.  
xDownload electronic diary/PEF meter and remind patient to bring the device to the next 
visit
xCall IVRS/IWRS to register visit and obtain treatment kit number 
xDispense and administer IMP
- Patients will be monitored at the study site for a minimum of 30 minutes after the 
injection.
- For patients (or caregivers) willing to self-administer IMP:
xProvide instructions on preparation, self-i njection and dose. Allow the patient (or 
caregiver) to perform the injection under the supervision of the Investigator or 
delegate, and provide feedback on technique . Verify that the training for IMP self-
injection is documented in the patient‚Äôs st udy file. Instruct patients to administer 
IMP at q2w intervals.
- For patients (or caregivers) unable or unwilling to self-administer IMP: Arrangements 
must be made for the patient to receive IMP injections at the study site as unscheduled 
visits, or for qualified site personnel and/or a professional caregiver to administer IMP 
at home at q2w intervals.   
xDispense patient (self-inj ection) Home Dosing Diary
xRemind patients to use salbutamol/albuterol or levosalbutamol/levalbuterol as reliever 
medication throughout the study. Instruct patient to record usage in the electronic diary.
xRemind patient to continue thei r stable dose of ICS in combin ation with one or two other 
controllers as used during the screening period an d instruct patient to record daily usage in 
the electronic diary. 
xRemind patient to withhold bronchodilators acco rding to their action duration, for example, 
withhold last dose of salbutamol/albuterol or  levosalbutamol/levalbuterol for at least [ADDRESS_405998] 12 hours (ultra-long acting LABA like 
vilanterol should be withheld for at least 24 hours) and withhold the last dose of LAMA 
for at least 24 hours prior to next visit.
xSchedule a site visit 4 weeks later (Week 16 ¬± 3 days) and as k patient to come in at 
approximately the same time of this visit (fasting if morning visit). 
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: 1 
Property of the [COMPANY_011] Group - Page 8310.1.9 Visit 9 (Week 16)
xCheck compliance to IMP; record all c oncomitant medication use; inquire about 
AEs/SAEs and background asth ma therapy tolerability 
xReview patient Home Dosing Diar y for content and completeness 
xMeasure vital signs (blood pressure, heart rate , respi[INVESTIGATOR_1487], body temperature, weight 
for all patients and height for adolescents only) 
xAdminister ACQ-[ADDRESS_405999] 
RI¬ïKRXU
xPerform spi[INVESTIGATOR_038]
- Spi[INVESTIGATOR_328707] a wash 
out period of bronchodilators according to their action duration, for example, 
withholding the last dose of salbutamol/albut erol or levosalbutamol/levalbuterol for at 
least [ADDRESS_406000] 12 hours (ultra-long 
acting LABA like vilanterol should be withhe ld for at least 24 hours) and withholding 
the last dose of LAMA for at least [ADDRESS_406001] (for women of childbearing potential) 
xPerform blood sampling (fasting if morning visi t, prior to IMP administration) for the 
following tests:
- Clinical laboratories,  
- Systemic drug concentration  
- Blood sample for pre-vaccine IgG for patie nts who have signed a specific informed 
consent for vaccine assessment and who pl an to receive a vaccine in the coming 6 
weeks (refer to Section 9.3.4) 
- Blood sample for post-vaccine IgG for patients who have signed a specific informed 
consent for vaccine assessment and who have  received a vaccine in the past 3 to 4 
weeks (preferred but up to 6 weeks allowed) (refer to Section 9.3.4) 
xAdminister health care resour ce utilization questionnaire. 
xDownload electronic diary/PEF meter and remind patient to bring the device to the next 
visit
xCall IVRS/IWRS to register visit and obtain treatment kit number
xReview instructions on self-injection and dos ing and dispense patient (self-injection) 
Home Dosing Diary
xDispense and administer IMP
- For those patients willing a nd trained to perform self-i njection:  The patient (or 
caregiver) will perform the injection of IMP at q2w intervals.  
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: 1 
Property of the [COMPANY_011] Group - Page 84- For patients (or caregivers) unable or unwilling to self-administer IMP: Arrangements 
must be made for the patient to receive IMP injections at the study site as unscheduled 
visits, or for qualified site personnel and/or a professional caregiver to administer IMP 
at home at q2w intervals.   
xRemind patients to use salbutamol/albuterol or levosalbutamol/levalbuterol as reliever medication throughout the study. Instruct patient to record usage in the electronic diary. 
xRemind patient to continue thei r stable dose of ICS in combin ation with one or two other 
controllers as used during the screening period an d instruct patient to record daily usage in 
the electronic diary. 
xRemind patient to withhold bronchodilators acco rding to their action duration, for example, 
withhold last dose of salbutamol/albuterol or  levosalbutamol/levalbuterol for at least [ADDRESS_406002] 12 hours (ultra-long acting LABA like 
vilanterol should be withheld for at least 24 hours) and withhold the last dose of LAMA 
for at least 24 hours prior to next visit.
xSchedule a site visit 4 weeks later (Week 20 ¬± 3 days) and as k patient to come in at 
approximately the same time of this visit (fasting if morning visit). 
10.1.10 Visit 10, 12, 13, 15, 16, 17 (Week 20, 28, 32, 40, 44, 48)
xCheck compliance to IMP; record all c oncomitant medication use; inquire about 
AEs/SAEs and background as thma therapy tolerability
xReview patient Home Dosing Diar y for content and completeness 
xMeasure vital signs (blood pressure, heart rate , respi[INVESTIGATOR_1487], body temperature, weight 
for all patients and height for adolescents only) 
xAdminister ACQ-7  
xMeasure exhaled nitric oxide (only applicable for Visit 10 and Visit 17) 
- Exhaled nitric oxide assessment is conducted prior to spi[INVESTIGATOR_125392] a fast 
RI¬ïKRXU
xPerform spi[INVESTIGATOR_038]
- Spi[INVESTIGATOR_328707] a wash 
out period of bronchodilators according to their action duration, for example, 
withholding the last dose of salbutamol/albut erol or levosalbutamol/levalbuterol for at 
least [ADDRESS_406003] 12 hours (ultra-long 
acting LABA like vilanterol should be withhe ld for at least 24 hours) and withholding 
the last dose of LAMA for at least [ADDRESS_406004] (for women of childbearing potential) 
xPerform blood sampling (fasting if morning visi t, prior to IMP administration) for the 
following tests:
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: 1 
Property of the [COMPANY_011] Group - Page 85- Clinical laboratories include hematol ogy and serum chemistry (see Section [IP_ADDRESS] for 
details)
- At Visit 17, for patients who will continue in the OLE study, obtain blood samples for 
hepatitis screen (HBs Ag, HBs Ab, HBc Ab  including HBcAb IgM and total, and HCV
Ab). In case of results showing HBs Ag (negative) and HBc Ab total (positive), a HBV DNA testing must be performed prior to inclusion to OLE in order to determine 
eligibility. In case of results showing HCV Ab (positive), a HCV RNA testing must be 
performed prior to inclusion to OLE in order to determine eligibility.  
- At Visit 17, for patients who will continue in the OLE study, obtain blood sample for 
HIV screen (Anti-HIV-1 and HIV-2 antibodies)  
- At Visit 17, for patients who will continue in the OLE study, obtain blood sample for 
ANA test. Note: Anti- GV'1$DQWLERG\ZLOOEHWHVWHGLI$1$LVSRVLWLYH¬ïWLWHU 
- Obtain blood sample for pre-vaccine IgG for patients who have signed a specific 
informed consent for vaccine assessment a nd who plan to receive a vaccine in the 
coming 6 weeks (refer to Section 9.3.4). 
- Obtain blood sample for post-vaccine IgG for patients who have signed a specific 
informed consent for vaccine assessment and who have received a vaccine in the past 3 
to 4 weeks (preferred but up to 6 we eks allowed) (refer to Section 9.3.4) 
xAt Visit 17, for patients who plan to particip ate in the OLE study, perform chest X-ray or 
MRI (MRI is for [LOCATION_013] only) if available chest imaging (X-ray, CT, MRI) is over 12 months from entry into the OLE study. 
xDownload electronic diary/PEF meter and remi nd patient to bring the device to the next 
visit
xCall IVRS/IWRS to register visit and obtain treatment kit number
xReview instructions on self-injection and dos ing and dispense patient (self-injection) 
Home Dosing Diary
xDispense and administer IMP
- For those patients willing a nd trained to perform self-i njection:  The patient (or 
caregiver) will perform the injection of IMP at q2w intervals.  
- For patients (or caregivers) unable or unwilling to self-administer IMP: Arrangements 
must be made for the patient to receive IMP injections at the study site as unscheduled 
visits, or for qualified site personnel and/or a professional caregiver to administer IMP 
at home at q2w intervals.   
xRemind patients to use salbutamol/albuterol or levosalbutamol/levalbuterol as reliever 
medication throughout the study. Instruct patient to record usage in the electronic diary. 
xRemind patient to continue thei r stable dose of ICS in combin ation with one or two other 
controllers as used during the screening period an d instruct patient to record daily usage in 
the electronic diary. 
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: [ADDRESS_406005] dose of salbutamol/albuterol or  levosalbutamol/levalbuterol for at least [ADDRESS_406006] 12 hours (ultra-long acting LABA like 
vilanterol should be withheld for at least 24 hours) and withhold the last dose of LAMA 
for at least 24 hours prior to next visit.
xSchedule a site visit 4 weeks la ter (¬±3 days) and ask patient to come in at approximately 
the same time of this visit (fasting if morning visit). 
10.1.11 Visit 11, 14, 18 (Week 24, 36, 52 / End-of-Treatment Visit)
xCheck compliance to IMP; record all c oncomitant medication use; inquire about 
AEs/SAEs and background asth ma therapy tolerability 
xReview patient Home Dosing Diar y for content and completeness 
xMeasure vital signs (blood pressure, heart rate , respi[INVESTIGATOR_1487], body temperature, weight 
for all patients and height for adolescents only) 
xPerform physical examination (only a pplicable for Visit 11 and EOT visit)
xAdminister ACQ-[ADDRESS_406007] 
RI¬ïKRXU
xPerform spi[INVESTIGATOR_038]
- Spi[INVESTIGATOR_328707] a wash 
out period of bronchodilators according to their action duration, for example, 
withholding the last dose of salbutamol/albut erol or levosalbutamol/levalbuterol for at 
least [ADDRESS_406008] 12 hours (ultra-long 
acting LABA like vilanterol should be withhe ld for at least 24 hours) and withholding 
the last dose of LAMA for at least [ADDRESS_406009]-bronchodilator FEV 1 should be determined. 
xAdminister AQLQ(S), h ealth care resource utilizati on questionnaire, EQ-5D-5L, SNOT-
22 (only for those patients with bilateral na sal polyposis and/or chronic rhinosinusitis), 
RQLQ(S) +12 in those patients with alle rgic rhinitis and HADS  (HADS-A and HADS-D
subscales).
xPerform 12-lead electrocardiography (ECG)
xObtain urine for urinalysis (dip stick) If any assessment on the dipstick is abnormal, a urine 
sample should be sent to the central laboratory for testing. 
xPerform urine dipstick pregnancy test (for women of childbearing potential) 
xPerform blood sampling(fasting if morning vis it, prior to administration of IMP) for the 
following tests:
- Clinical laboratories,
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: 1 
Property of the [COMPANY_011] Group - Page 87- Serum immunoglobulins (total IgG, IgG subclasses1-4, IgM and IgA), 
- Systemic drug concentration,  
- Anti-drug antibodies (only applicab le for Visit 11 and Visit 18),
- Biomarker set, Periostin (Only applicable  for Visit 18, refer to Section 9.3.2) and 
Antigen-specific IgE (only applicable for Vi sit 11 and Visit 18, refer to Section 9.3.2) 
- Archival serum for those patients who have signed a specific Future Use of Specimens 
informed consent (refer to Section 9.4) 
- Blood sample for pre-vaccine IgG for patie nts who have signed a specific informed 
consent for vaccine assessment and who pl an to receive a vaccine in the coming 
6 weeks (refer to Section 9.3.4) 
- Blood sample for post-vaccine IgG for patients who have signed a specific informed 
consent for vaccine assessment and who have  received a vaccine in the past 3 to 
4 weeks (preferred but up to 6 week s allowed) (refer to Section 9.3.4) 
- Blood sampling for hepatitis B viral lo ad for patients in Japan or other 
countries/regions if there is local regula tory requirement who ar e HBs Ag negative and 
HBs Ab positive at screening. 
xDownload electronic diary/PEF meter and remind patient to bring the device to the next 
visit
xCall IVRS/IWRS to register visit and obtain treatment kit number (applicable for Visit 11 
and Visit 14) 
xDispense and administer IMP (only a pplicable for Visit 11 and Visit 14) 
- For those patients willing a nd trained to perform self-i njection:  The patient (or 
caregiver) will perform the injection of IMP at q2w intervals.  
- For patients (or caregivers) unable or unwilling to self-administer IMP: Arrangements 
must be made for the patient to receive IMP injections at the study site as unscheduled 
visits, or for qualified site personnel and/or a professional caregiver to administer IMP 
at home at q2w intervals.   
xRemind patients to use salbutamol/albuterol or levosalbutamol/levalbuterol as reliever medication throughout the study. Instruct patient to record usage in the electronic diary. 
xRemind patient to continue thei r stable dose of ICS in combin ation with one or two other 
controllers as used during the screening peri od (only applicable for Visit 11, Visit 14 and 
EOT visit  after which patients continue to pa rticipate the open label extension trial ) and 
instruct patient to record daily  usage in the electronic diary. 
xRemind patient to withhold bronchodilators acco rding to their action duration, for example, 
withhold last dose of salbutamol/albuterol or  levosalbutamol/levalbuterol for at least [ADDRESS_406010] 12 hours (ultra-long acting LABA like 
vilanterol should be withheld for at least 24 hours) and withhold the last dose of LAMA 
for at least 24 hours prior to next visit.
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: 1 
Property of the [COMPANY_011] Group - Page 88xSchedule a site visit 4 weeks (¬±3 days) and ask patient to come at approximately the same 
time of this visit (only for Visit 11 and Visit 14: fasting if  morning visit). 
xCall IVRS/IWRS to register the EOT date (only applicable for EOT visit)
At Visit 18 (EOT visit), for patients who will not continue with the open label extension, the 
controller medication regimen and dose used dur ing the randomized period  could be adjusted 
based on medical judgment of the pa tients‚Äô asthma control status. 
Patients who permanently discontinue the st udy treatment will perf orm early treatment 
discontinuation visit (ETD) at th e time of permanent treatment di scontinuation as well as EOT 
visit (visit 18) at planned Week  52. See section 1.3 for assessments to be performed at ETD and 
EOT visits and Section 10.3.4 for additional details. 
10.1.12 Visit 19 and Visit 20 (Week [ADDRESS_406011]-Treatment Period)
xRecord all concomitant medication use; i nquire about AEs/SAEs and background asthma 
therapy tolerability
xMeasure vital signs (blood pressure, heart rate , respi[INVESTIGATOR_1487], body temperature, weight 
for all patients and height for adolescents only) 
xAdminister ACQ-[ADDRESS_406012] 
RI¬ïKRXU
xPerform spi[INVESTIGATOR_038]
- Spi[INVESTIGATOR_328707] a wash 
out period of bronchodilators according to their action duration, for example, 
withholding the last dose of salbutamol/albut erol or levosalbutamol/levalbuterol for at 
least [ADDRESS_406013] 12 hours (ultra-long 
acting LABA like vilanterol should be withhe ld for at least 24 hours) and withholding 
the last dose of LAMA for at least [ADDRESS_406014]. This  will be verified before performing the measurements.
xPerform blood sampling (fasting if morn ing visit) for the following tests:
- Clinical laboratories,  - Systemic drug concentration  
xDownload electronic diary/PEF meter and remind patient to bring the device to the next 
visit
xRemind patients to use salbutamol/albuterol or levosalbutamol/levalbuterol as reliever 
medication throughout the study. Instruct patient to record usage in the electronic diary.
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: 1 
Property of the [COMPANY_011] Group - Page 89xRemind patient to continue the stable dose of ICS in combin ation with one or two other 
controller which was maintained over the ra ndomized treatment peri od (unless treatment 
modified based on medical judgment) and reco rd daily usage in th e electronic diary. 
xRemind patient to withhold bronchodilators acco rding to their action duration, for example, 
withhold last dose of salbutamol/albuterol or  levosalbutamol/levalbuterol for at least [ADDRESS_406015] 12 hours (ultra-long acting LABA like 
vilanterol should be withheld for at least 24 hours) and withhold the last dose of LAMA 
for at least 24 hours prior to next visit.
xSchedule a site visit 4 weeks la ter (¬±3 days) and ask patient to come in at approximately 
the same time of this visit (fasting if morning visit). 
10.1.13 Visit 21 (Week 64, End-of-Study Visit) 
xRecord all concomitant medication use; i nquire about AEs/SAEs and background asthma 
therapy tolerability
xMeasure vital signs (blood pressure, heart rate , respi[INVESTIGATOR_1487], body temperature, weight 
for all patients and height for adolescents only) 
xPerform physical examination
xAdminister ACQ-[ADDRESS_406016] 
RI¬ïKRXU
xPerform spi[INVESTIGATOR_038]
- Spi[INVESTIGATOR_328707] a wash 
out period of bronchodilators according to their action duration, for example, 
withholding the last dose of salbutamol/albut erol or levosalbutamol/levalbuterol for at 
least [ADDRESS_406017] 12 hours (ultra-long 
acting LABA like vilanterol should be withhe ld for at least 24 hours) and withholding 
the last dose of LAMA for at least [ADDRESS_406018]-bronchodilator FEV 1 should be determined. 
xAdminister AQLQ(S), h ealth care resource utilization questionnaire, EQ-5D-5L, SNOT-
22 (only for those patients with bilateral na sal polyposis and/or chronic rhinosinusitis), 
RQLQ(S)+12 in those patie nts with allergic rhinitis and HADS (HADS-A and HADS-D
subscales).
xPerform 12-lead electrocardiography (ECG)
xObtain urine for urinalysis (dip stick) If any assessment on the dipstick is abnormal, a urine 
sample should be sent to the central laboratory for testing. 
xPerform urine dipstick pregnancy test (for women of childbearing potential) 
xPerform blood sampling (fasting if morn ing visit) for the following tests:
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: 1 
Property of the [COMPANY_011] Group - Page 90- clinical laboratories, 
- serum immunoglobulins (total IgG, IgG subclasses1-4, IgM and IgA),  
- Systemic drug concentration,  - Anti-drug antibodies 
xDownload electronic diary/PEF meter and take back the device
xCall IVRS/IWRS to register the EOS date  
10.2 DEFINITION OF SOURCE DATA
Source data is all information in or iginal records and certified copi[INVESTIGATOR_122567], observations, or other activities in a clin ical trial necessary for the reconstruction and 
evaluation of the trial. Source data are contai ned in source documents. Source documents are 
original documents, data and records such as hosp ital records, clinic and office charts, laboratory 
notes, memoranda, pharmacy dispensing records, reco rded data from automated instruments, etc.
All the data collected in the e-CRF should be tran scribed directly from source documents.  Data 
downloaded from the study-associated central labora tories, spi[INVESTIGATOR_038], nitric oxide measurement, 
ECG, and patient electronic diary / PEF meter will be considered source data.
10.3 HANDLING OF PATIENT TEMPORARY OR PERMANENT TREATMENT 
DISCONTINUATION AND OF PATIENT STUDY DISCONTINUATION 
The IMP should be continued whenever possible.  In case the IMP is stopped, it should be 
determined whether the stop can be made tempor arily; permanent IMP discontinuation should be 
a last resort. Any IMP disconti nuation should be fully documented in the CRF. In any case, the 
patient should remain in th e study as long as possible.  
10.3.[ADDRESS_406019](s)
Temporary treatment discontinuatio n may be considered by [CONTACT_181280]. 
Reinitiation of treatment with the IMP will be done under close and appropriate clinical/and or 
laboratory monitoring once the Investigator will ha ve considered according to his/her best medical 
judgment that AE is sufficiently resolved and unl ikely to recur after resu ming therapy with IMP. 
In addition, the following conditions(s) will be causes for temporary treatment discontinuation: 
xInfections or infestations that do not respond to me dical treatment  
xAny laboratory abnormality that meets temporar y treatment discontinuation criteria as per 
Appendix K
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: [ADDRESS_406020](s)
Permanent treatment discontinuation is any tr eatment discontinuation associated with the 
definitive decision from the Investigator or the pa tient not to re-expose the patient to the IMP at 
any time. 
10.3.[ADDRESS_406021] of criteria for permanent treatment discontinuation
The patients may withdraw from treatment with th e IMP if they decide to do so, at any time and 
irrespective of the r eason, or this may be the Investigator‚Äôs  decision. All efforts should be made to 
document the reasons for treatment discontinuation and this should be documented in the CRF or 
e-CRF.
Patients must be withdrawn from the treatmen t (ie, from any further investigational product 
administration) for the following reasons:  
xAt their own request or at the request of th eir legally authorized representative (Legally 
authorized representative means an individua l or judicial or othe r body authorized under 
applicable law to consent on behalf of a prospe ctive patient to the patient‚Äôs participation in 
the procedure(s) involved in the research).
xIf, in the Investigator‚Äôs opi[INVESTIGATOR_1649], continuati on in the study would be  detrimental to the 
patient‚Äôs well-being 
xAt the specific request of the Sponsor 
xIn the event of a protocol de viation, at the discretion of th e Investigator or the Sponsor 
xAny code broken requested by [CONTACT_328745]. 
xPregnancy 
xAnaphylactic reactions or systemic allergic reactions that are related to IMP and require
treatment.
xDiagnosis of a malignancy during study, excludi ng carcinoma in situ of the cervix, or 
squamous or basal cell carcinoma of the skin. 
xAny opportunistic infection, such as TB or ot her infections whose nature or course may 
suggest an immunocompromised  status (See Appendix N). 
xSerum ALT >[ADDRESS_406022] and Total Bili rubin > 2ULN (See Appendix K). 
xSerum ALT > [ADDRESS_406023] if base line ALT < [ADDRESS_406024] or ALT >[ADDRESS_406025] if baseline ALT > [ADDRESS_406026] (Appendix K).
Any abnormal laboratory value or ECG parameter will be immediately rechecked for 
confirmation before making a decision of permanen t discontinuation of the IMP for the concerned 
patient.  
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: [ADDRESS_406027].
Patients who permanently discontinue the study medication will be asked and encouraged to 
return to the clinic for study visits and particip ate in assessments according to the visit schedule 
until the end of the study w ith a +/-5 day window (See S ection 1.3). Under exceptional 
circumstances when a patient cannot come to the site for the scheduled vi sit, a phone contact [CONTACT_328744]. Duri ng the phone contact, at least information about 
AEs, concomitant medication and asthma ex acerbation events should be collected.  
Patients who discontinue early from treatment may be asked to return to  the clinic to have 
additional ADA samples collected for analysis ba sed on the overall assessment of antibody titers 
and/or clinical presentation at  the time of discontinuation. 
All cases of permanent treatment discontinuation should be recorded by [CONTACT_328746]. 
10.3.[ADDRESS_406028] 
the patient (eg, contact[CONTACT_12531]‚Äôs family or pr ivate physician, reviewing available registries or 
health care databases), and to determine his/her he alth status, including at l east his/her vital status. 
Attempts to contact [CONTACT_328747]‚Äôs records (eg, times and dates 
of attempted telephone contact, receipt for sending a registered letter). 
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: [ADDRESS_406029] after 3 documented attempts via 2 different methods (phone, text, e-mail, certified 
letter, etc). 
The statistical analysis plan (SAP) will specify how these patients lost to follow-up for their 
primary endpoints will be considered. Patients who have withdrawn from the study cannot be 
rerandomized (treated) in the study. Their inclusi on and treatment numbers must not be reused.  
10.4 OBLIGATION OF THE INVESTIGATOR REGARDING SAFETY REPORTING 
10.4.1 Definitions of adverse events [IP_ADDRESS] Adverse event
An adverse event (AE) is any untoward medical occurrence in  a patient or clinical investigation 
patient administered a pharmaceutical product an d which does not necessarily have to have a 
causal relationship with this treatment.
Protocol defined asthma exacerbation events are collected as efficacy endpoints via the ‚ÄúAsthma 
Exacerbation Events‚Äù form. These events should not be reported as AEs unless they fulfill a seriousness criterion.
For this study, asthma exacerbations should be managed by [CONTACT_181283] / international asthma management guidelines.
[IP_ADDRESS] Serious adverse event
Aserious adverse event  (SAE) is any untoward medical  occurrence that at any dose:
xResults in death, or 
xIs life-threatening, or  
Note: The term ‚Äúlife-threatening‚Äù in the defin ition of ‚Äúserious‚Äù refers to an event in which 
the patient was at risk of death at the time of  the event; it does not refer to an event which 
hypothetically might have caused death if it were more severe.
xRequires inpatient hospi[INVESTIGATOR_73606], or 
xResults in persistent or significant disability/incapacity, or
xIs a congenital anomaly/birth defect 
xIs a medically important event
Medical and scientific judgment should be  exercised in deciding whether expedited 
reporting is appropriate in othe r situations, such as important medical events that may not 
be immediately life-threatening or result in death or hospi[INVESTIGATOR_326868] (ie, specific measures or corrective 
treatment) to prevent one of the othe r outcomes listed in the definition above. 
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: 1 
Property of the [COMPANY_011] Group - Page 94Note: The following list of medically important ev ents is intended to serve as a guideline for 
determining which condition has to be considered  as a medically important event. The list is 
not intended to be exhaustive: 
- Intensive treatment in an emergency room or at home for: 
- Allergic bronchospasm  
- Anaphylaxis (refer to Appendix M for Definition of Anaphylaxis) 
- Blood dyscrasias (ie, agra nulocytosis, aplastic anem ia, bone marrow aplasia, 
myelodysplasia, pancytopenia, etc),  
- Convulsions (seizures, epi[INVESTIGATOR_002], ep ileptic fit, absence, etc). 
- Development of drug dependence or drug abuse - ALT >[ADDRESS_406030] + total bilirubin >[ADDRESS_406031] or ALT increase > [ADDRESS_406032] 
- Suicide attempt or any event suggestive of suicidality 
- Syncope, loss of consciousness (except if documented as a consequence of blood 
sampling) 
- Bullous cutaneous eruptions - Cancers diagnosed during the study 
- Chronic neurodegenerative dis eases (newly diagnosed)  
[IP_ADDRESS] Adverse event of special interest
An adverse event of special intere st (AESI) is an AE (serious or  non-serious) of scientific and 
medical concern specific to the Sponsor‚Äôs pr oduct or program, for which ongoing monitoring and 
immediate notification by [CONTACT_328748]. Such events may require 
further investigation in order to characterize a nd understand them. Advers e events of special 
interest may be added or removed during a study by [CONTACT_12548]. 
For these AESIs, the Sponsor will be informed  immediately (ie, within 24 hours), per SAE 
notification described Section 10.4.4, even if not  fulfilling a seriousness criterion, using the 
corresponding pages in the CRF (to be  sent) or screens in the e-CRF. 
xAnaphylactic reactions or systemic allergic re actions that are related to IMP and require 
treatment (refer to Appendix M for Definition of Anaphylaxis) 
xSevere injection site reactions  that last longer than [ADDRESS_406033] one of the following criteria:
- Any serious infection (SAE) - Requires parenteral (intravenous, intramuscu lar, subcutaneous) antimicrobial therapy 
- Requires oral antimicrobial therapy for longer than 2 weeks 
- Is a parasitic infection - Is an opportunistic infection (see Appendix N ) 
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: 1 
Property of the [COMPANY_011] Group - Page 95Note:  antimicrobial therapy refers to  antibiotic, antiviral, and antifungal agents
xSignificant ALT elevation
- ALT >5 x the upper limit of normal (U LN) in patients with baseline ALT ¬î[ADDRESS_406034];
or 
- ALT >[ADDRESS_406035] if baseline ALT >[ADDRESS_406036] entered in a study with IMP/Noninvestigational medicinal 
product (NIMP);
- Pregnancy occurring in a female patient entered in the clinical trial or in a female 
partner of a male patient entere d in the clinical trial. It wi ll be qualified as an SAE only 
if it fulfills one of the seri ousness criteria (see Section [IP_ADDRESS]).
- In the event of pregnancy in a female participant, IMP should be discontinued.  
- Follow-up of the pregnancy in a female par ticipant or in a female partner of a male 
participant is mandatory until the outcome has been determined. 
xSymptomatic overdose (serious or non-serious) with IMP/NIMP
- An overdose (accidental or intentional) w ith the IMP is an event suspected by [CONTACT_328749] 11 days. The circumstances (ie, 
accidental or intentional) should be clearly specified in the verbatim and symptoms, if 
any, entered on separate adverse event forms.
- An overdose (accidental or intentional) w ith any NIMP is an event suspected by [CONTACT_328750]. The circumstances (ie, accidental or intentiona l) should be clearly speci fied in the verbatim and 
symptoms, if any, entered on separate AE forms. 
Of note, asymptomatic overdose has to  be reported as a standard AE.
10.4.2 Serious adverse events waived from expedited regulatory reporting to regulatory 
authorities
Not applicable.
10.4.3 General guidelines for reporting adverse events
xAll AEs, regardless of seriousness or re lationship to IMP/NIMP, spanning from the 
signature [CONTACT_206411] [CONTACT_181286], are to be recorded on the correspond ing page(s) or screen(s) of 
the CRF.
xWhen a safety event is categorized as a prim ary outcome, the event will be reported as an 
AE but will be waived from reporting to h ealth authorities providing an agreement has 
been reached with them.
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: [ADDRESS_406037] to 
IMP, corrective treatment/therapy given, additional investigations performed, outcome, and his/her opi[INVESTIGATOR_328708] r there is a reasonable possibili ty that the AE was caused 
by [CONTACT_179646](s). In studies that require the use of 
combined/multiple IMPs/NIMPs, the Global Safety Officer (GSO) with input from other 
appropriate study team members must determin e if the causal relationship will either be 
assessed for the combined product as a regime n or as distinct entities. The GSO must 
communicate this decision to the study team for inclusion in the protocol and AE CRF.
xThe Investigator should take appropriate measur es to follow all AEs until clinical recovery 
is complete and laboratory results have returned to normal, or until progression has been 
stabilized, or until death, in order to ensure the safety of the patients. This may imply that 
observations will continue beyond the last pla nned visit per protocol, and that additional 
investigations may be requested by [CONTACT_328751]. 
Patients who experience an ongoi ng SAE or an AESI with i mmediate notification, at the 
prespecified study end-date, should be followe d until resolution, stabilization, or death and 
related data will be collected.
xWhen treatment is prematurely discontinued, the patient‚Äôs observations will continue until
the end of the study as defined by [CONTACT_56485]. 
xLaboratory, vital signs or ECG abnormalities are to be recorded as AEs only if: 
- Symptomatic and/or 
- Requiring either corrective trea tment or consultation, and/or  
- Leading to IMP discontinuation or modification of dosing, and/or  
- Fulfilling a seriousness criterion, and/or - Defined as an AESI
The following table summarizes the reporting timelines: 
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: 1 
Property of the [COMPANY_011] Group - Page 97Adverse event / laboratory abnormality Reporting timeline
Serious adverse event Within 24 hours
Pregnanc y Within 24 hours
Overdose S ymptomatic Within 24 hours
Asymptomatic Routine
ALT elevation $/7!8/1LIEDVHOLQH$/7LV¬î8/1
ALT  > [ADDRESS_406038]  if baseline ALT is > [ADDRESS_406039] lon ger than 24 hours Within 24 hours
Infections as defined in Section [IP_ADDRESS]. Within [ADDRESS_406040] immediately:
xENTER (within 24 hours) the information related to the SAE in the appropriate screens of 
the e-CRF; the system will automatically send a notification to the monitoring team after approval of the Investigator within the e-CRF or after a standard delay.
xSEND (preferably by [CONTACT_3719] e-mail) a photocopy of all examinations carried out and the 
dates on which these examinations were perfor med, to the representa tive of the monitoring 
team whose name, fax number, and email addr ess appear on the clin ical trial protocol. 
Care should be taken to ensure that the patie nt's identity is protected and the patient's 
identifiers in the clinical trial are properly mentioned on any copy of a source document 
provided to the Sponsor. For la boratory results, include the laboratory normal ranges. 
xAll further data updates should be recorded in the e-CRF as appr opriate, and further 
documentation as well as additional inform ation (for laboratory data, concomitant 
medications, patient status, etc)  should be sent (by [CONTACT_3719] e- mail) to the monitoring team 
within 24 hours of knowledge of the SAE. In  addition, every effort should be made to 
further document any SAE that is fatal or life threatening within a w eek (7 days) of the 
initial notification.
xA back-up plan (using a paper CRF process) is available and should be used when the 
e-CRF system does not work. 
Any SAE brought to the attention of  the Investigator at any time after the end of the study for the 
patient and considered by [CONTACT_12552]/her to be caused  by [CONTACT_56486] a reasonable possibility, should 
be reported to the monitoring team. 
10.4.5 Guidelines for management of specific laboratory abnormalities
Decision trees for the management of certain laboratory abnormalities by [CONTACT_326926] K.
The following laboratory abnormalities should be monitored, documented, and managed 
according to the related flow chart in protocol appendices. 
xNeutropenia 
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: 1 
Property of the [COMPANY_011] Group - Page 98xThrombocytopenia 
xIncrease in ALT
xAcute renal insufficiency
xSuspi[INVESTIGATOR_328709]: In some clinical trials these laboratory abnormalities can be considered as AESIs. For this 
study, only significant ALT increase will be considered as AESIs (see Section [IP_ADDRESS])  
In addition, on treatment eo sinophil counts >3000 cells/ ŒºL (3.0 giga/L) are to be reported as AEs.
10.5 OBLIGATIONS OF THE SPONSOR 
During the course of the study, the Sponsor  will report in an expedited manner: 
xAll SAEs that are both unexpected and at le ast reasonably related to the IMP (S[LOCATION_003]R), to 
the regulatory authorities, IECs/IRBs as a ppropriate and to the Investigators.    
xAll SAEs that are expected and at least reas onably related to the IMPs to the regulatory 
authorities, according to local regulations.
In this study, some AEs are c onsidered related to the underlying condition and thus will not be 
considered unexpected [eg, wheezing related to asthma].
Any other AE not listed as an expected event in th e Investigator‚Äôs Brochure  or in this protocol 
will be considered unexpected. 
For safety, the treatment code will be unbli nded by [CONTACT_328752] s adverse drug reaction (S[LOCATION_003]R) and reasonably 
associated with the use of the IMP according to eith er the judgment of the Investigator and/or the 
Sponsor. 
In case of a S[LOCATION_003]R, [COMPANY_011] Global Pharmacovig ilance and Epi[INVESTIGATOR_328710].
The Sponsor will report all safety observations ma de during the conduct of the trial in the clinical 
study report.
10.[ADDRESS_406041] therapeutic 
monoclonal antibodies.
Allergic reactions may be defined as an imm unologically mediated response to a pharmaceutical 
and/or formulation agent in a sensitized person. Signs and symptoms are often experienced during 
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: [ADDRESS_406042] severe form of 
allergic reactions, refer to Appendix M ‚ÄúDefinition of  Anaphylaxis‚Äù, which describes the clinical 
criteria for the diagnosis of anaphylaxis. 
Patients should be monitored for at least [ADDRESS_406043] (AESI) (within 24 hours, for further 
details, see AESI definition in Section [IP_ADDRESS] and Appendix M) and st udy medication must be 
permanently discontinued. ADA and PK samples will be  collected near the onset and resolution of 
the AESI for any additional analysis. 
10.6.[ADDRESS_406044] dose level (300 mg weekly), 
severe injection site reactions, are considered as a potential ri sk. Patients who experience an 
injection site reaction must be cl osely monitored for the possibility of a more intense injection site 
reaction with a future injection. Any severe inje ction reaction that lasts over 24 hours will be 
reported as an AESI with immediate notificati on. ADA and PK samples will be collected near the 
onset and resolution of the AESI  for any additional analysis. 
Prophylactic treatment/premedication for an Injection Site Reaction is not permitted.
10.6.[ADDRESS_406045] been associated with an increased risk of infection, including 
opportunistic infection.  As a precautionary measur e, the Investigator is  required to carefully 
monitor for any signs or symptoms of infec tion such as, but not limited to, increased body 
temperature, malaise, weight loss, sweats, cough, dys pnea, pulmonary infiltrates, or serious febrile 
systemic illness.
Since dupi[INVESTIGATOR_181222]- 5ƒÆSUHYHQWLQJ,/ -4 and IL-13 activation of their respective 
receptors, it inhibits the T-helper 2 (Th2) cyt okines production. Infections with a diversity of 
helminthic parasites elicit eosi nophilia via stimulation of Th2-like  lymphocyte responses. The Th2 
response is characterized by [CONTACT_328753]-4, IL-[ADDRESS_406046]'s immune response and by [CONTACT_181291], includ ing its distribution, migration, and development 
within the infected host. Ther efore, patients treated with dupi[INVESTIGATOR_328711]. 
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: 1 
Property of the [COMPANY_011] Group - Page 100In order to minimize this risk, any patient with  an active parasitic inf ection should be excluded 
from the study. Similarly, patients with suspected pa rasitic infection, or t hose at high risk of 
parasitic infection are also excluded, unless c linical and (if necessary) laboratory assessments 
have ruled out active infection before randomiza tion. During the study, appearance of signs or 
symptoms (such as abdominal pain, cough, diarrh ea, fever, fatigue hepatosplenomegaly) that 
could be associated with a parasitic infection should  be carefully evaluated, especially if there is a 
history of parasitic exposure th rough recent travel to/ or residen ce in endemic areas, especially 
when conditions are conducive to infection (eg, exte nded stay, rural or slum areas, lack of running 
water, consumption of uncooked, undercooked, or ot herwise potentially contaminated food, close 
contact [CONTACT_328754] s, etc.). Subsequent medical assessments (eg, stool exam, blood 
tests, etc.) must be performed in order to rule out parasitic infection/infestation. Patients with 
confirmed parasitic infections during the study should be reported as AESI with immediate 
notification.    
Infections defined in Section [IP_ADDRESS] should be reported as  AESIs within 24 hours. 
A complete diagnostic work-up should be perf ormed (i.e., cultures, histopathological or 
cytological evaluation, antigen dete ction and serum antibody titers).  Patients should be referred to 
an infectious disease specialist if deemed ne cessary for diagnostic work up and appropriate 
treatment.
Infections or infestations that do not respond to medical treatment should have study drug 
discontinued until the infection is resolved. 
For any opportunistic infection, su ch as TB or other infections whose nature or course may 
suggest an immunocompromised status (See Appendix N ), patients must be permanently 
discontinued from study medication. 
10.6.4 Elevated liver function tests
No pre-clinical and clinical data has suggested any hepatic toxicity of dupi[INVESTIGATOR_12458]; however, as a 
general consideration of clini cal development, the administration of immunosuppressant or 
immunomodulating agents may represent an ad ditional risk factor for hepatotoxicity.  
Hepatitis virus tests and liver function tests (LFT) will be performed at Visit 1, prior to 
randomization to exclude those patient s with high risk of hepatitis in fection or severe liver injury 
from this study (Refer to Section 7.2 and Section [IP_ADDRESS]).
In order to closely follow potentia l liver abnormalities, assessment  of total protein, albumin, total 
bilirubin (in case of values above the norma l range, differentiation in conjugated and 
non-conjugated bilirubin), alanine aminotransferase, aspartate am inotransferase, and alkaline 
phosphatase are measured as part of th e clinical laboratory testing (Refer to Section [IP_ADDRESS] ).  
Guidance for the investigation of elevated ALT as well as concurrent management of IMP is 
provided in Appendix K.
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: 1 
Property of the [COMPANY_011] Group - Page [ZIP_CODE].7 ADVERSE EVENTS MONITORING
All events will be managed and reported in co mpliance with all applicable regulations, and 
included in the final clinical study report. 
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: [ADDRESS_406047] to the 2 pr imary endpoints: annualized rate of severe 
exacerbations during the 52-week treatment peri od and absolute change from baseline in FEV 1at 
Week 12. Assuming the number of severe exacer bations follows a negative binomial distribution 
with a dispersion parameter of 2, a placebo a nnualized rate of exacerbations being 0.6, a 
randomization ratio of 2:2:1:1, with 1638 rando mized patients (546 for each dupi[INVESTIGATOR_328646] 
273 for each matching placebo group), the study will have 99% power to detect a 55% relative 
risk reduction (ie, annualized rate of 0.27 for the dupi[INVESTIGATOR_24769]) in the annualized rate of 
severe exacerbations at the 2- WDLOHGVLJQLILFDQFHOHYHORIƒÆ  05.  Assuming 42% patients with a 
baseline eosinophil count ¬ïFHOOV¬ó/  giga/L), approximately 690 patients ([ADDRESS_406048] acebo) will provide 91% power to detect a 
55% relative risk reduction for the subgroup. Assu ming a common standard deviation of 0.5 L, 
1638 patients will provide 98% power to detect a tr eatment difference of 0.15 L in the change of 
FEV 1from baseline at Week 12 fo r the overall population, and 690 pa tients will provide 88% 
power to detect a treatment difference of 0.18 L for patients with a baseline eosinophil count ¬ï
cells/ /ŒºL (0.3 giga/L). The overall study recruitment will continue until at least 1638 patients in 
total and 690 patient VZLWKHRVLQRSKLOV¬ïFHOOV ŒºL (0.3 giga/L) are randomized. The 
recruitment for patients on trea tment of medium dose of ICS will stop when approximately [ADDRESS_406049] been randomized  into the study. In addition, approximately 84 
adolescent patients will be randomized.
Patients will be randomized using a 2:2:1:1 ra ndomization ratio for dupi[INVESTIGATOR_12458] 300 mg q2w and 
dupi[INVESTIGATOR_12458] 200 mg q2w, placebo q2w in 2 mL an d placebo q2w in 1.14 mL respectively.  
Randomization will be stratified by [CONTACT_654] (<18 years, ¬ï\HDUV at screening, ce ntral eosinophil 
count (FHOOV¬ó/¬ïFHOOV ŒºL) at screening, ICS dose level (medium, high) and country. 
In addition, in order to have addi tional patients treated with dr ug manufactured using the intended 
commercial process, approximately 220 patients will be  randomized in addition to the originally 
planned sample size (1638). 
11.[ADDRESS_406050] of all patients with a treatment kit number allocated and recorded in 
IVRS database, and regardless of whet her the treatment kit was used or not.
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: 1 
Property of the [COMPANY_011] Group - Page 103Patients treated without being ra ndomized will not be considered as randomized and will not be 
included in any efficacy population, but will be  included in the safety population.   
11.3 ANALYSIS POPULATIONS
11.3.1 Efficacy populations
The analysis population for the efficacy endpoint s will be intent-to-tr eat (ITT) population. The 
two primary endpoints will also be analyzed in the HEos ITT population. 
ITT population: all randomized population analyzed  according to the treatment group allocated by 
[CONTACT_328755].
HEos ITT population:  ITT population with baseline eosi QRSKLOV¬ïFHOOV PL. 
11.3.[ADDRESS_406051]-treatment Period or till the rollover to 
the extension study. 
In addition:  
xRandomized patients for whom it is unclear whether they took the study medication will 
be included in the safety population as randomized. 
11.3.[ADDRESS_406052] dose of the study medication. 
Patients will be analyzed according to the treatment actually received.
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: 1 
Property of the [COMPANY_011] Group - Page [ZIP_CODE].4 STATISTICAL METHODS
11.4.1 Extent of study treatment exposure and compliance
The extent of study treatment exposure and co mpliance will be assessed and summarized by 
[CONTACT_179650].
[IP_ADDRESS] Extent of investigational medicinal product exposure
Duration of IMP exposure is defined as:  last dose date ‚Äì first dose date + 14 days, regardless of 
unplanned intermittent discontinuations. 
[IP_ADDRESS] Compliance 
An administration is considered compliant if an  injection is performed, regardless the actual 
amount of solution injected. The loading dose wi ll be considered as two administrations. No 
imputation will be made for patients with missing or incomplete data. 
Treatment compliance will be summarized descri ptively (N, Mean, SD, Median, Min, and Max). 
The percentage of patients with compliance is <80% will be summarized.  
11.4.2 Analyses of efficacy endpoints 
[IP_ADDRESS] Analysis of primary efficacy endpoints 
The annualized rate of severe exacerbation even ts will be analyzed using a negative binomial 
regression model. The model will include the total number of events occurring during the 
52 weeks as the response vari able, with the treatment group, age, region (pooled country), 
baseline eosinophil strata, baseline ICS dose leve l and number of severe exacerbation events 
within [ADDRESS_406053] 
model with repeated measures (MMRM) approac h. The model will include change from baseline 
in FEV 1 values up to Week 12 as response variable s, and treatment, age, sex, height, region 
(pooled country), baseline eosinophil strata, base line ICS dose level, visi t, treatment by-visit 
interaction, baseline FEV 1value and baseline-by-visit interacti on as covariates. An unstructured 
correlation matrix will be used to model the with in-patient errors. Parameters will be estimated 
using restricted maximum likelihood method w ith the Newton-Raphson algorithm. Statistical 
inferences on treatment comparisons for the change from baseline in FEV 1at Week [ADDRESS_406054] model. For pati ents discontinuing the treatment before Week 12, 
off study-treatment FEV 1 values measured up to Week 12 will be included in the primary 
analysis. 
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: 1 
Property of the [COMPANY_011] Group - Page 105Subgroup analyses will be performed for the tw o primary endpoints using the same methods by 
[CONTACT_328756]HRVLQRSKLOOHYHOV¬ïFHOOV»ù/YVFHOOV»ù/DQ G¬ïFHOOV»ù/YVFHOOV»ù L). 
[IP_ADDRESS].1Analysis of annualized event rate
The annualized rate of exacerbation events, includ ing severe exacerbation events resulting in 
hospi[INVESTIGATOR_328712], will be analyzed using the same way 
as for severe exacerbation events.  
[IP_ADDRESS].2Analysis of Time to event variables
Time to event (eg, LOAC, severe exacerbation) will be analyzed using a Cox regression model with time to event as the dependent variable, a nd treatment, age, number of asthma exacerbation 
events within 1 year prior to the study, region (pooled country),  baseline eosinophil strata and 
baseline ICS dose level as covariates. The Kapl an-Meier method will be used to respectively 
estimate the probabilities that a patient would experience events at Week 12, 24, 36 and 52 per 
each treatment group. 
[IP_ADDRESS].3Analysis of change from baseline for other continuous variables
The change from baseline for other continuous e ndpoints will be analyzed using MMRM in the 
same fashion as for the endpoint of FEV 1. The covariates to be include d are treatment, age, region 
(pooled country), baseline eosinophil strata, base line ICS dose level, visi t, treatment-by-visit 
interaction, corresponding baseline value and baseline-by-visit in teraction. Sex and height will be 
included as covariates only in the models for spi[INVESTIGATOR_328649].  
Descriptive statistics including number of patient s, mean, standard error and LS means will be 
provided. In addition, differences in LS means, the corresponding 95% CI and the p-value will be 
derived from the MMRM model for comparison of dupi[INVESTIGATOR_209335].
Change from baseline at other time point s will be analyzed in the same way.
[IP_ADDRESS].4Subgroup analysis
To assess the consistency in treatment effects across the subgroup levels , subgroup analyses will 
be performed for the primary efficacy endpoint s with respect to baseline eosinophil level ¬ï
FHOOV»ù L YVFHOOV»ù L DQG¬ïFHOOV»ù/YVFHOOV»ù/ age group, gender, region, 
race, background ICS dose levels, background controller medication type, baseline FEV 1,
predicted FEV 1%, ACQ-5, weight, BMI, sm oking history, atopic medical history, age of onset of 
asthma and number of asthma exacerbation ev ents within 1 year prior to the study. 
[IP_ADDRESS] Multiplicity considerations
To strongly control the type-I e rror rate for the primary family (two primary endpoints and two 
doses), a hierarchical testing procedure will be applied at a 2-sided 5% significant level, ie, each 
hypothesis will be formally tested only if the pr eceding one is significant at the 5% level. The 
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: 1 
Property of the [COMPANY_011] Group - Page 106hierarchy of the tests will be: 1) annualized severe exacerbation rate for 300 mg q2w versus 
placebo, 2) absolute change from baseline in FEV 1 at Week 12 for 300 mg q2w versus placebo, 3) 
annualized severe exacerbation rate for 200 mg q2 w versus placebo, 4) absolute change from 
baseline in FEV 1 at Week 12 for 200 mg q2w versus placebo. 
If both doses are significant fo r both primary endpoints, a selec tive set of secondary endpoints 
will be tested following a hierarchical testing pro cedure at a 2-sided 5% significant level. The list 
of secondary endpoints to be tested in the hierarch ical order will be specified in SAP. The overall 
familywise error rate will be strongly controlled  at a 2-sided 5% level for all tested endpoints 
across dose groups.
[IP_ADDRESS] Handling of missing data 
Sensitivity analyses excluding the additional off-treatment measurements up to Week 52 will be 
performed to corroborate the primary analyses. The reason and pattern of missing data will be 
carefully examined and tippi[INVESTIGATOR_328713]. The details will be specified in the SAP. 
[IP_ADDRESS] Loading dose evaluation
To examine if inclusion of the loading dose may impact demonstration sustained efficacy regard 
to exacerbations, additional sensitivity analyses of the annualized rate of severe exacerbation will 
be performed by [CONTACT_328757] 
[ADDRESS_406055] 12 
weeks, two dupi[INVESTIGATOR_328714].   
11.4.3 Analyses of safety data
The summary of safety results will be presen ted by [CONTACT_1570]. Th e results of the two 
placebo groups will be presented separately. All sa fety analyses will be performed on the safety 
population using the following common rules:
The baseline value is defined generally as the last  available value before the first dose of IMP.  
The following definitions will be applied to laboratory parameters, vital signs and ECG.
xThe potentially clinically si gnificant abnormality (PCSA) values are defined as abnormal 
values considered medically important by [CONTACT_56493]/thresholds based on literature review  and defined by [CONTACT_326932], vital signs and ECG. 
xPCSA criteria will determine which patients ha d at least 1 PCSA during the on-treatment 
period, taking into account all evaluations  performed during the on-treatment period, 
including unscheduled or repeated evaluations.  The number of all such patients will be the numerator for the on-treatment PCSA percentage.  
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: 1 
Property of the [COMPANY_011] Group - Page [ZIP_CODE].4.3.1 Adverse events
Adverse event incidence tables will presen t by [CONTACT_9313] (SOC) (sorted by 
[CONTACT_56496]), high-level group te rm (HLGT), high level te rm (HLT) and preferred 
term (PT) sorted in alphabetical order for eac h treatment group, the number (n) and percentage 
(%) of patients experiencing an AE.  Multiple occurrences of the same event in the same patient will be counted only once in the tables with in a treatment phase. The denominator for 
computation of percentages is the safe ty population within each treatment group. 
Proportion of patients with at least one treatmen t emergent adverse event (TEAE), serious TEAE
and TEAE leading to discontinuation of the study will be tabulated by [CONTACT_1570]. In
addition TEAEs will be described according to maximum intensity and relation to the study drug. 
None treatment emergent serious AE, None  treatment emergent AE leading to study 
discontinuation will be summarized separately.
[IP_ADDRESS].1 AESI 
The following summaries will be generated: 
xIncidence of each AESI will be  tabulated by [CONTACT_1570].  
xThe time-to-first event analyzed using K- M methods and displayed as K-M plots 
(cumulative incidence (%) versus time based on K-M estimates) will be provided to depi[INVESTIGATOR_328715]. When TEAE st art date or worsening date is partially
available, the maximum of the earliest possi ble TEAE start date and the treatment start
date will be used. When TEAE start date or  worsening date is completely missing, the 
treatment start date will be used. 
xAn overview summary of the nu mber (%) of patients with 
- any TEAE
- any serious AE (regardless of treatment-emergent status)
- any treatment-emergent SAE- any AE leading to death - any TEAE leading to permanent study drug discontinuation 
- any TEAE by [CONTACT_11196], correc tive treatment, and final outcome 
- cumulative incidence at specified time poi nts (K-M estimates at 1 week, 4 weeks, 
12 weeks, 24 weeks and 52 weeks) 
AESI definitions and the method to identif y AESIs will be specified in the SAP. 
[IP_ADDRESS].2Death
The following deaths summaries will be generated:
xNumber (%) of patients who died by [CONTACT_328758] (TEAE, on-study) and reasons for death 
summarized on the safety population by [CONTACT_328759] 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: 1 
Property of the [COMPANY_011] Group - Page 108xDeath in nonrandomized patients or ra ndomized and not treated patients   
xTEAE leading to death (death as an outcome  on the AE CRF page as reported by [CONTACT_3786]) by [CONTACT_148274] , HLGT, HLT and PT showing number (%) of patients 
sorted by [CONTACT_179654], HLT, and 
PT. 
Patient data listings will be  provided for all AEs, TEAEs, SAE, AEs leading to study 
discontinuation, AESIs and deaths. 
[IP_ADDRESS].3Clinical Laboratory Evaluation, Vital Signs and electrocardiogram data 
Results and change from baseline for the paramet ers will be summarized by [CONTACT_328760], endpo int, minimum and maximum value. Summary 
statistics will include number of patients, m ean, standard deviation, median, Q1, Q3, minimum 
and maximum.  
The proportion of patients who had at least one incidence of PCSA at any time during the TEAE
period will be summarized by [CONTACT_1570]. Shift tables showing changes with respect to the 
baseline status will be provided.
Listings will be provided with flags indicating clinically out-of range values, as well as PCSA
values.
[IP_ADDRESS] Vaccine response
For patients who receive vaccination, vaccine response parameters will be summarized by 
[CONTACT_328761].
11.4.4 Analyses of systemic drug concentration, anti-drug antibodies and 
pharmacodynamic variables
[IP_ADDRESS] Drug concentration analysis
Concentrations of functional dupi[INVESTIGATOR_328716], SD, standard error of the m ean (SEM), coefficient of variation (CV%), 
minimum, median, and maximu m by [CONTACT_181300]. 
Concentrations of functional dupi[INVESTIGATOR_328717]-
linear mixed effects modeling if wa rranted. Additional details of the analysis plan and the results 
will be provided in a separate document.
[IP_ADDRESS] Anti-drug antibodies analysis
Incidence of positivity in  the ADA assay will be assessed as ab solute occurrence (n) and percent 
of patients (%), presented by [CONTACT_328762]. Listi ng of all ADA titer levels will be provided for
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: [ADDRESS_406056] of ADA on safety and efficacy may be provided.   
ADA at baseline will be summarized by:
[CONTACT_328763] (%) of patients with a baseli ne sample negative in the ADA assay. 
xNumber (%) of patients with a base line sample positive in the ADA assay.
xThe summary statistics (including number, median, Q1, Q3, minimum and maximum) of 
the titer for patients positive in  the ADA assay at baseline. 
ADA incidence and titer will be provided for the following: 
xNumber (%) of patients nega tive in ADA assay at all times
xNumber (%) of patients positiv e in ADA assay at any time
xNumber (%) of patients w ith treatment-emergent ADA
xThe summary statistics (including number, median, Q1, Q3, minimum and maximum) of 
the peak post-baseline titer for patients with treatment-emergent ADA
xNumber (%) of  patients with transient treatment-emergent ADA
xNumber (%) of patients with pe rsistent treatment-emergent ADA
Titer values (Titer value category)
The minimum titer for samples positive in the ADA assay is based on the minimum required 
dilution of the assay. 
     Low (Titer < 1000) 
0RGHUDWH¬î7LWHU¬î
     High (Titer > 10,000) 
More details will be specified in SAP.
[IP_ADDRESS] Pharmacodynamics
The values to be used as baselines will be thos e collected on Day 1 (predo se assessments). If any 
of the scheduled assessments on Da y 1 are technically di squalified (eg, insufficient sample), then 
values determined at Screening can be used as baseline.
For all parameters, raw data, absolute changes from baseline and percent changes from baseline 
will be summarized in descriptive sta tistics by [CONTACT_11571]. 
Summary plots (mean +/- standard error of the mean) on raw data, absolute changes from baseline 
and percent changes from baseline w ill be provided by [CONTACT_1570]. 
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: 1 
Property of the [COMPANY_011] Group - Page [ZIP_CODE].4.5 Analyses of Patient Reported Outcomes (Health-related Quality of Life/health
economics variables
Change from baseline in the following variable s: global measure of AQLQ(S) and the four 
domains, the quantitative variables of EQ-5D-5L (s ingle index utility), the anxiety and depression 
scores of HADS will be analyzed with an MMRM approach described previously for the 
continuous efficacy variables. Descriptive statistic s including number of patients, mean, standard 
error and LS means will be provided.  In additi on, difference in LS means, the corresponding 95% 
CI‚Äôs and the p-values will be provided for comparison between dupi[INVESTIGATOR_24765]. 
SNOT-22 (only for those patients with bilateral na sal polyposis and/or chronic rhinosinusitis) and 
RQLQ(S)+12 (only for those patients with comorbid  allergic rhinitis) will be analyzed using the 
similar approach.
11.5 INTERIM ANALYSIS
There is no interim analysis  planned for this study.  
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: 1 
Property of the [COMPANY_011] Group - Page [ZIP_CODE] ETHICAL AND REGULATORY CONSIDERATIONS
12.1 ETHICAL AND REGULATORY STANDARDS
This clinical trial will be conducted by [CONTACT_37922], the Investigator, dele gated Investigator staff 
and Subinvestigator, in accordance with the pr inciples laid down by [CONTACT_941] 18th World Medical 
Assembly (Helsinki, 1964) and all applicable amendments laid down by [CONTACT_56501], and the ICH guidelines for good clinical  practice (GCP), all a pplicable laws, rules 
and regulations. 
This clinical trial will be reco rded in a free, publicly accessible, internet-based registry, no later 
than [ADDRESS_406057] patient enrollment, in compliance with applicable regulatory 
requirements and with [COMPANY_011] public  disclosure commitments.  
12.2 INFORMED CONSENT
The Investigator (according to applicable regula tory requirements), or a person designated by [CONTACT_3786], should fully inform the patient (a nd the parent[s] or guard ian[s] for pediatric 
patients) of all pertinent aspects of the clini cal trial including the wr itten information given 
approval/favorable opi[INVESTIGATOR_213658] / Institutional Ethics Committee 
(IRB/IEC). All participants should be informed to  the fullest extent pos sible about the study in 
language and terms they are able to understand.  
Prior to a patient‚Äôs partic ipation in the clinical trial, the informed consent form should be signed, 
name [CONTACT_56535] [CONTACT_13935] (for adult patients) or patient‚Äôs parent(s) for pediatric patients or by [CONTACT_42036]‚Äôs legally acceptable repr esentative, and by [CONTACT_37994].  A c opy of the signed and dated written informed 
consent form will be provided to the patient (for a dult patients) or patient‚Äôs parent(s) for pediatric 
patients. Local law must be observed in deciding whether 1 or both parents/guardians consent is 
required for pediatric patients.  If only [ADDRESS_406058] document the reason for only 1 parent or guardian‚Äôs signature. 
In addition, participants will assent as detail ed below or will follow the Ethics Committee 
(IRB/IEC) approved standard practice for pediatric participants at ea ch participating center (age of 
assent to be determined by [CONTACT_1201]‚Äôs/IEC‚Äôs or  be consistent with the local requirements):
Pediatric participants who can read the assent form will do so before writing their name [CONTACT_282195]. 
Pediatric participants who can write  but cannot read will have the asse nt form read to them before 
writing their name [CONTACT_25084]. 
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: [ADDRESS_406059] the assent 
form read to them in presence of an impartial w itness, who will sign and date the assent form to 
confirm that assent was given.
The informed consent form and the assent form used by [CONTACT_181302]‚Äôs Informed Consent must be reviewed and approved by  [CONTACT_328764] (IRB/IEC) fo r approval/favorable opi[INVESTIGATOR_1649].
In relation with the population of patients exposed in the trial, ie, pediatric/minor patients, the 
IRB/IEC should ensure proper advice from specialis t with pediatrics exper tise (competent in the 
area of clinical, ethical and psychosocial problems in the field of pediatrics) according to national 
regulations. This should be documented.
Prior to collection of blood for pharmacogenetics,  the optional pharmacogenetic informed consent 
form (written) should be signed, name [CONTACT_328780] i n, and personally dated by [CONTACT_328765]‚Äôs legally acceptable re presentative, and by [CONTACT_328766]. A copy of the signed and date d written optional informed consent form will be 
provided to the subject. 
Prior to collection of blood for evaluation of vaccine response, the opt ional vaccine response 
informed consent form (written) should be signed, name [CONTACT_181314], and personally dated by [CONTACT_328767]‚Äôs legally acceptable representative, and by [CONTACT_16994]. A copy of the signe d and dated written optional informed consent 
form will be provided to the subject. 
Prior to collection of blood fo r archiving of serum, the optional Future Use of Specimens 
informed consent form (written) should be signed, name [CONTACT_181314], and personally dated by [CONTACT_328767]‚Äôs legally acceptable representative, and by [CONTACT_16994]. A copy of the signe d and dated written optional informed consent 
form will be provided to the subject. 
The main study informed consent form, the opti onal Pharmacogenetic informed consent form, 
optional Vaccine Response informed consent form and the Future Use of Specimens informed 
consent form to be used by [CONTACT_112108]'s informed consent must be 
reviewed and approved by [CONTACT_179656] 
(IRB/IEC) for approval/favorable opi[INVESTIGATOR_1649]. 
If the race/ethnic origin of the patients will be collected in the clinical trial, the scientific 
justification should be specified. 
12.[ADDRESS_406060]/INDEPE NDENT ETHICS COMMITTEE (IRB/IEC)
As required by [CONTACT_1295], the Investigator or the Sponsor mu st submit this clinical trial 
protocol to the appropriate IRB/IEC, and is requ ired to forward to the respective other party  a 
copy of the written and dated approval/favorable  opi[INVESTIGATOR_56398]/IEC 
composition. 
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: 1 
Property of the [COMPANY_011] Group - Page 113The clinical trial (study number, clinical trial protocol title an d version number), the documents 
reviewed (clinical trial protocol, informed consen t form, Investigator‚Äôs Brochure, Investigator‚Äôs 
curriculum vitae [CV], etc) and the date of the review should be clearly stated on the written 
(IRB/IEC) approval/favorable opi[INVESTIGATOR_1649].
IMP will not be released at the study site and th e Investigator will not st art the study before the 
written and dated approval/favorable opi[INVESTIGATOR_56399].
During the clinical trial, any am endment or modification to the c linical trial protocol should be 
submitted to the IRB/IEC before implementation, unless the change is necessary to eliminate an immediate hazard to the patients, in which cas e the IRB/IEC should be informed as soon as 
possible. It should also be informed of any event likely to affect the sa fety of patients or the 
continued conduct of the clinical trial, in particular any change  in safety. All updates to the 
Investigator‚Äôs Brochure will be sent to the IRB/IEC.
A progress report is sent to the IRB/IEC at least annually and a su mmary of the clinical trial‚Äôs 
outcome at the end of the clinical trial. 
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: 1 
Property of the [COMPANY_011] Group - Page [ZIP_CODE] STUDY MONITORING
13.1 RESPONSIBILITIES OF THE INVESTIGATOR(S)
The Investigator is required to ensure compliance with all procedures required by [CONTACT_56507] (i ncluding security rules). The 
Investigator agrees to provide reliable data and all information requested by [CONTACT_56508] (with the help of the CRF, Discrepa ncy Resolution Form [DRF] or other appropriate 
instrument) in an accurate and legible manner accor ding to the instructions provided and to ensure 
direct access to source documents by [CONTACT_56509].
If any circuit includes transfer of data particular attention should be paid to the confidentiality of 
the patient's data to be transferred.
The Investigator may appoint such other indi viduals as he/she may deem appropriate as 
Subinvestigators to assist in the conduct of the c linical trial in accordance with the clinical trial 
protocol. All Subinvestigators shall be a ppointed and listed in a timely manner. The 
Subinvestigators will be supervised by [CONTACT_328768]. The 
Investigator will provide them with a copy of the clinical tr ial protocol and all necessary 
information. 
13.[ADDRESS_406061] of the clinical trial as regards ethics, clinical trial protocol 
compliance, and integrity and validity of the data  recorded on the CRFs. Thus, the main duty of 
the monitoring team is to help the Investigator and the Sponsor maintain a high level of ethical, 
scientific, technical and regulatory quality  in all aspects of the clinical trial.
At regular intervals during the clinical trial, th e site will be contact[INVESTIGATOR_530], through monitoring visits, 
letters or telephone calls, by a representative of  the monitoring team to review study progress, 
Investigator and patient compliance with clinical  trial protocol requirements and any emergent 
problems. These monitoring visits will include bu t not be limited to review of the following 
aspects: patient informed consent, patient recruitment and follow-up, SAE documentation and 
reporting, AESI documentation and reporting, AE documentation, IMP allocation, patient 
compliance with the IMP regimen, IMP accountabili ty, concomitant therapy use and quality of 
data.
13.[ADDRESS_406062] the source 
documents, except for the pre-identified source da ta directly recorded in the CRF. The informed 
consent form will include a statement by [CONTACT_19127]‚Äôs duly authorized 
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: 1 
Property of the [COMPANY_011] Group - Page 115personnel, the Ethics Committee (IRB/IEC), and the regu latory authorities to ha ve direct access to 
original medical records  which support the data on the CRFs (eg, patient's medical file, 
appointment books, original laboratory record s, etc). These personne l, bound by [CONTACT_206396], must maintain the confidentiality of all personal identity or personal medical information (according to confidentiality and personal data protection rules). 
13.4 USE AND COMPLETION OF CASE REPORT FORMS (CRFS) AND ADDITIONAL 
REQUEST 
It is the responsibility of the Investigator to maintain adequate and accurate CRFs (according to 
the technology used) designed by [CONTACT_328769] r ecord (according to Sponsor instructions) all 
observations and other data pertinent to the clin ical investigation in a timely manner. All CRFs 
should be completed in their entiret y in a neat, legible manner to en sure accurate in terpretation of 
data.
Should a correction be made, the corrected inform ation will be entered in the e-CRF overwriting 
the initial information. An audit trai l allows identifying the modification. 
Data are available within  the system to the Sponsor as soon as they are entered in the e-CRF.
The computerized handling of the data by [CONTACT_328770] (DRF) to 
which the Investigator is obliged to respond by [CONTACT_19130]. The 
requests with their responses w ill be managed through the e-CRF.
13.[ADDRESS_406063] of computerized  systems used for the study is provided in a separate document 
which is maintained in the Spons or and Investigator study files.
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: [ADDRESS_406064] notify the Sponsor prio r to destroying any study essential documents 
following the clinical trial completion or discontinuation. 
If the Investigator's personal situation is such that archiving can no longer be ensured by [CONTACT_12552]/her, 
the Investigator shall inform the Sponsor and th e relevant records shall be transferred to a 
mutually agreed upon designee.  
14.3 CONFIDENTIALITY
All information disclosed or provided by [CONTACT_941] S ponsor (or any company/institution acting on their 
behalf), or produced during the clinical trial, including, but not limited to, the clinical trial 
protocol, personal data in relati on to the patients, the CRFs, the Investigator's Brochure and the 
results obtained during the course of the clinical tr ial, is confidential, prior to the publication of 
results. The Investigator and any person under his/her authority agree to undertake to keep 
confidential and not to disclose the informati on to any third party w ithout the prior written 
approval of the Sponsor. 
However, the submission of this clinical trial protocol and other necessary documentation to the 
Ethics committee (IRB/IEC) is expressly pe rmitted, the IRB/IEC members having the same 
obligation of confidentiality. 
The Subinvestigators shall be bound by [CONTACT_328771]. The Investigator 
shall inform the Subinvestigators of the c onfidential nature of the clinical trial.
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: [ADDRESS_406065] party's account. 
14.4 PROPERTY RIGHTS
All information, documents and IMP provided by [CONTACT_3433] e Sponsor or its designee are and remain the 
sole property of the Sponsor. 
The Investigator shall not and sh all cause the delegated Investigat or staff /Subinvest igator not to 
mention any information or the Product in any app lication for a patent or for any other intellectual 
property rights.
All the results, data, documents and inventions, whic h arise directly or indirectly from the clinical 
trial in any form, shall be the immediat e and exclusive property of the Sponsor. 
The Sponsor may use or exploit all the results at  its own discretion, wit hout any limitation to its 
property right (territory, field, c ontinuance). The Sponsor shall be  under no obligation to patent, 
develop, market or otherwise use th e results of the clinical trial.
As the case may be, the Investigator and/or th e Subinvestigators shall provide all assistance 
required by [CONTACT_1034], at the Sponsor's expe nse, for obtaining and defending any patent, 
including signature [CONTACT_56538]. 
14.5 DATA PROTECTION
xThe patient's personal data, which are included in  the Sponsor database shall be treated in 
compliance with all applicable laws and regulations;
xWhen archiving or processing personal data pe rtaining to the Investig ator and/or to the 
patients, the Sponsor shall take all appropriate measures to sa feguard and prevent access to 
this data by [CONTACT_151357]. 
xThe Sponsor also collects specific data rega rding Investigator as well as personal data 
from any person involved in the study which may be included in the Sponsor‚Äôs databases, shall be treated by [CONTACT_328772].
Subject race or ethnicity will be collected in this study because th ese data are required by [CONTACT_181305] (eg, on Af ro-American population for FDA, on Japanese population for the 
PMDA in Japan, or on Chinese population for the CFDA in China). 
Analyses of subject genetic data will be conducted as described in the protocol as this is needed 
for pharmacogenetics analyses requi red for the purpose of the study or by [CONTACT_12721]. 
The data collected in this study will only be us ed for the purpose(s) of the study and to document 
the evaluation of the benefit/ risk  ratio, efficacy and safety of the product(s). They may be further 
processed if they have been anonymized. 
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: 1 
Property of the [COMPANY_011] Group - Page [ZIP_CODE].6 INSURANCE COMPENSATION
The Sponsor certifies that it has taken out a liabil ity insurance policy coveri ng all clinical trials 
under its sponsorship.  This insurance policy is in  accordance with local laws and requirements. 
The insurance of the Sponsor does not relieve th e Investigator and the collaborators from any 
obligation to maintain their ow n liability insurance policy. An insurance certificate will be 
provided to the IECs/IRBs or re gulatory authorities in countries requiring this document.  
14.7 SPONSOR AUDITS AND INSPECTIONS BY [CONTACT_328773], Good Clinical Practice and 
applicable regulatory requirements,  the Investigator should permit auditing by [CONTACT_328774]. 
The Investigator agrees to allo w the auditors/inspectors to have  direct access to his/her study 
records for review, being understood that these personnel is bound by [CONTACT_328775], and as 
such will not disclose any personal id entity or personal medical information. 
The Investigator will make every effort to help with the performance of the audits and inspections, 
giving access to all necessary f acilities, data, and documents.
As soon as the Investigator is notified of a pla nned inspection by [CONTACT_328776], he will inform 
the Sponsor and authorize the Sponsor to participate in this inspection. 
The confidentiality of the data verified and the protection of th e patients should be respected 
during these inspections. 
Any result and information arising from the in spections by [CONTACT_328777] y authorities will be 
immediately communicated by [CONTACT_67852]. 
The Investigator shall take appropriate measures required by [CONTACT_179662]. 
14.8 PREMATURE DISCONTINUATION OF THE STUDY OR PREMATURE CLOSE-OUT
OF A SITE
14.8.1 By [CONTACT_328778], for any reason, including but not limited to the following:  
xThe information on the product leads to doubt as to the bene fit/risk ratio; 
xPatient enrollment is unsatisfactory;
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: 1 
Property of the [COMPANY_011] Group - Page 119xThe Investigator has received from the Spons or all IMP, means and information necessary 
to perform the clinical trial and has not incl uded any patient after a reasonable period of 
time mutually agreed upon; 
xNon-compliance of the Investigator or Subinve stigator, delegated staff with any provision 
of the clinical trial protocol, and breach of th e applicable laws and regulations or breach of 
the ICH GCP;
xThe total number of patients are included earlier than expected; 
In any case the Sponsor will not ify the Investigator of its decision by [CONTACT_56525]. 
14.8.2 By [CONTACT_328779]/her participa tion upon thirty (30) days' prior written notice if 
the study site or the Investigator for any reas on becomes unable to perform or complete the 
clinical trial. 
In the event of premature discont inuation of the study or prematur e close-out of a site, for any 
reason whatsoever, the appropriate IRB/IEC a nd regulatory authorities should be informed 
according to applicable regulatory requirements.
14.9 CLINICAL TRIAL RESULTS
The Sponsor will be responsible for preparing a cl inical study report and to provide a summary of 
study results to the Investigator.
14.10 PUBLICATIONS AND COMMUNICATIONS
The Investigator undertakes not to make any publi cation or release pertaining to the study and/or 
results of the study prior to the Sponsor‚Äôs written  consent, being understood that the Sponsor will 
not unreasonably withhold its approval. 
As the study is being conducted at multiple site s, the Sponsor agrees that, consistent with 
scientific standards, a primary presentation or  publication of the study results based on global 
study outcomes shall be sought. However, if no multicenter publication is submitted, underway or 
planned within twelve (12) months of the comple tion of this study at all sites, the Investigator 
shall have the right to publish or  present independently the results of this study in agreement with 
other Investigators and stakeholde rs. The Investigator shall provi de the Sponsor with a copy of 
any such presentation or publication for review a nd comment at least 30 days in advance of any 
presentation or submission for publication.  In  addition, if requested  by [CONTACT_1034], any 
presentation or submission for publication shall be  delayed for a limited time, not to exceed 90 
days, to allow for filing of a pate nt application or such other ju stified measures as the Sponsor 
deems appropriate to establish and preserve its proprietary rights. 
The Investigator shall not use th e name(s) of the Sponsor and/or its employees in advertising or 
promotional material or publicati on without the prior wr itten consent of the Sponsor. The Sponsor 
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: 1 
Property of the [COMPANY_011] Group - Page 120shall not use the name(s) of the Investigator and/or  the collaborators in advertising or promotional 
material or publication without having receive d his/her and/or their prior written consent(s).
The Sponsor has the right at any time to publish the results of the study. 
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: 1 
Property of the [COMPANY_011] Group - Page [ZIP_CODE] CLINICAL TRIAL PROTOCOL AMENDMENTS
All appendices attached hereto and referred to herein are made part of this clinical trial protocol.
The Investigator should not implem ent any deviation from, or changes of the clinical trial protocol 
without agreement by [CONTACT_326937]/favorable opi[INVESTIGATOR_20291]/IEC of an amendmen t, except where necessary to e liminate an immediate hazard(s) 
to clinical trial patients, or when the change(s) in volves only logistical or administrative aspects of 
the trial. Any change agreed upon will be record ed in writing, the wr itten amendment will be 
signed by [CONTACT_179665].
Any amendment to the clinical tr ial protocol requires written approval/favorable opi[INVESTIGATOR_56400]/IEC prior to its implementation, unl ess there are overriding safety reasons.
In some instances, an amendment may require a change to the informed consent form. The 
Investigator must receive an I RB/IEC approval/favorable opi[INVESTIGATOR_328718] s hould be re-collected if 
necessary.
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: [ADDRESS_406066] P, Chanez P, Siraudin L, Nicoloyannis L,  Duru G. Costs of asthma are correlated with 
severity: A 1 year prospaective study. Eur Respir J. 2002;19:61-7 
2. Levine SJ, Wenzel SE. Narrative review: The role of Th2 immune pathway modulation in the 
treatment of severe asthma and its phenotypes. Ann Intern Med. 2010;152:232-7 
3. Global Initiative for Asthma (GINA). Gl obal Strategy for Asthma Management and 
Prevention. Ed 2014, available at www.ginasthma.org 
4. Abdel-Razzak Z, Loyer P, Fautrel A, Gautier JC, Corcos L, Turlin B,  et al. Cytokines down-
regulate expression of major cytochrome p- 450 enzymes in adult human hepatocytes in 
primary culture. Mol. Pharmacol. 1993;44(4):707-715. 
5. Christensen H, Hermann M. Immunological re sponse as a source to variability in drug 
metabolism and transport. [ADDRESS_406067] of cytokines 
on the expression of drug transporters, cytoch rome P 450 enzymes and chemokine receptors in 
human PBMC. British Journal of Pharmacology. 2009;156(3):497-508 
7. Miller MR, Hankinson J, Brusasco  V, Burgos F, Casaburi R, Coat eset A,et al. Standardization 
of spi[INVESTIGATOR_038]. Series ‚Äò‚ÄòATS/ERS TASK FORCE: Standardization of Lung Function Testing"  
Edited by [CONTACT_181308] V, Crapo R, and Viegi G. Eur Resir J. 2005;26:319-338. 
8. Juniper EF, O'By[CONTACT_21143], Guyatt GH, Ferrie PJ , King DR. Development and validation of a 
questionnaire to measure asthma control. Eur Respir J. 1999;14(4):902-7. 
9. Juniper EF, Svensson K, Mork AC, Stahl E. Measurement properties and interpretation of 
three shortened versions of the asthma c ontrol questionnaire.  Respir Med. 2005;99:553-8. 
10. Norman GR, Sloan JA, Wyrwich KW. Point/C ounterpoint, Interpretation of Changes in 
Health-related Quality of Life, The Remarkable  Universality of Half a Standard Deviation 
Medical Care, (41):5,582‚Äì592 
11. Juniper EH, Guyatt GH, Willan A, Griffith LE.   Determining a minimal important change in a 
disease-specific quality of  life questionnaire.  J Clin Epi[INVESTIGATOR_5541]. 1994;47(1):81-[ADDRESS_406068]. Clin Otolar. 2009;34(5):447-54 
13. Zigmond AS, Snaith PR. The Hospi[INVESTIGATOR_5620]. Acta Psychiatr Scand. 
1983;67(6):361‚Äì70 
Amended Clinical Trial Protocol 04  26-May-2017
SAR231893-EFC13579-dupi[INVESTIGATOR_181143]: [ADDRESS_406069] of Mindfulness-
Based Therapy on Anxiety and Depression: A Me ta-Analytic Review.J Consult Clin Psychol. 
2010 April ; 78(2): 169‚Äì83. 
15. Milo A Puhan, Martin Frey, Stefan B√ºchi,  Holger J Sch√ºnemann.The minimal important 
difference of the hospi[INVESTIGATOR_328719] w ith chronic obstructive 
pulmonary disease. Health and Qu ality of Life Outcomes 2008, 6:46. 
16. Langley RG, Feldman SR, Han C, Schenkel B,  Szapary P, Hsu MC, et al. Ustekinumab 
significantly improves symptoms of anxiety, depr ession, and skin-related quality of life in 
patients with moderate-to-seve re psoriasis: Results from a randomized, double-blind, placebo-
controlled phase III trial 2010 J AM  ACAD DERMATOL 63(3): 457-65. 
17. Stelara EMA approved Summary of Product Char acteristics (SmPC or SPC), available at 
http://www.ema.europa.eu. 
18. EUroQol Group. EuroQol-a new facility for the m easurement of health-related quality of life. 
Health Policy 1990;16(3):199-208 
19. Sullivan P, Lawrence WF, Ghushchyan A. A Nati onal Catalog of Preferen ce-Based Scores for 
Chronic Conditions in the [LOCATION_002] Med Care 2005 43(7):736‚Äì49. 
20. Brusselle G, Michils A, Louis R,  Dupont L, Va n de Maele B, Delobbe A, et al. ‚Äò‚ÄòReal-life‚Äô‚Äô 
effectiveness of omalizumab in patients with severe persistent allergic asthma: The PERSIST study 2009 Respi[INVESTIGATOR_328720] 103(5):1633-42
21. Juniper EF, Guyatt GH, O'By[CONTACT_21143], Viveiros  M. Aqueous beclomethasone dipropi[INVESTIGATOR_328721]" regular versus "as required" use in  the treatment of seasonal allergic rhinitis J 
Allergy Clin Imunol 1990:863 (3Pr1) :380-6. 